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Hoi! 
Leuk dat je deze brief leest. Ik wil je graag uitleggen waar mijn boek over gaat. 
Stel je voor: een meisje van 12 jaar is ziek en moet naar het ziekenhuis. De dokter 
vertelt welke ziekte ze heeft en hoe ze beter kan worden. Maar de dokter vertelt 
ook nog iets anders. Ze vraagt of het meisje mee wil doen aan een wetenschappe-
lijk onderzoek. Daarmee wil de dokter een nieuw medicijn voor de ziekte testen. Er 
zullen 100 kinderen meedoen aan het onderzoek. De ene helft krijgt het nieuwe 
medicijn. De andere helft krijgt het oude medicijn. Je weet van tevoren niet welk 
medicijn je gaat krijgen. De dokter gaat dan kijken welk medicijn het beste werkt. 
Het meisje stelt er vragen over: 
Meisje: wat moet ik dan allemaal doen? 
Dokter: je moet een maand lang iedere dag het medicijn nemen. Eén keer 
per week moet je bloed laten prikken. Ook moet je één keer een hele dag 
naar het ziekenhuis komen. Dan krijg je een infuus in je arm. Daarmee 
wordt dan zes keer bloed afgenomen.  
Meisje: doet dat pijn? 
Dokter: dat kan soms een beetje pijn doen. Het ene kind vindt het verve-
lender dan het andere. 
Meisje: wat is er mis met het oude medicijn? 
Dokter: het oude medicijn werkt best goed maar we denken dat het nieu-
we beter werkt. Het oude medicijn heeft ook bijwerkingen. Sommige 
kinderen krijgen er spierpijn van. 
Meisje: waarom krijg ik dan niet gewoon het nieuwe medicijn als dat beter 
is? 
Dokter: we weten nog niet zeker of het beter is. Dat gaan we juist onder-
zoeken. Misschien werkt het wel minder goed. 
Meisje: kan ik er dan ook juist zieker van worden? 
Dokter: dat is een goede vraag. We hebben vooronderzoek gedaan. Eerst 
hebben we kleine beetjes van het medicijn aan kinderen gegeven. En dan 
steeds iets meer. Als er bijwerkingen kwamen dan hielden we meteen op. 
De hoeveelheid die we nu geven is dus veilig. Maar er kan altijd iets onver-
wachts gebeuren.  
Meisje: móét ik meedoen met het onderzoek? 
Inleiding voor kinderen 
 
9 
Dokter: nee dat hoeft niet. Als je het niet wil dan hoeft het niet. Jij beslist 
samen met je ouders of je mee wil doen. 
Meisje: wat gebeurt er als ik niet mee wil doen? 
Dokter: dan krijg je gewoon het oude medicijn. 
Meisje: en hoef ik dan niet het infuus? 
Dokter: nee dat hoeft dan niet. Je moet dan wel een keer bloed laten prik-
ken. Dat moet om te kijken of je echt weer beter bent. 
Meisje: vindt u dat ik mee moet doen? 
Dokter: ik vind daar niets van. Het is jouw keuze. 
Meisje: moet ik nu beslissen? 
Dokter: nee hoor. Je mag er thuis over nadenken, samen met je ouders. Je 
krijgt ook deze brief mee. Daarin staat alles nog een keer uitgelegd over dit 
onderzoek. Deze folder krijg je ook. Daarin staat wat wetenschappelijk on-
derzoek precies is en hoe het werkt. 
 
Dit boek gaat over kinderen die net als dit meisje meedoen aan medisch-
wetenschappelijk onderzoek. Daar komt veel bij kijken. Niet zomaar ieder onder-
zoek mag gedaan worden. Waarom mag dat eigenlijk niet? En waarom is 
onderzoek doen belangrijk? 
Zieke kinderen willen we snel beter maken. Daar hebben we goede behandelingen 
voor nodig, bijvoorbeeld medicijnen. Een goede behandeling betekent een 
behandeling die veilig is en goed werkt. Maar dat moet wel eerst onderzocht 
worden, ook bij kinderen. Want een kinderlichaam werkt anders dan een vlwassen 
lichaam. Toch krijgen kinderen vaak medicijnen die nog niet goed zijn onderzocht. 
Er is dus meer onderzoek nodig. 
Maar soms is onderzoek doen gevaarlijk. Je kunt bijvoorbeeld een onverwachte 
bijwerking krijgen of juist zieker worden van een nieuw medicijn. Dat kun je van 
tevoren niet weten omdat het nog niet is onderzocht. We noemen dat risico’s. 
Ook is meedoen aan onderzoek vervelend of zwaar voor kinderen. Veel kinderen 
vinden het bijvoorbeeld eng om bloed te laten prikken. We noemen dat belasting. 
Kinderen kunnen vaak ook nog niet zelfstandig beslissen of ze mee willen doen 
aan onderzoek. Daarom zijn er regels waaraan onderzoekers zich moeten houden 
als ze een onderzoek willen doen met kinderen.  
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Onderzoek doen is dus nodig om zieke kinderen beter te kunnen maken. Dat is 
een goede reden om wel onderzoek met kinderen te doen. Maar meedoen aan 
onderzoek kan ook gevaarlijk en vervelend zijn. Dat is weer een reden om het niet 
te doen.  
Dit heet een dilemma: een situatie waarin je niet weet wat je moet doen omdat er 
redenen voor én tegen zijn. Veel wetenschappers hebben al over dit dilemma 
nagedacht. Toch is het nog niet opgelost. Er zijn nog steeds vragen waarop nog 
geen goed genoeg antwoord is gekomen. Bijvoorbeeld: wat is de beste manier om 
erachter te komen of een onderzoek niet te gevaarlijk of te vervelend is voor 
kinderen? En hoe vervelend is meedoen aan onderzoek eigenlijk voor kinderen? 
Naar deze, en ook nog andere vragen heb ik onderzoek gedaan. Dit boek is een 
verslag van mijn onderzoek.  
Met mijn onderzoek wil ik weer een stukje verder komen in het oplossen van het 
dilemma. We willen beter weten hoe we én zoveel mogelijk onderzoek kunnen 
doen, én kinderen goed kunnen beschermen. Het boek is geschreven voor andere 
wetenschappers. Daardoor is het best ingewikkeld en ook nog in het Engels. Maar 
dit boek gaat over kinderen, over jullie dus. Ik vind het belangrijk dat ook kinderen 
te weten kunnen komen waar mijn onderzoek over gaat. Aan het einde van het 
boek vind je een samenvatting voor kinderen. Daarin staat welke vragen ik heb 
gesteld en welke antwoorden ik heb gevonden. Dank je wel voor het lezen! 
 
Wendy Bos 
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'Begin at the beginning, go on till you come to the end, then stop.'(1) With these 
words, from his masterpiece Alice’s Adventures in Wonderland, Lewis Carroll 
taught his readers an important lesson on storytelling. Silly as it may sound, it is in 
fact a rather important lesson that many still have to learn. The problem of a fuzzy 
and unclear story may well be that it did not begin at the beginning, or did not 
stop when it already came to the end. Yet, stories on ethics rarely come with 
endings, for the simple reason that ethics does not end. They are ever-evolving 
stories, because they are prone to changing perspectives, developing arguments 
and input from the real world. As such, there can never be a true ending. For good 
storytelling in the field of ethics, given the lack of true endings, we have to 
carefully choose where to stop and clarify why we chose that point. The same is 
true for the beginning. 
This story is about the ethics of including children in clinical research and it began 
in 2011. By that time quite a long tradition of research into the moral justification 
and the moral limits of including children in clinical studies, had already arisen. 
This thesis builds on the rather large body of literature on this topic, as well as on 
the many legal and ethical regulations and guidelines that came into force ever 
since the horrific experiments with humans during World War II first proved on a 
large scale that such regulation is needed.(2) When I started my research project 
in 2011, another doctoral thesis on the moral limits of medical research with 
children had just been completed.(3) That thesis focused on regulating so-called 
non-therapeutic research, i.e. research from which the participants themselves are 
unlikely to benefit. Around that time, both paediatric researchers and the central 
committee on research involving human subjects (CCMO) had requested more 
opportunities for this kind of research.(4-6) In that thesis Westra researched how 
to facilitate more non-therapeutic research (specifically in the Netherlands) while 
still properly protecting participating children against undue research risks and 
burdens. At the end of that research project certain questions had remained 
unanswered. These questions are where my research project began. 
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BACKGROUND 
THE CENTRAL DILEMMA 
Paediatric research ethics evolves around a central dilemma, presenting two 
undesirable choices. To put it extremely simple; one choice is to accept that many 
childhood diseases cannot be (properly) treated and that many children receive 
treatments that have not been (properly) tested in children, and as such have not 
been (properly) proven safe and effective. The other choice is to include children, 
i.e. vulnerable persons who cannot (fully) consent, in medical research studies that 
can possibly harm them. As neither of the options are acceptable, the solution 
should be found somewhere in between those choices, and should be as balanced 
and as well-argued as possible. It is the main pursuit of paediatric research ethics 
to find the most reasonable balance. 
First, let us look closer at those two choices. On one side there are those child-
hood diseases for which no cure has yet been found. Moreover, a large part of 
drug prescriptions for children occur off-label or unlicensed, i.e. are prescribed 
differently than how they are registered. Off-label drug use takes various forms, 
e.g. use for a different age group, a different indication or a different dosage.(7) 
Numbers of off-label and unlicensed drug use in paediatrics vary substantially 
between countries and hospitals. Percentages range from 11% to 80%. (8-13) The 
varying numbers partly relate to varying age- and patient groups, varying hospital 
settings, but also to the chosen methodologies and the lack of consensus on the 
definition of off-label and unlicensed drug use. Off-label prescription rates are 
highest in newborns, and mainly concern dosage adjustment.(7) The consequen-
ces of off-label use are not fully known. Clearly, children cannot be considered 
small adults, as their metabolism and capacity for drug absorption differs not only 
quantitatively from adults, but also qualitatively. Hence merely adjusting dosages 
to the body weight is potentially harmful. Metabolism, for example, differs a lot 
between the different age groups. Newborns still have an underdeveloped 
metabolism and need smaller doses than weight-adjusted doses, whereas toddlers 
and pre-schoolers have higher metabolising capacities and as such they might 
require higher doses than weight-adjusted doses.(14) 
The lack of proper treatments for childhood diseases, plus the high off-label 
prescription rates show the need for more research in the field of paediatrics. Yet 
the development of new drugs and other interventions and testing them in 
humans (in this case children) is never without risk. The exact reason why medical 
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research is carried out is because the safety, the tolerability and/or the effect of 
the studied intervention are still unknown.  
That brings us to the other side of the story. While the need for more paediatric 
research is compelling, research participation always comes with a certain degree 
of uncertainty and thereby with a certain degree of risk. To protect research 
participants against undue harm, all medical research with humans is strictly 
regulated. There are, among other requirements, two central ethical requirements 
for doing research with humans. Before any human participants can be included in 
a medical research study, the research protocol has to be approved by a research 
ethics committee (REC) and the participants have to provide informed 
consent.(15)  
Children, however, are more vulnerable than adults. Moreover, the younger they 
are, the less capable they are of deciding about research participation.(16-18) 
Children therefore need and deserve extra protection, as compared to adults, and 
special protective measures for them have been put in place. Research with 
children may only be carried out if it is impossible to yield the same data with 
research in adults. Moreover, children cannot (fully) provide informed consent, but 
still research participation should not be involuntary.(19) As a solution, the parents 
have to provide proxy consent, and both the parents and research professionals 
should be vigilant to the child’s (un)willingness to participate.(20) Children should 
be informed about the purpose, the procedures and the risk and burden of the 
study in a way that suits their level of understanding.(21) Also, they should be 
involved in the decision-making to an extent that suits them. Children who can 
provide assent; defined as affirmative agreement, should be asked for assent.(22-
24) Should a child express dissent or objection, then that child should not be 
included in the study.(25) 
Also with regard to the acceptability of risk and burden, stricter rules apply for 
research with children, especially for research without the prospect of direct 
benefit. For example, research that is designed to study the pharmacokinetics of a 
drug is usually not likely to benefit the participants themselves. Although the 
applicable (inter)national legal documents and ethical guidelines use different 
wordings, many require that the risks and burdens of a paediatric research study 
without the prospect of direct benefit are no more than minimal.(26-30) Yet, this 
seeming agreement on setting an upper limit for risks in paediatric research 
without potential direct benefit still leaves plenty of room for debate about the 
operationalisation of such a requirement. Both the content of the term direct 
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benefit and the definition of minimal risk (and burden) have been discussed 
extensively by paediatricians and ethicists. Examples are the question whether 
phase I studies should be regarded as offering direct benefit, and the question 
whether minimal risk should be an absolute or a relative standard.(31-38) 
THE NETHERLANDS 
The governance of paediatric research in the Netherlands has been criticised for 
being overly on the protective side. With studies that were not approved in the 
Netherlands, but nevertheless were allowed to be performed in other countries, 
the idea arose that the Dutch law was more restrictive than necessary.(39) This 
led to a debate about the question whether the law on medical research with 
human subjects should be changed in order to expand the possibilities for inclu-
ding children in research without direct benefit. The Dutch Medical research 
involving human subjects Act (WMO) in its former shape used a slightly stricter 
version of the minimal risk requirement, namely that research without direct 
benefit should involve no more than negligible risk and minimal burden.(30) 
Changing the law was a long process. Already in 2007, several paediatricians and 
the CCMO voiced their first requests for expanding the possibilities for including 
children in research without direct benefit.(4-6) The Committee Doek (named 
after the chairman) that got the task of investigating the need to expand the law, 
advised that the ‘negligible risk and minimal burden’ requirement should be 
removed altogether. The committee argued that research can be acceptable if it 
provides some direct benefit either for the participants themselves or to the 
patient group to which the participants belong. Arguments mentioned in the 
report were harmonisation with the European regulatory framework, and the 
recognition of children older than 12 as persons with rights who should have the 
opportunity to decide about higher-risk research participation themselves.(40) 
The arguments and the recommendations of the Committee Doek were criticised 
for focusing only on the Clinical Trials Directive (as almost all other relevant 
documents do set an upper limit for risk and burden, the Directive being an 
exception) and for arbitrarily setting a threshold at 12 years of age, while allowing 
higher risk and burden for all age groups.(41) Ultimately the advice of the Com-
mittee Doek was not adopted in the draft of the revised law. Instead, the 
American standard of ‘a minor increase over minimal risk (and burden)’ was used 
in the new proposal.(42) Meanwhile, the European Clinical Trials Regulation was 
drafted and approved in April 2014, which would, as soon as it would come into 
force, directly govern all drug trials in all EU member states. Any deviations from 
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the newly drafted Regulation that were less strict, could apply to non-drug studies 
only. In that light, the unavoidable outcome was that the national law got adjusted 
to the Regulation. Ultimately, the revised national law passed the House of 
Representatives (Tweede Kamer) in 2015, and the Senate (Eerste Kamer) in 2016. 
The new requirement is that research without the prospect of direct benefit 
imposes only ‘minimal risk and minimal burden related to the standard treatment 
of the patient’.(29) The exact interpretation of this requirement still remains to be 
seen, but it has already been noted that relating the acceptable level of risk and 
burden to the standard treatment of the patient, is potentially harmful.(43) 
RELEVANCE 
Despite the fact that paediatric research ethics is a much-studied field, practice 
shows that there are still questions that have not yet been answered satisfactorily. 
Examples are questions about the acceptability of risk and burden and about how 
to react to signs of discomfort and dissent during research participation. REC 
members and research professionals recognise that these are still relevant and 
important questions. Improving ethical review practice as well as improving the 
monitoring of children during the performance of clinical research would expect-
edly contribute to the protection of children as research participants. In chapter 3 
of this thesis a case is presented which illustrates clearly that there are still 
unsolved issues. 
AIMS 
With this thesis I aim to contribute to the strengthening of the existing ethical 
framework that protects minor research participants against undue harm. As said 
before, my work builds on quite a long research tradition in which moral positions 
and arguments have been discussed extensively.(3, 33, 44, 45) The bigger and 
broader issues have received much attention and nowadays the regulatory 
framework governing paediatric research is fairly well founded.(15) Central 
medical-ethical principles like non-maleficence, respect for persons and respect 
for (growing) autonomy have gained a firm position in all relevant guidelines.(46) 
Yet, nailing down important principles in legal documents is not the end of the 
story. What is written in laws and guidelines says little about the practical implica-
tions of those principles and requirements and even less about how they are 
complied with. For example, the principle of respect for a child’s dissent is found 
in different wordings in all research ethics documents.(26, 28-30, 47) But the 
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content of the notion of dissent is inconsistent among these documents, as is 
guidance on operationalising this principle (this is discussed extensively in chapter 
8).(48) The need for clarity, precision and transparency are recurring topics 
throughout this thesis. 
An overarching aim of my work is to strengthen the position of children by 
providing them with the exact amount of protection they need and deserve, while 
at the same time recognising their capacities and respecting their views and 
experiences. Instead of regarding children as mere subjects of study, I would, 
among others, suggest to regard them as partners in the research project.(16) To 
respect children as persons and appreciate their involvement in research projects, 
would expectedly foster their sense of autonomy and the development of their 
self-esteem.(49) This idea is reflected in several parts of this thesis. In chapter 6, 
for example, I propose a more precise method for assessing risks and benefits 
during the ethical review process. This precision helps to identify more explicitly 
which studies can be reasonably proposed to children, while also making sure that 
acceptable studies are not rejected unnecessarily. Moreover, in chapter 8 recom-
mendations are provided for monitoring children who participate in research, 
which focus explicitly on voluntariness and experienced burden. 
METHODOLOGICAL APPROACH 
Research ethics is an interdisciplinary field that investigates questions of different 
nature from various perspectives. Philosophical questions on the moral justifica-
tion of, and on the moral conditions for including children in medical research are 
only part of the project of paediatric research ethics. As research with humans is 
so strictly regulated by law, research ethicists inevitably have to face legal 
questions as well. Moreover, research ethics is a discipline that aims to foster 
ethical research practice and for that reason it is of great importance to always 
look at what happens in practice. Empirical data are needed, for example to 
identify the actual problems and concerns, as well as to uncover experiences or 
views of the people involved.  
This thesis is positioned on exactly that intersection of the philosophical, the legal 
and the empirical domain. The moral reasoning found in this thesis represents a 
process of theoretical testing, modification and experimentation.(50) It is a rather 
general and broad method of reflective thinking, taking into account possible 
moral positions and relating them to moral principles with the aim to reach a well-
balanced conclusion.(51)  
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For this thesis, I used legal and empirical knowledge to inform and fuel my moral 
reflective thinking. A central research approach that can be found throughout all 
chapters is a strong focus on clarifying and defining concepts and problems as 
clearly and precise as possible. A clear and precise starting point is a prerequisite 
for a meaningful and progressive normative reflection. Chapter 6, 7, and 8 are the 
best examples of this research approach. The analysis of legal articles and articles 
from ethical guidelines and their relation to generally accepted ethical principles is 
interwoven in the normative reasoning. For our study on the procedure-level 
approach to ethical review (chapter 6) we have analysed research protocols and 
REC decisions from the archives of several RECs. To uncover the views of paedia-
tricians on research burden for children, a questionnaire study was carried out 
(chapter 7). Throughout the entire course of our study we have discussed our 
research progress and results with professionals in the field of paediatric research 
(research nurses, paediatricians and REC members), through focus groups, 
workshops and group discussions. The normative conclusions presented in this 
thesis result from the combination of these methods. 
OUTLINE AND RESEARCH QUESTIONS 
The topics that are presented in the chapters 2 to 5 concern background ques-
tions. In chapter 2 the European regulatory landscape is sketched in order to 
clarify against what legal background the ethical discussion takes place. After 
that, in chapter 3 we discuss a case. This concerned a protocol on Duchenne 
Muscular Dystrophy that was approved in Belgium and Sweden but not in the 
Netherlands. We took the case of this protocol to start a discussion on the 
acceptability of risk and burden. This discussion revealed also other questions that 
are still unanswered. By means of a short epilogue these questions are pointed 
out. In chapter 4 we focus on children as vulnerable research subjects, and 
compare them to another group of vulnerable research subjects; dementia 
patients. We investigated in what morally relevant aspects these two groups are 
different and on what aspects they are similar and how those differences and 
similarities are represented in laws and ethical guidelines. Then, during the course 
of our research project, the new European Clinical Trials Regulation was drafted 
and approved. In chapter 5 we present a critical analysis of the new Regulation. In 
our view, the new Regulation fails to guarantee the quality of the review process. 
The main concerns described in this chapter are the quality of the risk-benefit 
assessment and the quality of ethics committees. 
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The chapters 6, 7 and 8 concern the three main subprojects of my research 
project. The subproject presented in chapter 6 focuses on the risk-benefit assess-
ment carried out by Research Ethics Committees. As the line between research 
that can, and research that cannot directly benefit the participating children can 
sometimes be rather thin and indistinct, several ethicists have proposed to shift 
the focus from protocols as a whole, to the individual procedures within that 
protocol.(52-55) Our study aimed at finding how large the grey area between 
research with-, and research without the prospect of direct benefit actually is and 
thereby to identify the need for assessing risks and benefits on the procedure-
level. Secondly, we aimed at exploring possible practical drawbacks of the 
implementation of a procedure-level approach in the practise of ethical review. To 
this end the following research questions were formulated: - To what extent are there elements without direct benefit 
in paediatric intervention studies with direct benefit and 
vice versa? - What are the practical drawbacks for using a procedure-
level approach to ethical review? 
In chapter 7 the second subproject is presented. For Research Ethics Committees 
it is often difficult to estimate how burdensome research participation will be for 
children. Existing data on this topic are rather limited and it would be helpful if 
more empirical data on the burden of medical research procedures for children 
were available.(56-59) This study aimed to generate more knowledge on the 
burden associated with several widely used research procedures. The following 
research question was asked: - What is the burden of several research procedures for 
children, according to paediatricians? 
The third subproject is presented in chapter 8. When participating in clinical 
research, children sometimes show signs of discomfort, discontent, distress 
and/or dissent. Such signs can be rather vague and hard to interpret, especially in 
young children. If such behaviour continues, the question may rise whether it is 
still justified to keep a child in a trial. Guidance on this issue is scarce, incomplete 
and inconsistent.(25, 60) With our study we aimed to provide clear guidance and 
practical recommendations for deciding whether to stop research participation of 
a certain child. In order to provide such guidance the following research question 
had to be answered: 
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- When, and on what ground should signs of discontent 
and dissent lead to withdrawing a child from a trial? 
Ultimately, all parties involved need practical proposals for the improvement of 
ethical research conduct. In chapter 9, the general discussion, I will not only 
present the main conclusions of our research project, but will also identify missed 
opportunities concerning the recent regulatory changes, and I will present my 
ideas on the possible ways forward for the future of paediatric research ethics. 
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ABSTRACT  
Over the past decades, clinical research has increasingly been subjected to ethical 
requirements and legal regulation. The specific focus of ethical and legal frame-
works on competent adults, however, has created an ambivalent attitude towards 
paediatric clinical research. On the one hand, minors are regarded as a vulnerable 
population that deserves additional protection against the risks and burdens 
involved in clinical research. On the other hand, the population of minors should 
not be denied (or not get timely) access to the benefits of clinical research. In this 
paper, we will explore the legal regulation and ethical guidance that currently 
governs paediatric clinical research in the European Union and discuss the future 
challenges in this field. In addition, we will discuss major ethical concerns in 
paediatric clinical research, with a focus on the acceptability of research risks and 
the informed consent process. In the discussion, we will address key concerns in 
both regulating paediatric clinical research and implementing ethical and legal 
requirements in the actual paediatric research conduct.  
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INTRODUCTION  
Over the past decades, clinical research has increasingly been subjected to ethical 
requirements and legal regulation. Since World War II, landmark codes of ethical 
research conduct have been drafted and legal regulation has been issued in the 
United States, the European Union (EU), and many other countries. Despite the 
considerable diversity in ethical and legal requirements, there has always been 
consensus on the cornerstones of ethical research conduct. For example, the 
doctrine of informed consent, the premise that the interest of science and society 
should not prevail over those of the individual, and the fact that human subjects 
should never be exposed to unnecessary risks in clinical research have been 
widely endorsed from the very start.  
The historical efforts to secure an adequate protection of human subjects in 
clinical research have been grafted on a paradigmatic research subject: the 
competent adult. This specific focus, however, has created an ambivalent attitude 
towards paediatric clinical research. On the one hand, minors are regarded as a 
vulnerable population that deserves additional protection against the risks and 
burdens of clinical research. Such protection could not be maximised further than 
in a full exclusion of minors from clinical research. On the other hand, the popula-
tion of minors should not be denied (or not get timely) access to the benefits of 
clinical research. The impressive share of drugs that are prescribed off-label or 
unlicensed in paediatric practice however, clearly indicates that research in 
competent adults does not automatically generates timely advancements in the 
diagnosis, care, and treatments for minors.(1) Minors are not just small adults, and 
omitting to conduct clinical trials in the population of minors turns minors into so-
called therapeutic orphans.(2, 3) By consequence, the conduct of paediatric 
clinical trials is indispensible to catch up with the lack of licensed drugs that are 
labelled for paediatric use.  
However, from an ethical and legal point of view, the conduct of paediatric clinical 
trials is a precarious enterprise. It often remains difficult to balance scientific 
advancement with the adequate protection of minors.(4, 5) In addition, several 
hurdles such as difficult recruitment, market issues (e.g. a problematic return on 
investment for paediatric clinical research), and restrictive regulation (e.g. risk 
thresholds for research without the prospect of direct benefit) may be hard to 
surpass.  
In this paper, we will explore the legal regulation and ethical guidance that 
currently governs paediatric clinical research and discuss the future challenges in 
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this field. It must be emphasised that the applicable ethical and legal frameworks 
are often formulated in general terms, while paediatric research is a very hetero-
geneous landscape. As such, these frameworks may fail to respond directly to the 
specific ethical issues that come to the surface in practice. Certain issues therefore 
call for an appropriate ethical approach, which cannot be derived easily from the 
available ethical and legal guidance. Box 1 lists a number of such issues.  
 
Box 1: Recognised problems from a clinical point of view in critically ill minors 
1. The compassionate use at an individual base of a last resort drug (Imatinib) 
for pulmonary hypertension originally labelled as an anti-cancer drug. 
2. The conduction of first in men studies such as new amino acid composition 
for parenteral nutrition in extreme low birth weight infants in the absence 
of adult data. 
3. The application of a therapeutic modality (for instance liquid ventilation 
with an organ preservation substance) in the absence of safety data. 
4. Invasive foetal treatment modalities guided by industrial progress and not 
supported by properly designed RCTs. 
5. Opportunistic sampling of residual blood samples from routine laboratory 
test, as well as dry blood spot sampling with the aim to determine drug 
levels. 
6. Diagnostic procedures such as PET-scans to obtain normal values for the 
age-dependent distribution of opioid receptor isoforms in the central  
nervous system needed radioactive labelled substance. 
THE REGULATION OF ETHICAL ISSUES IN PAEDIATRIC CLINICAL  
RESEARCH IN THE EUROPEAN UNION  
In the European Union, diverse legislative bodies have promulgated various 
supranational and national regulations over the past 15 years. They aimed to 
harmonise existing standards of good clinical practice and to facilitate and 
encourage paediatric clinical research.(6) At the supranational level, three differ-
ent regulations govern paediatric research conduct. First, the Council of Europe 
issued the European Convention for the Protection of Human Rights and Dignity 
of the Human Being with Regard to the Application of Biology and Medicine in 
1997 (further, the Oviedo Convention).(7) In 2005, this convention was supple-
mented with an additional protocol on biomedical research.(8) To date, the 
Oviedo Convention is binding for the 17 EU member states (and 12 countries 
outside the EU) that have signed and ratified it. The Convention specifically 
addresses the issue of paediatric research in Article 17 (Box 2).  
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Box 2: Oviedo Convention—Article 17 
Protection of persons not able to consent to research  
1. Research on a person without the capacity to consent as stipulated in  
Article 5 may be undertaken only if all the following conditions are met: 
i. the conditions laid down in Article 16, sub-paragraphs i to iv, are  
fulfilled; 
ii. the results of the research have the potential to produce real and  
direct benefit to his or her health;  
iii. research of comparable effectiveness cannot be carried out on  
individuals capable of giving consent;  
iv. the necessary authorisation provided for under Article 6 has been 
given specifically and in writing; and  
v. the person concerned does not object. 
2. Exceptionally and under the protective conditions prescribed by law, where 
the research has not the potential to produce results of direct benefit to the 
health of the person concerned, such research may be authorised subject to 
the conditions laid down in paragraph 1, sub-paragraphs i, iii, iv and v above, 
and to the following additional conditions: 
i. the research has the aim of contributing, through significant  
improvement in the scientific understanding of the individual's  
condition, disease or disorder, to the ultimate attainment of results 
capable of conferring benefit to the person concerned or to other 
persons in the same age category or afflicted with the same disease 
or disorder or having the same condition; 
ii. the research entails only minimal risk and minimal burden for the  
individual concerned.  
Second, Directive 2001/20/EC (further, the Clinical Trials Directive) mainly aims at 
a harmonisation of the provisions regarding good clinical practice and the facilita-
tion of multicentre clinical trials across the borders of individual EU member 
states.(9) All EU member states were bound to implement this Directive into 
national law, with the freedom to adopt stricter provisions than those set down in 
the text of the Directive (as long as the standards of protection and time limits 
captured in the Directive were not violated). By consequence, there exists 
considerable variety among the national laws that implemented the Clinical Trials 
Directive. Obviously, differences in domestic requirements between EU member 
states have to be taken into account when conducting a trial in a specific EU 
member state. The Clinical Trials Directive specifically addresses the issue of 
involving minors in research in Article 4 (Box 3). 
Third, Regulation (EC) No. 1901/2006 (further, the Paediatric Regulation) requires 
that clinical trials in minors be planned and conducted for all new products 
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entering the market.(10) In this respect, sponsors must make a paediatric investi-
gation plan after phase I trials in adults have been completed (in certain cases, 
waivers are possible). In return for the efforts to plan and conduct trials in minors, 
the Paediatric Regulation offers considerable rewards in the form of a prolonga-
tion of market exclusivity. The Paediatric Regulation also arranged the establish-
ment of a paediatric committee within the European Medicines Agency that is 
(among other tasks) primarily responsible for the scientific assessment and 
agreement of paediatric investigation plans and for the system of waivers and 
deferrals thereof. In contrast to the European Convention and the European 
Directive, the Paediatric Regulation is exclusively dedicated to clinical research in 
minors. 
 
Box 3: Clinical Trials Directive—Article 4  
Clinical trials on minors  
(a) In addition to any other relevant restriction, a clinical trial on minors may be 
undertaken only if:  
(b) the informed consent of the parents or legal representative has been 
obtained; consent must represent the minor's presumed will and may be 
revoked at any time, without detriment to the minor; 
(c) the minor has received information according to its capacity of understand-
ing, from staff with experience with minors, regarding the trial, the risks and 
the benefits;  
(d) the explicit wish of a minor who is capable of forming an opinion and 
assessing this information to refuse participation or to be withdrawn from 
the clinical trial at any time is considered by the investigator or where ap-
propriate the principal investigator; 
(e) no incentives or financial inducements are given except compensation;  
(f) some direct benefit for the group of patients is obtained from the clinical 
trial and only where such research is essential to validate data obtained in 
clinical trials on persons able to give informed consent or by other research 
methods; additionally, such research should either relate directly to a clini-
cal condition from which the minor concerned suffers or be of such a 
nature that it can only be carried out on minors;  
(g) the corresponding scientific guidelines of the Agency have been followed; 
(h) clinical trials have been designed to minimise pain, discomfort, fear and any 
other foreseeable risk in relation to the disease and developmental stage; 
both the risk threshold and the degree of distress have to be specially de-
fined and constantly monitored; 
(i) the Ethics Committee, with paediatric expertise or after taking advice in 
clinical, ethical and psychosocial problems in the field of paediatrics, has 
endorsed the protocol; and  
(j) the interests of the patient always prevail over those of science and society. 
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DIVERSITY AND INCONSISTENCY OF THE CURRENT REGULATION  
Unfortunately, the legal frameworks that govern paediatric clinical research in the 
EU contain contradictory provisions and lack internal consistency in several 
matters. With regard to non-beneficial research, for example, Article 17.2 of the 
Oviedo Convention stipulates that in the absence of a direct benefit to the 
individual research participant, a minor can be involved in research only if the 
study entails minimal risks and minimal burdens. However, Article 4e of the 
Clinical Trials Directive simply requires ‘some direct benefit’ for the group of 
patients. This indicates that the Oviedo Convention endorses a more restrictive 
policy than the Clinical Trials Directive and implies that early stage drug develop-
ment may be compromised in member states that have signed and ratified the 
Oviedo Convention. Also with regard to the right of a minor to veto participation 
in clinical research, contradictory provisions exist: Article 4c of the Clinical Trials 
Directive stipulates that the (principal) investigator must consider the explicit 
wish of a minor to refuse or discontinue participation (given that the minor is 
capable of assessing information and forming an opinion), whereas Article 17.1v of 
the Oviedo Convention states that minors cannot be involved in a study when 
they object to research participation. Thus, the Oviedo Convention grants minors 
a more extensive decision making capacity than the Clinical Trials Directive does.  
In addition to these contradictory provisions, the European legal framework 
contains numerous contingencies that require extensive interpretation. It is not 
clear, for example, what must be understood to be an acceptable risk–benefit 
ratio, what it means to ‘consider’ the explicit wish of a minor, how the capacity of 
minors to make decisions can be assessed, or why the Clinical Trials Directive 
refers to minor research participants as ‘patients’ and links benefits to the ‘group 
of patients’. The fact that many terms are not clearly defined is likely to negatively 
affect the implementation of the European legal framework and creates the need 
for accurate guidance and support.  
At the level of domestic regulation, requirements for the inclusion of minors in 
clinical research (e.g. age criteria) vary from country to country. This obviously 
has profound implications for the conduct of multinational trials.(11) The differ-
ences in interpretation and assessment of the acceptability of risks among 
European member states have important consequences. For example, trial 
protocols can be rejected in one member state because the risks or burdens 
exceed the applicable minimal risk and minimal burden thresholds, but still take 
place in other European member states, where these thresholds are not adopted 
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into national law. Obviously, this may be rather frustrating for researchers and 
minor patients and their parents who are committed to the trial. It also might 
concentrate certain types of non-beneficial research in a selected number of EU 
member states, while successful trials will result in drug licenses that cover all EU 
member states. This generates important justice related issues.  
The premise that risks and burdens call for a proportionate counterpart, by 
preference in the form of a direct benefit to the research subject, challenges the 
involvement of minors in phase I trials or the use of healthy controls in paediatric 
clinical trials. There is considerable controversy over the fact that some risks and 
burdens would not need any compensation and that mere altruism can have a 
place in clinical research.  
ETHICAL ISSUES IN PAEDIATRIC CLINICAL RESEARCH  
The extensive body of legal regulation that has been developed over the past 15 
years has not reduced the need for sound ethical reflection. In this paper, we will 
discuss two major ethical concerns in paediatric clinical research: the acceptability 
of research risks and the informed consent process.  
ACCEPTABILITY OF RESEARCH RISKS  
Clinical trials entail risks and burdens. Minors are a vulnerable population, and one 
should be vigilant to expose vulnerable subjects to risks and burdens. Therefore, 
procedures have been set up to review the acceptability of risks and burdens in 
paediatric clinical trials, in which research ethics committees play a prominent 
role. The main rationale behind the assessment of research risks is that such risks 
call for compensation. This rationale is made operational in the principle of 
proportionality, according to which risks can be justified by a proportionate 
counterpart, for example in the form of a direct benefit to the research subject. 
Against this background, therapeutic or beneficial research (research that is likely 
to generate a direct benefit for the subject involved) is often distinguished from 
non-therapeutic or non-beneficial research (research that is not likely to generate 
a direct benefit for the subject involved). While proportionality can be regarded 
as a general principle, exceptions are possible. Very small risks and burdens (often 
defined as minimal risks and minimal burdens) for example can be deemed 
acceptable without a proportionate compensation in the form of a direct benefit 
to the research subject.  
In practice, deciding upon risks is a precarious enterprise. First, it is hard to 
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measure benefits, risks and burdens and to assess their proportionality in a 
reliable way. Although risks may be determined using objective criteria or other 
systems for risk evaluation(12), such criteria do not account for the subjective 
personal experience of risks, burdens, and benefits of research subjects, which 
may be closely related to their condition, disease and personal experience.  
Second, also the review of risks and burdens by ethics committees is not a 
mechanical or fully objective procedure. Indeed, the deliberation of one and the 
same protocol by different ethics committees may have significantly different 
outcomes. Several factors, such as differences in the composition of ethics 
committees (which varies from country to country) or differences in the methods 
and procedures (e.g., for assessing risks), may nourish diversity in outcome. For 
example, in many European countries non-beneficial research is subjected to a 
stringent minimal risk and minimal burden threshold, while in others, the law 
makes no explicit distinction between therapeutic and non-therapeutic research, 
and proportionality between risks and benefits is not linked to specific risk 
thresholds.  
INFORMED CONSENT FOR PAEDIATRIC CLINICAL RESEARCH  
The doctrine of informed consent has been widely used to serve two functions. 
Legally, informed consent settles the relationship between the researchers and 
the subjects participating in the research. Ethically, informed consent serves as an 
operational implementation of the principle of respect for persons. As such, 
informed consent is meant to protect research subjects from deception, coercion, 
and abuse.  
In its original design, the doctrine of informed consent has been grafted on the 
paradigmatic research subject of the competent adult. As such, valid decisions to 
participate in research must in principle be made voluntarily and by legally 
competent adults, after being duly informed on the nature, significance, implica-
tions, and risks and burdens of the research. For several reasons, this paradigm 
has serious workability problems when applied to the setting of paediatric clinical 
research. First, due to age restrictions, most minors are not capable of granting 
legally valid consent, as they may not have reached the age of majority.(13) 
Second, the capacity to understand and assess information is often still underde-
veloped in minor research subjects. As a result, minors may lack the competence 
necessary to make rational decisions and it may be difficult to inform minors duly. 
Third, parents enjoy considerable discretion in the way they raise their children 
and all the decisions that this entails. Against this background, parents are almost 
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always involved in decisions to enrol a minor in a clinical trial, even when the 
minor is mature enough to make decisions on his or her own.  
The involvement of a competent adult acting as a proxy decision maker is thus 
most often required to enrol a minor in a clinical trial. Obviously, such involvement 
of a proxy does not preclude minors from playing an active role in decisions about 
clinical trial participation. Quite the reverse, if parental consent is to be held to the 
same ethical standard as informed consent provided by a competent adult, the 
child who is participating in research must somehow be involved in the decision 
making process. Several decision making strategies, including (1) dual consent (by 
the minor and the proxy decision maker), (2) consent by the proxy and assent 
(affirmative agreement of a minor to participate in research) by the minor, and (3) 
respect for the dissent of the child, therefore aim at encouraging shared decision 
making and a fair differentiation of decision authority between the proxy decision 
maker and the minor research subject.  
VULNERABILITIES IN THE INFORMED CONSENT PROCESS  
Informed consent, proxy consent, assent, and dissent are simple in design. In 
practice, however, (proxy) informed consent, informed assent, and dissent are 
complex and precarious processes, in which all involved face important obstacles.  
First, informed consent is delicate because understanding what it means to 
participate in research appears hard to realise in practice. For example, research 
shows that parents sometimes do not remember having consented to enrol their 
child in a clinical trial.(14-16) Also the understanding of information and recalling 
what one has consented to are difficult tasks. In this respect, Chappuy and 
colleagues have described an apparent discrepancy between the evaluation of the 
adequacy of information by parents, and the actual understanding and recalling of 
this information by these parents.(16) Parents also tend to overestimate their 
understanding in comparison to an assessors’ estimation of parental understand-
ing.(17) In addition, specific elements such as random allocation and potential risks 
are difficult to understand for parents. The parental understanding of the concept 
of random assignment, for example, has been shown to be doubtful.(18, 19) In a 
study by Ballard and colleagues, only 5% of the parents who understood the study 
also understood the potential risks.(14) The poor understanding of information 
applies to the consent as well as to the assent process.(20, 21)  
Second, informed consent presupposes a distinction between research and 
therapy. In paediatrics, however, research does not necessarily start where 
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therapy ends. This is particularly true for the setting of paediatric oncology, where 
nearly all patients are receiving their treatments in the context of research. But 
also in other settings, several factors may blur the theoretically rigid distinctions 
between therapy and research. For interventional studies for example, it may not 
suffice for parents to be informed about the trial, the risks and the benefits 
according to the specificities described in the study protocol. Rather, they may 
want to know why it would be worthwhile for their child to participate in this trial, 
taking the medical history and current treatment regimen into account. As such, 
trials may enter the therapeutic realm. In addition, minors and their parents often 
find it difficult to understand and keep in mind the difference between research 
and therapy, which may induce ‘therapeutic misconceptions’ in the informed 
consent process.(22) Therefore, when research is framed in a therapeutic context, 
it is of key importance that research is also distinguished from therapy. In this 
respect, it is particularly important to communicate for example what the patient 
can expect after the trial has been terminated.  
Third, the considerable differentiation in expertise, tasks, and responsibilities 
among minors, their parents, and clinicians constitutes asymmetric relationships 
that complicate decisions on research participation.(23) This asymmetry creates a 
dependency of minors and their parents upon each other and upon clinicians to 
provide, explain, and frame information, which raises serious ethical concerns 
about conflicts of interests, uncritical loyalty towards physicians, and information 
bias.(24-27) Nonetheless, all of these issues can be addressed adequately and 
need not be a hurdle to the establishment of relationships of mutual trust between 
all individuals involved in the decision.(28, 29) 
Fourth, one should be vigilant that informed consent does not become mere 
‘documented consent’. For several reasons, the signature of a document by no 
means guarantees a duly informed, well-considered and rational decision. The fact 
that informed consent is granted by competent persons does not imply that 
competences are actually used to take a stance towards a study protocol. Ration-
ality is not necessarily the golden standard of all important decisions that are 
made in life. Other factors (particularly tacit elements like hope, trust, or depend-
ency) may shape decisions to grant informed consent. Several studies indicate 
issues that work against rational decision-making, such as inadequacies in under-
standing research and emotional distress.(16-18, 20, 30, 31) Moreover, Pinxten 
suggested that consent discussions can be well-considered and rational decisions, 
but might be a priori decisions as well, representing and confirming a positive (or 
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negative) stance towards research that parents already had before recruit-
ment.(32) Also, time constraints and the urgency of the situation may influence 
the consent process, for example in emergency settings, or when inclusion in the 
protocol must be completed shortly after the diagnosis of a serious disease.  
DISCUSSION AND CONCLUSION  
Dealing with the ethical issues in paediatric clinical research is complex and 
delicate. Now that a growing body of ethical reflection and legal regulation aims 
to guide the ethical conduct of clinical trials in Europe for more than ten years, it 
is important to reflect on how the available ethical and legal frameworks affect 
actual practice. For example, do the current ethical and legal frameworks ade-
quately respond to the needs of the different stakeholders involved in the actual 
conduct of paediatric clinical research? And (how) are available guidelines 
implemented in practice? When addressing these questions, several considera-
tions should be taken into account.  
First, it must be emphasised that ethics, the law, and ethics committees do not 
establish ethical research conduct as such. Researchers and other health care 
professionals play a key role in the practical realisation of ethical research con-
duct. The evolution of newer ways of data acquisition such as opportunistic 
sampling, dry blood spot technology, and the development of bio banks renders 
new challenges as well. Ethical requirements and legal regulations need to be 
interpreted and applied in practice, taking into account the heterogeneity of the 
paediatric population and the large diversity of research projects.  
Second, one should be vigilant not to confuse the operational implementation of 
ethical principles, with the successful approach of ethical concerns as such. For 
example, obtaining signed informed consent does not automatically imply respect 
for persons.  
Third, one should always keep in mind that it is all about the minor. In this respect, 
minors should not only get opportunities to participate in decisions concerning 
their health and/or participation in clinical research, they should also be given the 
freedom to take or leave these opportunities as they wish. For example, respect 
for minors may be fostered by maximising their participation in the informed 
consent process (taking their understanding and maturity into account). Still, one 
should also consider the wish of a minor not to take part in the informed consent 
process, even if the minor concerned is sufficiently mature and capable of under-
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standing what the trial is about. According to the current ethical and regulatory 
frameworks, however, this may not always be fully possible in practice, for 
example when assent or dual consent is explicitly required.  
Finally, the challenge ahead is to foster ethical conduct in all involved. The mere 
existence of ethical reflection and legal regulation, by no means, implies a suc-
cessful translation to practice. In addition, it would be unreasonable to expect 
from minors and their parents to just own the skills and know-how that are 
required to make well–considered decisions on participation in a clinical trial. 
However, at present, easily accessible support for minors and their parents in 
deciding on research participation is still largely lacking. The same holds for the 
challenging tasks that researchers or other medical practitioners face in paediatric 
clinical trials. Therefore, efforts should be made to employ the vast and unex-
plored potential of empowering all involved for the advancement of ethical 
conduct in paediatric clinical research.  
APPENDIX 
The paper on which this chapter was based, was written in 2012 and published in 
2013. At that time the new European Clinical Trials Regulation was being drafted 
but not yet approved. On April 2nd 2014 the European Parliament approved the 
new Regulation, which will repeal the Clinical Trials Directive as soon as it comes 
into force, expectedly in 2017.(33)  
With regard to research with children, the Regulation differs from the Directive on 
several points. Some differences concern small details, while others are more 
substantial. The relevant article from the Directive (article 4) was shown in box 3 
of this chapter. Article 32 of the Regulation is presented underneath. Important 
differences as compared to article 4 of the Directive are underscored. In chapter 
4, chapter 5 and in the general discussion of this thesis, the changes in the 
Regulation and their implications are further discussed. 
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Box 4:  Clinical trials on minors (article 32 of the Clinical Trials Regulation) – differences as compared to 
article 4 of the Clinical Trials Directive are underscored 
1. A clinical trial on minors may be conducted only where, in addition to the 
conditions set out in Article 28, all of the following conditions are met:  
 
(a) the informed consent of their legally designated representative has been 
obtained;  
(b) the minors have received the information referred to in Article 29(2) in a 
way adapted to their age and mental maturity and from investigators or 
members of the investigating team who are trained or experienced in 
working with children;  
(c) the explicit wish of a minor who is capable of forming an opinion and 
assessing the information referred to in Article 29(2) to refuse participa-
tion in, or to withdraw from, the clinical trial at any time, is respected by 
the investigator;  
(d) no incentives or financial inducements are given to the subject or his or 
her legally designated representative except for compensation for ex-
penses and loss of earnings directly related to the participation in the 
clinical trial;  
(e) the clinical trial is intended to investigate treatments for a medical  
condition that only occurs in minors or the clinical trial is essential with 
respect to minors to validate data obtained in clinical trials on persons 
able to give informed consent or by other research methods;  
(f) the clinical trial either relates directly to a medical condition from which 
the minor concerned suffers or is of such a nature that it can only be 
carried out on minors;  
(g) there are scientific grounds for expecting that participation in the  
clinical trial will produce:  
i. a direct benefit for the minor concerned outweighing the risks and 
burdens involved; or  
ii. some benefit for the population represented by the minor  
concerned and such a clinical trial will pose only minimal risk to, and 
will impose minimal burden on, the minor concerned in comparison 
with the standard treatment of the minor's condition.  
2. The minor shall take part in the informed consent procedure in a way 
adapted to his or her age and mental maturity. 
3. If during a clinical trial the minor reaches the age of legal competence to 
give informed consent as defined in the law of the Member State  
concerned, his or her express informed consent shall be obtained before 
that subject can continue to participate in the clinical trial.  
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ABSTRACT 
Studies of innovative therapies for muscular dystrophy raise unique ethical issues. 
The disease is currently untreatable and relentlessly progressive. A number of 
potentially efficacious treatments are being developed. Those treatments, like all 
treatments, may have unforeseen adverse effects. But patients and families, facing 
a bleak future, may be willing to take the gamble and try those treatments. Many 
doctors are eager to study them. But should research ethics committees (RECs) 
approve them? This chapter discusses these issues and recounts the ways that 
one such study elicited different responses from different RECs. 
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INTRODUCTION 
To protect minors from undue harm in clinical trials, a variety of protective 
measures exist in national and international legislation and ethical guidelines. 
Some measures are used worldwide, such as the requirements of proxy consent 
and ethical review. Other measures differ between countries. For example, some 
countries use the minimal risk threshold for non-therapeutic research while others 
do not. 
The European Union (EU) offers a fascinating setting to consider the strengths 
and weaknesses of various protective measures, since regulations vary within the 
EU. In 2001, the European Parliament and the Council of the European Union 
issued The Clinical Trials Directive to govern research involving human subjects.(1) 
This directive did not adopt a specific risk threshold for non-therapeutic research 
in children. In fact, the directive does not distinguish between therapeutic and 
non-therapeutic research at all. Recently, a new regulation that will replace the 
current directive has been voted in the European Parliament. In this regulation, 
which is directly applicable in all EU member states, the assessment of risks for 
paediatric clinical trials will be harmonised.(2, 3) The Council of Europe’s Conven-
tion on Human Rights and Biomedicine (1997), which is only binding upon those 
European countries that have signed and ratified it, requires that non-therapeutic 
research in children entails no more than minimal risk and minimal burden.(4) By 
consequence, applicable regulation and corresponding review practices may vary 
among member states, and by consequence the risks in a single protocol may be 
assessed differently in different member states. Note that, not unimportantly, if a 
trial results in a market authorisation for a new drug, it will cover the entire EU, 
including the member states in which the trial was rejected. 
It is beyond dispute that minors should be protected against risks of harm when 
participating in research. A minimal risk threshold for non-therapeutic research 
can help protect minors in two ways. First, the threshold itself is a way of prohibit-
ing studies that are deemed too risky. Second, the focus on non-therapeutic 
research can remind ethics committees of the fact that exposing children to risks 
and burdens solely for research reasons requires adequate justification. The 
concept of minimal risk is, however, notoriously difficult to define. Different 
definitions can lead to decisions about research protocols that might prevent 
breakthroughs for patients with urgent and unmet medical needs.  
This chapter discusses a trial carried out in 2008, with minor patients with Du-
chenne Muscular Dystrophy (DMD). It was approved in Belgium and Sweden, but 
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rejected in the Netherlands, where the law and review practices are more restric-
tive. 
THE CASE  
In 2008, a Dutch research team submitted a protocol of a clinical trial investigat-
ing the safety, pharmacokinetics, and effects of subcutaneous injections of an 
antisense oligonucleotide (AON) in children with DMD for review in three EU 
member states simultaneously: The Netherlands, Belgium and Sweden.  
The trial concerned a follow-up of a proof-of-concept study in the Netherlands, in 
which a single dose of PRO-051 (GSK-2402968, Drisapersen) was administered 
intramuscularly to 4 patients.(5) DMD patients would be eligible for the study if 
they were between 5 and 16 years of age, and had no evidence of dystrophin on 
previous diagnostic muscle biopsies. They also had to have mutations that could 
be corrected by means of inducing exon 51 skipping. This might lead to dystrophin 
production in the muscles. The eligibility criteria also included an estimated life 
expectancy of 6 months or more, no serious pre-existing medical conditions, and 
no respiratory insufficiency that made them assisted ventilation dependent. 
Concurrent treatment with glucocorticoids was allowed. 
Children enrolled in the study would receive weekly abdominal subcutaneous 
injections of an AON (0.5 to 6 mg per kilogram of body weight, with 3 patients 
receiving each dose) for 5 weeks. During that time, they would have blood and 
urine samples collected for pharmacokinetic and safety measurements. Adverse 
events would be recorded. Efficacy would be assessed by measurements of 
muscle strength, pulmonary function tests and (two or three) muscle biopsies. No 
control group was included in the study. Instead, the pre-study state of each child 
would be the control. After an interval of 6 to 15 months after the last dose, all 
patients would enter a 12-week open-label extension phase, during which they all 
would receive the AON at a dose of 6.0 mg per kilogram body weight per week. 
The submitted protocol was approved in Belgium and Sweden. In the Netherlands, 
however, the reviewing ethics committee regarded the protocol as unacceptable 
and proposed major changes to the design of the trial. As a consequence, the 
researchers decided to conduct their study only in Belgium and Sweden. The 
different responses turned on different ideas about the riskiness of the trial.  
To support the discussion of the strengths and weaknesses of the different 
regulatory regimens that apply within the EU (and the appropriateness of the 
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strategy chosen in the new European Clinical Trials Regulation, that was recently 
voted in the European Parliament), we invited the principal investigator, a repre-
sentative from both the Dutch and Belgian reviewing committees and a patient 
advocate to comment on this case. Lastly, two independent professionals, who 
have not been involved in this case, comment on this case.  
JAN VERSCHUUREN - PRINCIPLE INVESTIGATOR 
The trial should have been approved for several reasons. First, the objectives were 
important: DMD is most frequently caused by a genetic defect which prevents the 
RNA from translating into protein and results in no (or only a trace amount of) 
dystrophin in the muscles. The study was designed to show whether the admin-
istration of AON could restore the production of dystrophin protein. Second,  
although clinical trials should preferentially be conducted in adults who are 
capable of giving informed consent, the mode of action of the AON and the 
clinical features of DMD make it impossible to conduct a trial in adult patients with 
the disease. More specifically, the severe muscle loss that DMD patients develop 
over time makes it impossible to find a sufficiently large group of eligible adult 
patients. In addition, healthy volunteers would provide no alternative to adult 
patients, since the AON would actually cause DMD in healthy persons. 
Objections to the study focused on the unknown risks of AON. Because the risks 
could not be precisely quantified, they were deemed to be too high for a trial that 
involved children. This assessment ignores important features of DMD. The 
severity of DMD, its profound impact on the lives of the children and parents, its 
relentlessly progressive nature, and the fact that there is no treatment to modify 
the course of the disease make DMD a unique clinical problem. These features of 
the disease should be considered in weighing the risks of an experimental treat-
ment against the risks of untreated disease. DMD patients may be willing to 
accept more risks and burdens than others would allow them to. That is not 
irrational. It must therefore be recognised that an objective risk standard may not 
do justice to this subjective experience of risks and burdens. Finally, the distinc-
tion between therapeutic and non-therapeutic (in the Dutch law described as 
research with or without a direct benefit to the research subject) may be arbitrary 
and unnecessarily block research. By definition, a clinical trial is not a therapy. The 
whole track from phase I tot phase III clinical studies together, however, may 
potentially result in therapy for the patient and the group. In this track, it is hard to 
define exactly where the therapeutic dimension starts in.  
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MONIQUE AL AND GERARD KOËTER - DUTCH ETHICS COMMITTEE 
The Dutch Central Committee on Research with Humans (CCMO), a national 
ethics committee, reviewed both this study and the initial safety study to which 
this study was a follow-up.  
With respect to the trial design, the follow-up study changed the mode of admin-
istration, the dosage and the frequency of administration in comparison to the 
initial safety study. The CCMO judged that such a profound change could hinder 
the correct interpretation of the data and considered the step from a singular 
intramuscular administration to a multiple subcutaneous administration unjusti-
fied. The committee recognised the importance of the trial, but preferred a more 
step-by-step approach where PRO-051 would be administered to healthy adults 
first, to see whether it would reach the muscle after subcutaneous administration.  
The CCMO also focused on the burdens of the research protocol. We judged them 
to be more than minimal. The protocol called for twelve hospital visits, including 
five 24-hour hospitalisations, a skin biopsy, two muscular biopsies, twelve blood 
samples, two insertions of a venous cannula, an MRI of the lower legs, many 
walking tests, muscle tests (including spirometry) and five subcutaneous injec-
tions. The CCMO suggested that the protocol would be more acceptable if fewer 
muscle biopsies were required.  
Therefore, the committee proposed changes in the design leading to a lower 
burden in the investigated boys. If the researchers had adopted these changes, 
the protocol could have been reconsidered by the CCMO. 
ELIZABETH VROOM - PATIENT REPRESENTATIVE 
The Duchenne Parent Project has been involved in the development of the 
antisense technique and the use of AON for DMD in the Netherlands since 1998. 
Our organisation was very disappointed in the decision by the Dutch CCMO that 
led researchers to move their study of this novel technology to other European 
countries. Not having the protocol approved in the Netherlands made the Dutch 
Duchenne community miss out on the opportunity to build up experience with this 
new technology in the Netherlands. In addition, Dutch patients, who could 
potentially benefit from this compound, were prevented access to the trial 
compound, not only during the 4 weeks of the trial but also during the open label 
extension trial that followed. In neighbouring countries, research did enable 
therapeutic breakthroughs for which we are very grateful. We were disappointed, 
of course, that follow-up studies showed less success than we hoped for. We 
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continue to work with regulatory agencies in Europe and the United States to see 
whether this approach to treatment can be approved.  
We regret to have encountered several hurdles to having this trial taking place in 
the Netherlands. First, in spite of plans to change it, the Dutch law is stricter than 
in some other European countries, which made it more difficult to get approval for 
this trial. Second, we feel that some of the suggestions of the Dutch ethics 
committee were ethically questionable. For example the suggestion to give the 
drug to healthy volunteers did not acknowledge prior work showing that, in 
healthy patients, the drug could cause harm by disrupting dystrophin production. 
In such situations, ethics committees need to ask for the advice of external 
experts.  
Most importantly, the ethics committee should have considered the opinions of 
patients and parents regarding risks and burdens of the treatment protocol.(6) 
After all, they are the ones who take the burdens and the risks when participating. 
Many parents and patients would have been willing to participate. By not consid-
ering the viewpoints of patients and parents, the committee made it impossible 
for Dutch centres to participate in studies that were approved in other European 
countries.  
WALTER VAN DEN BOGAERT - BELGIAN ETHICS COMMITTEE  
The Belgian law governing clinical trials and the protection of research subjects 
has specific requirements for trials in minors. In January 2008 this trial was 
accepted by the Ethical Committee of the UZ Leuven. The committee judged that 
the protocol was fully compliant with the Belgian law. More specifically, the 
committee judged that the legal requirement of a ‘potential medical benefit’ was 
met. It also assessed that appropriate measures had been taken to provide minor 
patients and their parents (or other legal representative) with correct and com-
plete information. By consequence, no additional comments or enquiries were 
sent to the principal investigator. 
INDEPENDENT COMMENTATORS 
MATTHEW P. MEYER  
For DMD, emerging therapeutics such as exon skipping PRO-051, in addition to 
protein regulators, cellular therapies and gene replacement therapies offer the 
ability to treat the root causes of disease rather than merely the symptoms. In 
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what would be an historic achievement, we may learn to slow, stop or even 
reverse the course for this terrible, progressive genetic disease. To do so, howev-
er, it may be necessary to challenge accepted norms in paediatric research ethics. 
We may need to develop new ways to think about the how discoveries travel 
from bench to bedside. 
The central question in new drug research is one focused on whether it is ac-
ceptable to expose children to unknown and potentially great risks while testing 
drugs that may not have any immediate benefits. In this case, the Dutch ethics 
committee is criticised for following established guidelines stipulating that 
research protocols must not be burdensome to paediatric participants and that 
the potential for harm must be firmly established from previous safety trials in 
adult subjects. By maintaining those standards, the research review board’s 
decision clashes with the values of the parents and patients, and ultimately 
obstructs potentially valuable clinical research for a vulnerable population of 
children. Parents, doctors, and ethicists all want to do what is best for children. 
But parents and doctors think that the best thing would be to accept research 
risks in the hope for a cure, while the ethicists maintain that risky research will be 
more harmful than beneficial for the child and should thus be restricted.  
In scenarios such as this, there is a delicate balance between parental values, 
patient assent, and objective measures of risk and benefit. All of these must be 
considered and held in perspective by research ethics committees. As evidenced 
by the Dutch chapter of the international organisation, Parent Project Muscular 
Dystrophy, families and patients are better informed and better connected with 
one another than ever before in history. As the ultimate stakeholders, members of 
this and other similar organisations for rare, serious and life-limiting diseases may 
have more influence on the design and conduct of clinical trials than they have 
had in the past. In situations such as muscular dystrophy, it will be harder and 
harder to maintain an inflexible framework of research ethics without taking into 
account the hopes of the patients and the burden of the disease on patients and 
families. It is my opinion that patients and families should be given a greater voice 
in the approval process for ethical research oversight. This needed change of the 
current standards will bring balance to the value of informed participation when 
risk cannot be completely avoided.  
Without changes in current standards, we will not be able to do research on rare 
and fatal paediatrics diseases. We will never be able to test potentially curative 
treatments. Research ethics committees must allow higher risk studies when a 
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child faces a progressive disease for which treatment must be provided during 
childhood. The usual idea that research be done first in competent adults does not 
apply in these situations. The research must be done in children or it will not be 
done at all.  
Children need to be protected from research risks. But the standard for judging 
those risks must be the risks associated with the child’s underlying disease. 
Regulations should recognise that it may be quite rational for parents and patients 
to consent to clinical research on drugs that have never been tried in humans and 
thus that may have unforeseen and unforeseeable risks. Such research is best 
done in settings where patients can be closely monitored, where risks and benefits 
are carefully quantified, and where data safety monitoring boards do not allow 
studies to continue when there is evidence that they are not working. But the only 
way to know what will work and what will not is to allow responsible clinical 
research trials on important emerging therapeutics.  
JOHN D. LANTOS  
In most countries, laws and regulations governing biomedical research were 
developed without much input from the patients who would be the research 
subjects. In many cases, those patients (or their parents) are not very happy with 
the current regulatory systems. The most famous instance in which patients 
opposed the regulations (and ultimately changed them) was the early days of 
research on treatments for Acquired Immunodeficiency Syndrome. Today, many 
other patient groups are trying to change the rules that govern research. Research 
regulations should reflect the values and preferences of the people who partici-
pate in research. This shouldn't be a terribly radical suggestion. But current 
systems, both in the United States and in Europe, often fail by these criteria. 
Research participants have little input into the choice of study questions, the 
study design, data analysis, or publication of results. More importantly, they have 
little input into the regulations that will allow or prohibit them from participating 
in studies. Perhaps it is time to change those regulations in order to better reflect 
the preferences of the research participants.  
FURTHER DEVELOPMENTS 
The study generated promising results that were published in the New England 
Journal of Medicine.(5) Follow-up research was initiated, and the AON was given 
breakthrough therapy designation by the US Food and Drug Administration. 
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Notwithstanding this impressive track record, it was recently announced that a 
Phase III placebo controlled trial of Drisapersen did not show a clinically meaning-
ful treatment difference between the active compound and the placebo for its 
primary endpoint showing clinical relevant improvement including a 12-minute 
walking test. Researchers and the company that manufactures the drug, plan 
further research with the compound.  
EPILOGUE 
This case, which resulted in opposing ethical review outcomes, evoked emotional 
reactions. This is not surprising. Duchenne Muscular Dystrophy is a relentless 
disease that has a huge impact on families. It is reasonable and understandable 
that DMD patients and their parents urgently wish for medical-scientific progress. 
The discussion in this chapter evolved for the greater part around taking the 
patient- and parent perspective into account during the ethical review process. 
While this is undoubtedly important, it has left some other important topics 
undiscussed. Those topics will be discussed in other chapters of this thesis. 
The actual main ethical question that we intended to discuss in this case was 
whether the risks and burdens of this protocol were acceptable and why. Should 
the research risks and burdens, as several of the commentators suggested, have 
been compared to those usually encountered by this patient group, or should they 
be compared to an absolute standard of minimal risk and burden? Moreover, it 
seems that according to the Dutch REC (CCMO), not only the actual degree of 
burden was problematic, but also that the burden was not minimised. Another 
question relevant to the ethical review process was whether this protocol could 
have offered possible direct benefit to the participants. Precise assessment of the 
risks, burdens and benefits is needed to properly answer these questions. This 
topic will be discussed in chapter 6 of this thesis. Remarks on a relative or an 
absolute standard of minimal risk and burden are given in the general discussion 
of this thesis. 
Secondly, after the risk-benefit assessment it may turn out that while the risks 
and/or burdens are higher than what the applicable law permits, the research 
project is so valuable and promising that it makes higher risks/burdens acceptable 
and should anyway be approved. It is important to create space for allowing such 
exceptions, but that should be done accurately and transparently. Also this topic 
is further discussed in the general discussion of this thesis. 
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In one of the commentaries the need for close monitoring of research participants 
was mentioned. Not only should monitoring focus on the safety of the participat-
ing children, but the voluntariness and the experienced burden should also be 
monitored. Obviously, this is important for all paediatric research. Yet it gains 
more importance once higher risks or burdens are accepted in exceptional cases. 
The need for proper guidance on monitoring children during research participa-
tion, as well as practical recommendations, is explicated in chapter 8. In the 
general discussion I reflect on making exceptions to the legal requirements for 
extra valuable and promising research. 
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ABSTRACT 
Children and patients with dementia are both vulnerable populations. Both groups 
are also relatively seldom included in biomedical research. Still, including them in 
clinical trials is necessary, since both groups are in need for scientific innovation 
and new therapies. Their dependence and limited decision-making skills increase 
their vulnerability, necessitating extra precautions when including them in clinical 
trials. Beside these similarities there are also differences between the groups. The 
most obvious one is that children have an entire life ahead of them and will 
become persons with certain ideals and preferences, while adults with dementia 
have lived a life in which they have expressed their ideals and preferences. While 
some of the available research guidelines recognise these differences and set 
specific requirements for groups of incapacitated adults and others for children, 
other documents do not differentiate and only set requirements for subjects 
unable to consent as a single category of subjects. In this chapter we analyse to 
what extent the similarities and differences between the two groups are repre-
sented in legal documents and ethical guidelines. The chapter presents an 
overview and an analysis of the requirements for doing research with children and 
dementia patients. We conclude with suggestions about how to better incorpo-
rate the morally relevant aspects of these two groups in legislation and ethical 
guidelines. 
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INTRODUCTION 
Children start their lives being dependent and without the capacities to make 
decisions. Adults who suffer from dementia, live their lives similarly being de-
pendent and having limited decision-making capacities. In informal language the 
analogy between young children and people with dementia is frequently referred 
to. People with dementia are said to behave childlike, or to ‘go back to child-
hood’.(1, 2) There are, however, profound differences between the two groups. 
The most obvious one being the fact that children have an entire life ahead of 
them and are expected to become persons with certain ideals and preferences, 
while people with dementia have lived an entire life and have expressed their 
ideals and preferences earlier on. Children are presumed to be (partly) incompe-
tent by default, while for adults it has to be demonstrated that they are 
incompetent. Moreover, dependence on others is normal for children, as well as a 
temporary state. For the elderly dependence on others is a loss after having lived 
their lives independently.  
One thing children and adults with dementia have in common is that medical 
research is highly needed for them.(3, 4) For many childhood diseases, as well as 
for dementia, no effective treatment exists and interactions with other medica-
tions are often unknown. Performing clinical trials on these groups is therefore 
absolutely necessary. At the same time the vulnerability of children and of 
dementia patients demands extra precautions when including them in research. 
The available legal documents and ethical guidelines regulating biomedical 
research therefore contain specific articles regulating research with incompetent 
populations. While some of the available laws and guidelines differentiate and set 
specific requirements for groups of incapacitated adults and other specific 
requirements for children, others do not differentiate and set generic require-
ments for all populations unable to consent.  
In this chapter we will provide an overview of the relevant articles in international 
legal documents and ethical guidelines concerning biomedical research with 
children and incapacitated adults. By pointing out the few differences and many 
similarities between protective measures for these two groups, we will show that 
only some of the morally relevant differences between the groups are acknowl-
edged in legislation and ethical guidelines. Furthermore, we will provide 
suggestions about how to better incorporate the morally relevant aspects in 
legislation and ethical guidelines, in order to better respect the dignity and well-
being of these two groups of vulnerable research subjects. 
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METHODS: ANALYSIS OF LEGISLATION AND ETHICAL GUIDELINES 
We selected eight influential legal and ethical documents that set rules or guide-
lines for conducting biomedical research with human subjects, and have focused 
on the articles that refer to subjects who are not able to provide informed con-
sent. None of the guidelines state specific rules for dementia patients. They are 
included in the group of incapacitated adults, which also includes for example 
mentally disabled persons and persons in a coma. Table 1 shows an overview of 
the documents that we analysed, as well as their scope and legal status. 
In each document we looked for articles addressing three topics related to the 
incompetence of children and dementia patients, namely 1) requirements for the 
consent procedure and dissent to participation, 2) the acceptability of risk and 
burden, and 3) protection during the trial including dissent to continue participa-
tion. All documents require that research with incompetent research subjects is 
group-related, meaning that research is only possible with this population and 
cannot be conducted with competent subjects. We will not elaborate any further 
on this requirement since it is fairly straightforward and the same in all selected 
documents. 
 
Table 1: Overview of analysed documents 
Document Scope Legal Status 
Declaration of Helsinki Medical research  
involving human subjects 
No legal force, ethical 
guideline of global 
influence 
Directive 2001/20/EC or 
Clinical Trials Directive 
Clinical drug trials Legally binding in all EU 
member states after  
implementation in  
national law 
Clinical Trials Regulation Clinical drug trials Directly binding upon all 
EU member states 
without prior implemen-
tation. Expected to come 
into force in 2016 
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European Convention  
on Human Rights and  
Biomedicine or  
Oviedo Convention 
Full range of research 
activities in the health 
field involving interven-
tions on human beings 
Applicable to those 
member states of the 
Council of Europe that 
have signed and ratified 
the convention 
Guideline for Good  
Clinical Practice or 
ICH GCP guideline 
Clinical drug trials International ethical and 
scientific quality stand-
ard. No legal force 
directly, but incorporated 
in (inter)national laws 
International Ethical 
Guidelines for Biomedical 
Research Involving  
Human Subjects or 
CIOMS guidelines 
Biomedical research  
involving human subjects 
Ethical guideline, no legal 
force 
Medical Research  
involving Human  
Subjects Act or 
WMO (Dutch  
abbreviation) 
All biomedical research 
involving human subjects, 
with specific require-
ments for drug trials  
(implementation of the 
Clinical Trials Directive) 
National law in the  
Netherlands 
US Code of Federal  
Regulations 
Biomedical research  
involving human subjects 
National law of the USA, 
no legal force in Europe 
but influential to  
European policymakers 
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OVERVIEW OF REQUIREMENTS IN LEGISLATION AND ETHICAL 
GUIDELINES 
REQUIREMENTS FOR THE CONSENT PROCEDURE 
The golden standard for acquiring a person’s permission to be included in re-
search is informed consent.(5) Clearly, incompetent persons cannot provide valid 
informed consent for research participation. All analysed documents require 
consent by a legal representative if the research subject himself cannot provide 
informed consent. The Dutch WMO and the European Clinical Trials Directive 
specifically mention that the consent of the legal representative should reflect the 
presumed will of the research subject.  
In addition to the consent of the legal representative, assent of the research 
subject is sometimes required. Assent can be understood as the incompetent 
participants’ agreement to participate in the trial and does not require full under-
standing of the study and the consequences of participation; therefore it does not 
have the same status as informed consent. What exactly assent is, is not always 
clear, as it is formulated diffusely in the analysed documents. An explicit or 
implicit refusal to participate in a trial is called dissent. Table 2 shows the relevant 
articles for the requirements for proxy consent, assent and dissent, and their exact 
wording. 
The Declaration of Helsinki requires seeking assent for all groups of incompetent 
research subjects.(6) The ICH GCP states that for all groups who cannot provide 
informed consent ‘the subject should, if capable, also sign and personally date the 
written informed consent’.(7) There is no further explanation of the meaning of 
this requirement; therefore it remains unclear whether this should be considered 
as assent. The other documents differentiate between incapacitated adults and 
children. Only some of the documents ask for the child’s assent when possible.(8-
12) The CIOMS guidelines, the Oviedo Convention and the US Code of Federal 
Regulations recognise the growing capacities and maturity of children throughout 
their childhood. Moreover the US Code of Federal Regulations states that the 
assent should actively be given and not merely result from failure to object. The 
Clinical Trials Directive and the Clinical Trials Regulation both set specific re-
quirements for the adaption of information about the trial to the age and level of 
maturity of children, by investigators trained or experienced in working with 
children.(13, 14) The Clinical Trials Regulation and the CIOMS guidelines require 
that in case the minor reaches the age of legal competence to give informed 
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consent during the research trial, informed consent then has to be obtained from 
them. 
Regarding incompetent elderly, the documents that do differentiate between 
children and incapacitated adults, have the prerequisite that the incapacitated 
adult takes part in the authorisation process as far as possible (Oviedo Conven-
tion) or according to his capabilities (CIOMS guidelines). Both the Clinical Trials 
Directive and the Clinical Trials Regulation state that research with incapacitated 
subjects is ‘only allowed if they have given, or have not refused to give, informed 
consent before the onset of their incapacity’. This can be interpreted as having to 
respect the wish of the research participant who was formerly competent to 
consent or to dissent to research participation. That would imply that this re-
quirement is only set for adults who previously have been able to make 
competent decisions and not for adults who have never been competent in the 
first place. In addition, the Clinical Trials Regulation states that ‘incapacitated 
adults will receive information about the trial in view of their capacity to under-
stand it’ and that ‘the subject shall as far as possible take part in the informed 
consent procedure’. Interestingly, both the Dutch WMO and the US Code of 
Federal Regulations differentiate between children and incapacitated adults, and 
require the assent of children, but not of incapacitated adults. 
With respect to dissent to research participation, the Declaration of Helsinki states 
that dissent should be respected. This requirement applies to all groups of 
incompetent research subjects. The Clinical Trials Directive states that the explicit 
wish of both a minor and of an incapacitated adult ‘who is capable of forming an 
opinion and assessing this information to refuse participation (…) from the clinical 
trial (…) is considered by the investigator or where appropriate the principal 
investigator’. In the Clinical Trials Regulation the wording was changed from 
‘considered’ to ‘respected’. The CIOMS guidelines state that a child’s refusal to 
participate should always be respected, while it states for incapacitated adults 
that in exceptional cases the refusal to participate may be overruled.  
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Table 2: Requirements for the consent procedure 
 
 
Consent by a legal 
representative 
Assent/dissent of 
minor 
Assent/dissent of 
incapacitated 
adults 
Declaration of  
Helsinki 
Informed consent 
from the legally 
authorised repre-
sentative (art. 27) 
When able to, 
assent [..] dissent 
should be respect-
ed (art. 29) 
When able to, 
assent [..] dissent 
should be respect-
ed (art. 29) 
ICH GCP Consent by the 
subject's legally 
acceptable Repre-
sentative  
(art. 4.8.8) 
The subject should, 
if capable also sign 
and personally date 
the written in-
formed consent 
(art. 4.8.12) 
The subject should, 
if capable also sign 
and personally date 
the written in-
formed consent 
(art. 4.8.12) 
Clinical Trials  
Directive 
The informed 
consent of the legal 
representative has 
been obtained; 
consent must  
represent the  
subject's presumed 
will (art. 4a & 5a) 
The explicit wish of 
a minor who is 
capable of forming 
an opinion and 
assessing this 
information to 
refuse participation 
[..] is considered by 
the investigator or 
where appropriate 
the principal 
investigator (art. 
4c) 
Inclusion in clinical 
trials of incapaci-
tated adults who 
have not given or 
not refused 
informed consent 
before the onset of 
their incapacity 
(art. 5) 
The informed 
consent of the legal 
representative has 
been obtained; 
consent must 
represent the 
subject's presumed 
will [..] (art. 5a) 
The explicit wish of 
a subject who is 
capable of forming 
an opinion and  
assessing this 
information to 
refuse participation 
[..] is considered by 
the investigator or 
where appropriate 
the principal  
investigator  
(art. 5c) 
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Clinical Trials  
Regulation 
Consent by a legal 
representative  
(art. 31.1a & art 
32.1a) 
The minors have 
received the 
information about 
the trial in a way 
adapted to their 
age and mental 
maturity and from 
investigators or 
members of the 
investigating team 
who are trained or 
experienced in 
working with  
children (art. 32.1b) 
The minor shall 
take part in the 
informed consent 
procedure in a way 
adapted to his or 
her age and mental 
maturity (art. 32.2) 
In case the minor 
reaches the age of 
legal competence 
to give informed 
consent, during the 
research trial his or 
her express  
informed consent 
has to be obtained 
(art. 33.2) 
Research with 
incapacitated 
subjects is only  
allowed if they 
have not given, or 
have not refused to 
give, informed 
consent before the 
onset of their  
incapacity (art. 31) 
The incapacitated 
subjects have 
received the 
information about 
the trial in a way 
adapted in view of 
their capacity to 
understand it  
(art. 31.1b) 
The subject shall as 
far as possible take 
part in the  
informed consent 
procedure  
(art. 31.3) 
 
 
Oviedo  
Convention 
Authorisation by a 
legal representative 
(art. 6.2 & 6.3) 
The opinion of the 
minor shall be  
taken into consid-
eration as an  
increasingly  
determining factor 
in proportion to his 
or her age and  
degree of maturity 
(art. 6.2) 
The individual 
concerned shall as 
far as possible take 
part in the authori-
sation procedure 
(art. 6.3) 
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CIOMS guidelines Consent by a  
parent or legal  
representative is 
given (Guidelines 14 
& 15) 
If such research 
subjects, including 
children, become 
capable of giving 
independent 
informed consent 
during the re-
search, their 
consent to contin-
ued participation 
should be obtained 
(Guideline 9) 
Agreement of each 
child has been 
obtained to the 
extent of the child’s 
capabilities (Guide-
line 14) 
The consent of 
each subject has 
been obtained to 
the extent of that 
person’s capabili-
ties. (Guideline 15) 
WMO Written consent of 
the subject’s  
parents or legal  
guardian (art. 6.1.c) 
The substitute 
consent [..] must 
represent the 
presumed will of 
the subject (art. 
6.3) 
Assent is required 
only if child is older 
than 12 years of age 
(art. 6.1b) 
 
US Code of  
Federal  
Regulations 
The investigator 
has obtained the 
legally effective 
informed consent 
of the subject or 
the subject's legally 
authorized repre-
sentative (45 CFR 
46.116) 
Adequate provi-
sions are made for 
soliciting the  
permission of each 
child's parents or 
guardian (45 CFR 
§46.408) 
Children capable of 
assenting must also 
express their 
willingness to 
participate (45 CFR 
§46.408) 
Failure to object 
should not, absent 
affirmative agree-
ment, be construed 
as assent (45 CFR 
46.402(b)) 
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ACCEPTABILITY OF RISK AND BURDEN 
To protect incompetent populations against disproportionate harm, specific 
protective rules regarding the acceptability of risk and burden in research trials 
have been formulated. The concept of risk is understood to refer to the combina-
tion of the probability and magnitude of some future harm.(15) A distinction can 
be made between research offering direct benefit to the participant (therapeutic 
research), and research that is unlikely to provide any direct benefit to the 
participant (non-therapeutic research). If the research is non-therapeutic, the 
general idea is that the research should contain no more than minimal risks and 
burden. If the research is therapeutic, all documents state that the benefits must 
outweigh the risks, as they also do for therapeutic research with competent 
adults. The requirement that research can be justified on the basis of a favourable 
risk/benefit assessment bears a close relation to the principle of beneficence.(5)  
Table 3 shows how exactly the requirements for accepting risks and burden in 
non-therapeutic trials are formulated. Most, though not all, documents allow for 
non-therapeutic research with incompetent subjects when the risks and burden 
are no more than minimal. The Clinical Trials Directive, however, does not make 
any distinction between therapeutic and non-therapeutic research and thereby 
does not set any upper limit for risk and burden for non-therapeutic research with 
children. All it requires is minimisation of risk and burden. For incapacitated adults 
however, research should either have a prospect of direct benefit to the group of 
patients, or, in case no such benefit is expected, produce no risk at all. It remains 
unclear why the distinction between therapeutic and non-therapeutic research 
only applies to incapacitated adults and not to children, as well as why, compared 
to research with incapacitated adults, higher levels of risk and burden would be 
acceptable for research with children.  
Some documents (the Declaration of Helsinki, the Clinical Trials Regulation and 
the Oviedo Convention) allow for non-therapeutic research with incompetent 
subjects when the risk and burden are no more than minimal. Similar require-
ments, such as negligible risk, minimised and low risk and a minor increase over 
minimal risk are found in other documents (WMO, ICH-GCP, US Code of Federal 
Regulations). The exact wordings can be found in table 3. The US Code of Federal 
Regulations does not provide any protective upper risk limits for research with 
incapacitated adults (while it does for minors). On the contrary, the Clinical Trials 
Directive sets stricter rules with respect to risks and burden for non-therapeutic 
research with incapacitated adults than for research with children. Research with 
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incapacitated adults is only allowed when there is a prospect of benefit outweigh-
ing the risks or when it produces no risk at all. 
Children and dementia patients are both vulnerable populations with limited 
decision-making capacities. It remains unclear what the basis would be for 
accepting different levels of risks and burden for the two groups of research 
subjects, as the Clinical Trials Directive and the US Code of Federal Regulations 
do. In our view, there are no relevant differences between these groups that could 
justify these differences in accepting risks and burden. 
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Table 3: Requirements for non-therapeutic research 
 
 Children Incapacitated adults 
Declaration of Helsinki Minimal risk and minimal 
burden (art. 28) 
Minimal risk and minimal 
burden (art. 28) 
ICH GCP The foreseeable risks to 
the subjects are low (art. 
4.8.14.b) 
Negative impact on 
persons well-being is 
minimised and low (art. 
4.8.14.c) 
The foreseeable risks to 
the subjects are low (art. 
4.8.14.b) 
Negative impact on 
persons well-being is 
minimised and low (art 
4.8.14.c) 
Clinical Trials Directive Some direct benefit for 
the group of patients is 
obtained from the clinical 
trial [..] (art. 4e) 
There are grounds for 
expecting that adminis-
tering the medicinal 
product to be tested will 
produce [..] or produce 
no risk at all (art. 5i) 
Clinical Trials Regulation Minimal risk and minimal 
burden (art. 32.g.ii) 
Minimal risk and minimal 
burden (art. 31.g.ii) 
Oviedo Convention Minimal risk and minimal 
burden (art. 17.ii) 
Minimal risk and minimal 
burden (art. 17.ii) 
CIOMS guidelines Risks are no more likely 
and not greater than the 
risk attached to routine 
medical or psychological 
examination of such 
persons. Slight or minor 
increases above such risk 
may be permitted when 
there is an overriding 
scientific or medical 
rationale for such increas-
es and when an ethical 
review committee has 
approved them  
(Guideline 9) 
Risks are no more likely 
and not greater than the 
risk attached to routine 
medical or psychological 
examination of such 
persons. Slight or minor 
increases above such risk 
may be permitted when 
there is an overriding 
scientific or medical 
rationale for such increas-
es and when an ethical 
review committee has 
approved them  
(Guideline 9) 
WMO Negligible risks and 
minimal burden (art. 4) 
Negligible risks and 
minimal burden (art. 4) 
US Code of Federal 
Regulations 
Minimal risks (§46.404) or 
the exception of a slight 
or minimal increase over 
minimal risk (§46.406) 
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PROTECTION DURING THE TRIAL - MONITORING AND WITHDRAWAL 
Competent research subjects always have the possibility to withdraw their 
consent at any time, for whatever reason. Incompetent research subjects do not 
have this option, as they could not consent in the first place. They therefore 
depend on others for protecting their well-being during the trial. In this paragraph 
we discuss protective measures that aim to safeguard the well-being of incompe-
tent subjects during the performance of the trial. They can roughly be categorised 
into monitoring the risk and burden and the obligation to withdraw a subject from 
a trial when necessary. If the subject is capable of expressing his wish to discon-
tinue participation, in other words objects to further participation, this wish should 
be respected; in the guidelines this is also called dissent. Dissent in this context 
means ‘the wish to discontinue participation’ and is not the opposite of consent or 
assent prior to inclusion. The measures being discussed in this paragraph appeal 
to the principles of respect for autonomy (even if this autonomy is underdevel-
oped or partly diminished) and of non-maleficence.(5) Table 4 shows the articles 
relating to these two categories. 
The need for monitoring the risks and burdens for research subjects seems to be 
obvious and important (ICH GCP, Clinical Trials Directive, Clinical Trials Regula-
tion, WMO), however, not all analysed documents have explicit rules for this. In 
order to provide sufficient protection for vulnerable research subjects, one needs 
to be sure that the level of risk and burden does not exceed the level that was 
found acceptable during the reviewing procedure. Only the ICH GCP guidelines 
state explicitly what the consequence of monitoring should be. Namely, subjects 
should be withdrawn if they appear unduly distressed. Monitoring should aim to 
protect the research subject against unexpected disproportionate harm. With-
drawing subjects who are unduly harmed or distressed, thus seems to be a logical 
consequence. 
Most documents set requirements for subjects who want to discontinue their 
participation in research. The Declaration of Helsinki stipulates that dissent should 
be respected. The Oviedo Convention phrases this slightly differently, mentioning 
that research may only be performed when ‘the subject does not object’. Further 
elaboration on how to interpret ‘objection’ is lacking. The Dutch WMO states for 
both incapacitated adults and children that, should they ‘object (…) the person in 
question will be excluded from participation’. How to respond to signs of objec-
tion is written in accompanying codes of conduct. There are separate codes for 
research with children, with incapacitated elderly persons and with mentally 
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disabled persons.(16-18) The US Code of Federal Regulations itself has no re-
quirements of this kind, but the accompanying guidebook for IRBs states that the 
child’s dissent should normally be respected. Only in cases of ‘research that offers 
the child the possibility of a direct benefit that is important to the health or well-
being of the child and is available only in the context of the research, (…) a child's 
dissent, which should normally be respected, may be overruled by the child's 
parents, at the IRB's discretion.(15) 
The Clinical Trials Directive states that the explicit wish of a minor and incapaci-
tated subject ‘who is capable of forming an opinion and assessing information to 
refuse participation or to be withdrawn from the clinical trial at any time is 
considered by the investigator or where appropriate the principal investigator’. In 
the Clinical Trials Regulation the wording is changed from ‘considered’ to ‘re-
spected’, which makes the requirement slightly stricter. Only the CIOMS guidelines 
differentiate between requirements for children and incapacitated adults. Where-
as the CIOMS guidelines state that a child’s refusal to continue participation 
should always be respected, the CIOMS guidelines do allow overruling refusal of 
incapacitated adults in exceptional cases. It remains unclear on what ground this 
differentiation is based.  
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Table 4: Protection during the trial 
 Monitoring Withdrawal 
Declaration of Helsinki  The potential subjects 
dissent should be re-
spected (art. 29) 
ICH GCP Subjects in these trials 
should be particularly 
closely monitored and 
should be withdrawn if 
they appear to be unduly 
distressed (art. 4.8.14) 
Subjects in these trials 
should be particularly 
closely monitored and 
should be withdrawn if 
they appear to be unduly 
distressed (art. 4.8.14) 
Clinical Trials Directive The risk threshold and 
degree of distress are 
closely monitored 
(art. 3g) 
The explicit wish of a 
minor/incapacitated 
subject who is capable of 
forming an opinion and 
assessing information, to 
refuse participation or to 
be withdrawn from the 
clinical trial at any time is 
considered by the 
investigator or where 
appropriate the principal 
investigator  
(art. 4c & 5c) 
Clinical Trials Regulation The risk threshold and the 
degree of distress are 
specifically defined in the 
protocol and constantly 
monitored (art. 28.1.e) 
The explicit wish of an 
incapacitated subject/ 
minor who is capable of 
forming an opinion and 
assessing information 
referred to in Article 
29(2), to refuse participa-
tion in, or to withdraw 
from, the clinical trial at 
any time, is respected by 
the investigator’ or where 
appropriate the principal 
investigator (art. 31.1c & 
32.1c) 
Oviedo Convention  The person concerned 
does not object  
(art. 17.1.v) 
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CIOMS guidelines  For children: Refusal to 
participate or continue 
participation should 
always be respected 
(Guideline 14) 
For incapacitated adults: 
a prospective subject's 
refusal to participate in 
research is always 
respected, unless, in 
exceptional circumstanc-
es, there is no reasonable 
medical alternative and 
local law permits overrid-
ing the objection  
(Guideline 15) 
WMO The risk threshold and the 
degree of distress have to 
specially defined and 
constantly monitored’ 
(art. 13.e.c), only for 
clinical  
trials 
Should an incompetent 
research subject object to 
the treatment adminis-
tered or behavioural 
strategy imposed, the 
person in question will be 
excluded from participa-
tion (art. 4.2) 
US Code of Federal  
Regulations 
 In cases of research that 
offers the child the 
possibility of a direct 
benefit that is important 
to the health or well-being 
of the child and is availa-
ble only in the context of 
the research, [..] a child’s 
dissent, which should 
normally be respected, 
may be overruled by the 
child’s parents, at the 
IRB’s discretion’ (IRB 
guidebook chapter 6) 
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DISCUSSION 
The wide variety of requirements found in legal and ethical guidelines concerning 
medical research with vulnerable groups of research subjects, shows that the 
morally relevant particularities of the different groups are not always acknowl-
edged. Children and dementia patients are morally similar in some respects, but 
rather different in others. Table 5 shows which documents differentiate between 
children and incapacitated adults and which documents do not. Besides some 
noteworthy differences between the groups of incapacitated adults and children, 
we have seen that there are a great number of legal documents and ethical 
guidelines with a variety of rules for conducting research with groups of incompe-
tent participants. The variation in these documents may hinder the guiding 
function these documents aim to provide. Both ethical guidance of research trials 
and the adequate protection of research subjects are not served by a multitude of 
requirements. 
SIMILARITIES 
Children and dementia patients both form vulnerable populations. They have 
reduced capacities to protect themselves from harm, and deserve additional 
protection against disproportionate harm in research. Beside their vulnerability 
they share the characteristic of having limited decision-making capacity. Their 
(partial) incapacity to make decisions is, however, not a permanent condition. The 
gradual process of either gaining or loosing autonomy is an important similarity 
between the two groups. For both children and dementia patients, there is a 
phase in which they are not yet, or not anymore, fully capable of deciding about 
research participation. People in a state of partial incapacity to decide need 
guidance or assistance in decision-making. Requiring proxy consent combined 
with the assent of the person concerned for participation in research would 
respect this state of partial decision-making incapacity. In our overview we 
showed that respect for the gradual process of gaining or loosing autonomy is 
expressed in some, but not all discussed documents. We argue that a phase of 
shared decision making is equally important and feasible for subjects who loose 
their decision-making capacity, as it is for subjects who are gaining competence, 
and that it should be a requirement for the research participation of both children 
and incapacitated adults. 
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Table 5:  Legal documents and ethical guidelines with different/similar requirements  
for children and incapacitated adults. 
 Documents that set  
different requirements  
for children and  
incapacitated adults 
Documents that set the 
same requirements for 
children and incapacitat-
ed adults, or make no 
distinction between the 
two groups 
Assent Clinical Trials Directive 
Clinical Trials Regulation 
Oviedo Convention 
WMO 
US Code of Federal  
Regulations 
Declaration of Helsinki 
ICH GCP  
CIOMS guidelines 
Acceptability of risks and 
burden in non-therapeutic 
trials 
Clinical Trials Directive 
US Code of Federal  
Regulations 
Declaration of Helsinki 
ICH GCP 
Clinical Trials Regulation 
Oviedo Convention 
CIOMS guidelines 
WMO 
Monitoring burden  ICH GCP 
Clinical Trials Directive 
Clinical Trials Regulation 
WMO 
Withdrawal/dissent CIOMS guidelines 
US Code of Federal  
Regulations 
 
Declaration of Helsinki 
ICH GCP  
Clinical Trials Directive 
Clinical Trials Regulation 
Oviedo Convention 
WMO 
 
With respect to the acceptability of risk and burden, there is no good reason for 
not providing elderly patients with the same level of protection as children. As for 
respect for dissent, one could even argue that signs of resistance and expressions 
of dissent should be taken more seriously in dementia patients than in children. 
Children are dependent beings by default, and are used to have decisions being 
taken for them, whereas elderly people might experience embarrassment and 
humiliation when things do not go according to their choice and their wish is not 
taken seriously enough. Such differences between children and dementia patients 
are morally relevant when it comes to how to treat them as research subjects, but 
are not represented in any of the analysed documents.  
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DIFFERENCES 
Despite the similarities between the two groups, there are also profound differ-
ences that are morally relevant. In our view, the most important difference is the 
fact that children have not yet (fully) formed preferences and wishes, whereas 
dementia patients have formerly lived independent lives and have had the chance 
to express their wishes earlier on. Interestingly, only two of the documents we 
analysed have a special requirement that appeals to the prior wishes of incapaci-
tated adults. Only the European Clinical Trials Regulation and the European 
Clinical Trials Directive require that the incapacitated adult has given or not 
refused to give informed consent before the onset of their incapacity. Possibly 
this is because there are no specific articles concerning dementia patients, as they 
fall under the broader category of incapacitated adults. We recommend taking 
into account formerly expressed wishes of dementia patients when possible, for 
example by means of advance directives specified for research participation. 
Dementia patients differ from some other groups of incompetent adults, for 
example mentally disabled persons, who have never been competent. It might be 
unfeasible to set requirements that do justice to the particularities of all groups of 
incapacitated adults. In order to respect the past autonomy of dementia patients, 
it is however necessary to treat them as a separate group, not as a part of the 
larger group of incapacitated adults or of incompetent persons in general (includ-
ing children). 
Children are in the process of becoming autonomous beings, and should be 
treated as such. Even though their growing capacities are recognised by requiring 
assent when possible, only two of the documents require the consent of the child 
as soon as it reaches the legal age of competence. However, in long-term research 
studies, children may become competent during the study. From the discussed 
documents, only the Clinical Trials Regulation and the CIOMS guidelines require 
explicitly that a child should be asked for his/her consent when he/she becomes 
competent during the trial. This may be a relatively rare situation, but it is none-
theless important to assure correct consent practices in these cases as well. We 
recommend that legislation and guidelines require the consent process to be 
repeated once a participating child reaches legal age during the performance of 
the research study.  
We have shown that children and dementia patients are morally similar in some 
respects, and different in others. These particularities should be reflected in legal 
documents and ethical guidelines concerning biomedical research. In our view, the 
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extra protective measures we suggest, contribute to better respecting the morally 
relevant particularities of both groups of research subjects.  
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On 2 April 2014, the European Parliament approved the new European Union 
Clinical Trials Regulation.(1) This regulation will replace the Clinical Trials Directive, 
which has failed to achieve its goal of simplifying the scientific and ethical review 
of clinical trials in the EU.(2, 3) Unlike the directive, the regulation has binding 
legal force in all EU member states. Important innovations include a central 
database and a partly coordinated review system. Both of these steps could help 
simplify the review system and improve the quality of assessments.  
However, when it drafted the regulation, quality improvement did not seem to be 
the European Commission’s main concern. Despite serious criticisms and several 
adjustments, the approved document may still impair, rather than improve, the 
quality of the ethical review of trial protocols.(4-9) This puts the protection of 
European research subjects at risk.  
Before discussing our two main concerns, we need to explain the new review 
system. Currently, all member states assess the request for authorisation of a 
multinational clinical trial independently of one another. To simplify and speed up 
authorisation, the European Commission has decided that the risk-benefit assess-
ment (and the preceding scientific assessment) should be performed in a 
coordinated manner.(5, 9) With this in mind, sponsors propose one member state 
to be the reporting one, and this member state makes the final decision on the 
risk-benefit assessment. The other member states are asked for their input, but 
within a very tight time frame. Their main task is to assess the ethical and local 
aspects, such as the informed consent material, the investigators’ qualifications, 
and the suitability of the trial site, for their own territory. Thus, two types of 
assessment run in parallel: the coordinated risk-benefit assessment (by the 
reporting member state, binding on all member states), and the assessment of the 
ethical and local aspects mentioned above (by all member states acting individu-
ally).  
We approve the idea of coordinating the assessment of multinational clinical trials. 
However, in the case of such centralised judgments, the quality of these judg-
ments should be guaranteed. This is not the case.  
We are mostly worried about the risk-benefit assessment being taken out of the 
ethical domain. The European Commission fails to acknowledge that this assess-
ment is widely regarded as a crucial part of ethical review.(10) As a result, the 
regulation does not require input from an ethics committee.(9) This is worrying 
because the purpose of ethics committees is to focus on the protection of 
potential research subjects. This perspective is indispensable when the risks of 
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harm and potential benefits of a clinical trial are being assessed. It is worth noting 
that studies may be ethically unacceptable, despite having a scientifically favour-
able harm-benefit balance, if the research question could be answered with fewer 
risks or burdens for the research subjects.  
Furthermore, some studies have a favourable harm-benefit balance because of the 
expected benefits for society but are not expected to benefit the research 
subjects themselves. Such studies should be evaluated very carefully, particularly 
when they involve children or others who are considered unable to provide 
informed consent.(10) The regulation provides guidelines for research in these 
groups, but applying these guidelines appropriately requires specific ethical 
expertise.(9) Ideally, a multidisciplinary committee with wide ethical expertise 
should critically assess the risks and potential benefits and demand changes in the 
design when needed.  
A complicating factor is that sponsors are free to choose the reporting member 
state. This might tempt sponsors to choose member states that are known for 
their less onerous assessments. Thus, when aiming for high quality review, the 
question of which body should perform the risk-benefit assessment cannot be left 
to the member states’ own discretion.  
Our second concern relates to the quality of the ethics committees. During the 
first public consultation round many respondents asked for quality standards and 
an accreditation system for these committees,(4) but the European Commission 
has ducked this request—a truly missed opportunity. This is because even though 
ethical matters are regarded as a national affair, the new regulation would provide 
a great opportunity for improving the widely varying quality of the EU’s ethics 
committees by setting clear quality standards.(11) Leaving these committees just 
as diverse as before means that European citizens of different member states 
cannot rely on the same level of protection. Moreover, if ethics committees are 
also involved in the coordinated risk-benefit assessment, which we have just 
argued for, every opportunity to improve their quality should be taken. The 
judgment of the ethics committee of the reporting member state will then cover 
the protection of the research subjects in all member states.  
We recognise that it will be difficult to make substantial changes to the new 
regulation now that it has been approved. However, it is wrong to rush through a 
system that is clearly inadequate. European research subjects deserve a clinical 
trials regulation that has a sound ethical basis. Therefore, we recommend that this 
new legislation is adjusted before coming into force.  
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In practical terms, we recommend that the ethics committee of the reporting 
member state should be assigned as the key figure in an integrated risk-benefit 
assessment system. In addition, this committee should be allowed enough time to 
take scientific advice from experts and to cooperate effectively with the ethics 
committees of the other member states. Lastly, a quality and accreditation system 
should be established for all ethics committees so that all trials are reviewed by 
competent committees.  
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ABSTRACT  
Background: Paediatric research protocols often consist of a combination of 
procedures with-, and procedures without the prospect of direct benefit (i.e. only 
for research purposes). However, the risks and anticipated benefits of a study are 
usually reviewed for the protocol as a whole. Our primary objective was to assess 
how frequently paediatric research protocols consist of a combination of proce-
dures with-, and procedures without the prospect of direct benefit. A secondary 
objective was to identify possible practical drawbacks of a procedure-level 
approach for RECs, which could impede the implementation of this method. 
Methods: 36 protocols labelled and reviewed as with-, and 36 protocols labelled 
and reviewed as without the prospect of direct benefit were analysed. For the 
secondary research question group discussions were held with research ethics 
committees.  
Results: Of the 36 protocols labelled without the prospect of direct benefit, in 15 
cases the study intervention was found to potentially benefit the participants 
(besides containing several procedures conducted for research purposes only). Of 
the 36 protocols labelled with the prospect of direct benefit, 34 were found to 
contain procedures that were done solely for research purposes (in addition to 
the potentially beneficial study intervention). Remarks during the group discus-
sions included the extra time and special expertise the methods would require 
during the review process, as well as the need for a clear format and definitions. 
Conclusions: Most paediatric research protocols include both procedures with, 
and procedures without direct benefit. A procedure-level approach may improve 
ethical review by doing more justice to the complexity of protocols. We propose a 
new definition of direct benefit, needed to distinguish between procedures with- 
and without the prospect of direct benefit. 
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INTRODUCTION 
Including children in medical research requires sensitive and careful ethical review 
of the risks and burdens involved. The reason is that children are vulnerable and 
not (fully) able to freely and deliberately choose to participate in research.(1) It is 
crucial to assess whether research protocols entail any potential direct benefits 
for the participants that can compensate for the risks and burdens.(1, 2) In the 
absence of direct benefit stricter requirements apply with regard to the permitted 
levels of risk and burden.(3-5)  
Usually the risks and benefits of a study are assessed for protocols as a whole. But 
in practice research protocols often consist of a combination of procedures 
conducted purely for research reasons, and procedures that might also directly 
benefit the participants.(6) For example, participation in interventional drug 
research may offer potential direct benefit to the subjects by administering a new 
drug, but frequently also involves undergoing extra procedures for the purpose of 
data collection. These two types of procedures require a different moral evalua-
tion. Procedures that are done solely for generating data should involve no more 
than minimal risk and burden, whereas for procedures that offer potential direct 
benefit, the risks and burdens should be proportional in relation to the anticipated 
benefit. If such complex research protocols are classified in totality as offering 
direct benefit, research ethics committees (REC) may not assess them sufficiently 
critically. As a result, children may be exposed to undue risks and burdens. And 
vice versa, when reviewing protocols in totality as not offering potential direct 
benefit, RECs may reject protocols unnecessarily. 
To tackle this problem, several ethicists have proposed to shift the primary focus 
in the risk-benefit assessment from the protocol as a whole, to the separate 
procedures within the protocol.(6-9) These procedure-level approaches, as we 
call them, focus on assessing the risks/burdens and potential benefits of the 
separate procedures before making an overall risk-benefit assessment for the 
study in total. Figure 1 provides a graphic representation of a procedure-level 
approach. 
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So far, only the new and yet to be approved CIOMS-guidelines clearly state that 
RECs must focus on separate procedures first. In paragraph 4 it is stated that “The 
risks and potential benefits of each individual research intervention or procedure 
in the study must first be evaluated. Then, in a second step, the aggregate risks 
and potential benefits of the entire study must be assessed and must be consid-
ered appropriate”.(10) However, neither the recently revised Declaration of 
Helsinki, nor the new European Clinical Trials Regulation makes any reference to a 
procedure-level focus.(3, 11) The US Code of Federal Regulations is ambiguous, as 
it speaks in some paragraphs of intervention or procedure and in others of 
study.(4)  
AIM 
With this paper we aim to give insight into the need for and feasibility of a 
procedure-level approach. Our primary objective was to assess how frequently  
paediatric research protocols consist of a combination of procedures with-, and 
procedures without the prospect of direct benefit. A secondary objective was to 
identify possible practical drawbacks for RECs, which could impede the imple-
mentation of this method.  
METHOD 
CONCEPTS AND DEFINITIONS 
The data analysis in this study relies on the chosen definitions of the used con-
cepts. We used the following definitions.  
- Procedure is used as an umbrella concept for all separate parts of a clinical 
study, including the studied interventions.  
- By procedure-level approach we mean a risk-benefit assessment that fo-
cuses first on each separate procedure, instead of a primary focus on the 
protocol as a whole. 
- By procedures without the prospect of direct benefit we mean procedures 
performed for data collection purposes; i.e. procedures that are not also in 
the medical interests of the participants. By procedures with the prospect 
of direct benefit, we mean procedures that may also directly benefit the 
participants. These definitions are most common in the guidelines and lit-
erature; terms like (non-)therapeutic or (non-)beneficial are more 
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controversial and therefore avoided. We use the same terminology for the 
full protocols; but this classification depends on the RECs that labelled and 
reviewed these protocols.  
- In our analysis we used the most common and rather general definition of 
direct benefit, namely; medical benefit that can reasonably be expected 
and is caused directly by a procedure in the study. It is broadly accepted 
that other types of benefit, such as collateral benefit, indirect benefit, aspi-
rational benefit and inclusion benefit, should not count as direct.(12-15) 
PILOT 
A pilot study was done in which we analysed four research protocols labelled 
without the prospect of direct benefit. We designed a case-record form to collect 
data from the protocols and adjusted it after the pilot study.  
DATA COLLECTION 
In the Netherlands RECs are supervised by a central committee (named CCMO) 
that reviews protocols that require special expertise, among them paediatric 
intervention studies without the prospect of direct benefit. We selected all 106 
files of the paediatric intervention studies in the database of the CCMO from the 
years 2006-2012. We excluded 1) protocols that had not been reviewed by the 
CCMO (for example because the researchers retracted them, or because they 
were passed on to another REC), 2) protocols that did not concern drug trials, 
vaccination trials, nutrition trials, diagnostic trials or surgical trials, 3) protocols 
that were rejected for reasons like poor quality or incompleteness, 4) protocols of 
which the researchers objected against us having access to their files and 5) 
protocols labelled and reviewed with the prospect of direct benefit (that were 
reviewed by the CCMO either because they required special expertise, or because 
they were labelled protocols with direct benefit later on in the review process). 
This resulted in a selection of 36 files. We selected an equal amount of paediatric 
protocols with the prospect of direct benefit (36 files) reviewed during the same 
period of time, from 3 of the 23 local Dutch RECs (these are qualified for review-
ing paediatric protocols with the prospect of direct benefit), namely the 
committee of the Leiden University Medical Centre in Leiden, the MEC-U in 
Nieuwegein and the committee of the Erasmus University Medical Centre in 
Rotterdam. We signed a confidentiality agreement before starting data collection. 
  
A procedure-level approach to the risk-benefit assessment 
 
83 
 
ANALYSIS 
The first research question was how frequently protocols consist of a combination 
of procedures with- and procedures without the prospect of direct benefit. 
Initially, WB analysed the protocols labelled with the prospect of direct benefit 
and AW analysed the protocols labelled without the prospect of direct benefit. 
Both analysed complex cases in either category. 
In the protocols labelled without the prospect of direct benefit, we identified the 
procedures that could potentially provide direct benefit for the participants. We 
limited ourselves to identifying the possibility of a direct benefit and did not judge 
whether the possible benefit could compensate for the risk and burden involved, 
as this is the next step in the risk-benefit assessment.  
For the protocols that were labelled with the prospect of direct benefit, we first 
looked for procedures that the researchers reported in the application form as not 
offering the prospect of direct benefit. We also checked every intervention that 
was the object of study, to see whether these study interventions could indeed 
provide any direct benefit, as the researchers claimed.  
GROUP DISCUSSIONS 
Our second research question was whether REC members would see practical 
drawbacks that could impede implementation of the procedure-level approach. 
To explore this question, we met with two Dutch RECs as well as with the assem-
bly of chairmen of all accredited RECs in the Netherlands. After presenting our 
results, we asked REC members what they would need to implement a procedure-
level approach in their review process. The practical applicability and feasibility of 
a procedure-level approach were discussed. The group discussions, which had an 
explorative character, were recorded and the mentioned concerns and ideas were 
collected.  
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Protocols with prospect of 
direct benefit  
(36) 
N (%)
Protocols without prospect of 
direct benefit  
(36) 
N (%)
Total  
 
(72) 
N (%)
Type of intervention
Drug 30 (83) 15 (42) 45 (63)
Vaccination 1 (3) 3 (8) 4 (6)
Nutrition 2 (6) 10 (28) 12 (17)
Diagnostic 1 (3) 8 (22) 9 (13)
Surgical 2 (6) 0 (0) 2 (3)
Phase
I 0 (0) 7 (19) 7 (10)
I / II 3 (8) 3 (8) 6 (8)
II 3 (8) 1 (3) 4 (6)
II / III 1 (3) 0 (0) 1 (1)
III 15 (42) 0 (0) 15 (21)
IV 5 (14) 1 (3) 6 (8)
Not applicable 6 (17) 23 (64) 29 (40)
Other research that involves drugs 3 (8) 1 (3) 4 (6)
Age of participants
Premature / preterm neonates 3 (8) 2 (6) 5 (7)
Term neonates 6 (17) 5 (14) 11 (15)
1 - 23 months 9 (25) 13 (36) 22 (31)
2 - 5 years 12 (33) 14 (39) 26 (36)
6 - 8 years 18 (50) 18 (50) 36 (50)
9 - 11 years 20 (56) 21 (58) 41 (57)
12 - 15 years 20 (56) 22 (61) 42 (58)
16 - 18 years 18 (50) 17 (47) 35 (49)
unspecified 4 (11) 1 (3) 5 (7)
Health status
Having / at risk for the disease studied 36 (100) 28 (78) 64 (89)
Not having / at risk for the disease studied 0 (0) 6 (17) 6 (8)
Unknown 0 (0) 2 (6) 2 (3)
Number of participants
1 - 10 0 (0) 4 (11) 4 (6)
11 - 20 0 (0) 11 (31) 11 (15)
21 - 40 6 (17) 7 (19) 13 (18)
41 - 75 7 (19) 1 (3) 8 (11)
76 - 100 6 (17) 5 (14) 11 (15)
101 - 250 9 (25) 4 (11) 13 (18)
250 + 8 (22) 4 (11) 12 (17)
Ethics approval
Positive 32 (89) 25 (69) 57 (79)
Negative 2 (6) 10 (28) 12 (17)
Not yet approved at time of data collection 2 (6) 1 (3) 3 (4)
Table 1: Characteristics of protocols 
  
Many protocols included children from various age groups; therefore the sum of the percentages is more than 100%. 
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RESULTS 
PROTOCOLS: GENERAL CHARACTERISTICS 
The characteristics of the analysed protocols are presented in table 1. Of the 72 
protocols 45 were drug trials, 12 were nutrition trials, 9 were diagnostic trials, 4 
were vaccination trials and 2 were surgical trials. The majority of the studies (89%) 
were carried out with children who either had the disease studied or were at risk 
for the disease. Children between the ages of 9 and 15 were represented most in 
the studies. 57 protocols were approved and 12 were rejected. The remaining 3 
protocols were still under review at the time of data collection.  
PROTOCOLS WITHOUT THE PROSPECT OF DIRECT BENEFIT 
Of the 36 protocols that were labelled without the prospect of direct benefit, 15 
were found to contain a procedure that could offer a direct benefit (in addition to 
one or more procedures that could not). In all of these cases it was the study 
intervention that offered the prospect of direct benefit. In 13 of the 15 cases, the 
researchers mentioned the possible benefit when applying for ethical review, but 
the REC nevertheless classified the protocol as without the prospect of direct 
benefit. Interestingly, in 8 of the other 21 protocols, i.e. the protocols in which we 
could not identify the possibility of direct benefit, the researchers also mentioned 
possible benefit.  
The 15 protocols in which the study intervention could be regarded as offering 
possible direct benefit, can be grouped into the following five categories:  
1. Five protocols concerned early phase drug trials studying a disease for 
which no or insufficient treatment exists. In these cases the drug would be 
administered in such a way (duration and dose) that a therapeutic benefit 
could reasonably be expected.  
2. In three cases, the protocol concerned research on the pathophysiology of 
a disease or on a new diagnostic test, but also included an intervention 
that could directly benefit the subjects. An example of a protocol in this 
category is a study aimed at a better diagnosis of early-stage asthma in 
children. As part of this study, recurrently wheezing children were treated 
with inhalation corticosteroids for two months, which could directly benefit 
their health.  
3. Two protocols concerned pilot studies. These studies were labelled with-
out a prospect of direct benefit because a possible therapeutic benefit 
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could not be statistically demonstrated; however, this effect nevertheless 
could be expected for the few individual participants.  
4. In three cases, the research intervention was not likely to directly benefit 
the subjects, but was likely to generate knowledge about the individual 
subjects that could contribute to better care for these subjects immediate-
ly after, which could be regarded as offering a diagnostic benefit. An 
example of a protocol in this category is a study on the more detailed im-
aging of a certain brain tumour including its susceptibility for a particular 
type of therapy. By participating in this study, the subjects could gain in-
formation that could afterwards help their doctors finding an adequate 
therapy, albeit in the form of experimental therapy or a follow up trial.  
5. The last two protocols included interventions of which part of the subjects, 
despite the aim of the study, could gain a preventive benefit. An example 
of a protocol in this category is a study on the responses of children with 
impaired immune systems to hepatitis A and B immunisation. Children at 
risk for these diseases could benefit from participating in this study if they 
appeared to respond well to the immunisation, by being protected against 
hepatitis A and/or B.  
PROTOCOLS WITH THE PROSPECT OF DIRECT BENEFIT 
Of the 36 protocols that were labelled with the prospect of direct benefit, 34 
contained procedures that could not offer any direct benefit. The shortest list of 
procedures without the prospect of direct benefit in a study labelled with the 
prospect of direct benefit was only one extra blood draw from an arterial line that 
was inserted in the context of standard care. At the other end of the range were a 
study that included 144 extra hospital visits during 11 years, and a study that 
included physical examinations, keeping a diary, a skin test, a chest radiograph, an 
ECG, a food intolerance test and 33 venipunctures. In between those two ends we 
found protocols with various lists of procedures. For example a randomised trial 
on monitoring strategies for asthma included completing 10 questionnaires, keep-
ing a diary and undergoing a (not clinically indicated) bronchial provocation test.  
Such procedures without the prospect of direct benefit mostly concerned 
measures for monitoring (side) effects of the (beneficial) intervention, but in some 
cases also concerned measures related to a separate research question, such as 
pharmacokinetics/dynamics. Occasionally, a protocol even contained an addition-
al intervention solely for research purposes. An example is a study consisting of 
two parts. For the first part 30 children would receive a new drug for 14 days in 
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order to test its safety and tolerability. Only in the second part of the study the 
drug would be compared to placebo. The committee did not approve the first 
part because it could not be considered as offering direct benefit. The first part 
was then only carried out in the United States.  
The two protocols that did not contain any procedures without a prospect of 
direct benefit were both trials in which all the data needed for the trial were 
obtained through procedures that were already done in the context of standard 
care of these patients.  
In 3 of the 36 protocols the potential direct benefit of the study intervention was 
questionable. For example one of the studies patients with obesity had to follow a 
certain diet for four weeks. It is doubtful whether a lasting effect can be expected 
from a four-week diet. One protocol raised doubt about whether it was an 
intervention study at all, as the participants were already using the drug that was 
studied. The REC eventually labelled it as an intervention study, even though it 
had the same doubts. 
REMARKS AND IDEAS FROM GROUP DISCUSSIONS 
The three group discussions with RECs led to remarks on the feasibility and 
workability of a procedure-level approach as well as to ideas on how to improve 
the method. Several REC members were concerned about the extra time the 
approach would cost, as reviewing protocols is already a time-consuming task. 
They were worried that differentiating between the two types of procedures 
would be difficult and would require a lot of experience with the method. Moreo-
ver, the need for a clear format was put forward, not only regarding the first step 
(categorising all research procedures), but also regarding the second (assessing 
these procedures) and third (making an overall judgment) steps. Several members 
mentioned that a procedure-level approach should not complicate the risk-benefit 
assessments more than necessary. 
Moreover, some participants made suggestions related to the quality of the 
method. They wondered whether the distinction between two types of proce-
dures is precise enough. During all three group-discussions it was suggested that 
it might be worthwhile to also differentiate between primary and secondary 
research questions within a research protocol. This would describe the value of 
each part of a protocol more precisely and it would make it easier for RECs to 
have protocols adjusted or to reject a part of the study. It was suggested that 
procedures that measure the safety and effect of the intervention should be 
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considered as procedures with the prospect of direct benefit, whereas those 
procedures that answer secondary research questions should be considered as 
offering no prospect of direct benefit. Lastly, the idea was raised that the risks and 
burdens of procedures without the prospect of direct benefit in research with the 
prospect of direct benefit, are usually outweighed by the net-benefit of the 
intervention. We will explore these issues further in the next section of this paper. 
DISCUSSION 
The assessment of risks in paediatric research protocols is usually done for the 
protocol as a whole, thereby labelling and evaluating the entire protocol as either 
with- or without the prospect of direct benefit. However, protocols often consist 
of a combination of procedures that can directly benefit the participants, and 
procedures that cannot. For this reason, several ethicists have proposed to focus 
on procedures instead of protocols when assessing the research risks and bur-
den.(6, 7, 16) We analysed 72 paediatric intervention studies to assess how 
frequently protocols consist of a combination of the two types of procedures. The 
majority of the protocols we analysed contained a combination of procedures 
with- and procedures without the prospect of direct benefit (68%). This number 
suggests that a protocol-level approach does not do enough justice to the 
complexity of paediatric research protocols and contributes to the idea that a 
procedure-level approach is a better way forward. 
42% of the protocols labelled without the prospect of direct benefit included a 
study intervention that could be regarded as offering a prospect of direct benefit 
for the participants. This is surprising, as one would suppose that with this possi-
bility of direct benefit, the protocol would have been labelled with the prospect of 
direct benefit. We expect that a more detailed definition of direct benefit will lead 
to a more accurate and uniform risk-benefit assessment, be it with the standard 
approach or with a procedure-level approach.  
When defining direct benefit, it is important to realise that when performing a 
risk-benefit assessment, labelling a procedure as holding the prospect of direct 
benefit (step 1), does not mean that this benefit automatically compensates for 
the risks and burdens (step 2). We suggest the following definition of an interven-
tion or other procedure with the prospect of direct benefit: an intervention or 
other procedure that forms a valid therapeutic, diagnostic or preventive option for 
the participants in the study at stake. By a valid option we mean that it can 
expectedly compete with other available (therapeutic/diagnostic/preventive) 
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options for the patient concerned, so that the patients will not receive inferior 
care.(6) Our proposed definition does justice to the fact that both the magnitude 
and the probability of the benefit may vary among the valid options. Moreover it 
excludes non-medical benefits (which cannot reasonably compensate for medical 
risks) as well as medical, but insignificant benefits. 
Using this definition would mean the following for the examples that we present-
ed in the result section, where we grouped the procedures with direct benefit in 
protocols labelled without direct benefit into five categories. The benefit in the 
example from category 2, the asthma diagnosis study, would qualify as direct 
benefit when only patients with an indication for inhalation steroids would be 
included in the study. The example from category 5, the hepatitis vaccine study, is 
similar. It would have fit our definition if only participants with a medical indication 
for hepatitis A and B prevention would have been included. In both examples this 
was not the case. Categories 1, 3 and 4 (the early phase drug trials with sufficient 
dosage and duration, the pilot studies and the studies likely to generate valuable 
knowledge about the individual patient) do fit our definition.  
Almost all of the protocols that were labelled with the prospect of direct benefit 
also contained procedures conducted purely for research purposes (94%). Of 
concern are the long lists of such extra research procedures. One can wonder 
whether RECs are always sufficiently critical to the risks and burdens of extra 
research procedures once there is a benefit expected for the subjects. This 
practice has been referred to as package deals, in which the possibility of direct 
benefit is used to justify disproportionally many extra research procedures.(13) 
Two of the examples in the result section (a study with 144 extra hospital visits 
during 11 years, and a study that included physical examinations, keeping a diary, a 
skin test, a chest radiograph, an ECG, a food intolerance test and 33 venipunc-
tures) may have been such package deals as they included so many extra 
research procedures, that they certainly raise doubt about whether the risks and 
burden of all those procedures could reasonably be compensated for by the 
benefit of the intervention. Both protocols were approved by the reviewing 
committee. In these cases a procedure-level approach would probably have 
provided a more accurate and fair risk-benefit assessment.(16)  
To explore the feasibility of a procedure-level approach, we discussed the method 
with REC members. Several members were concerned that the method would be 
too time consuming. We understand this concern, yet we expect the first step to 
be fairly easy once there is a more clear definition of direct benefit available, like 
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the one we suggested. In addition, a clear format would be helpful. Distinguishing 
between primary and secondary research questions, as was suggested, could 
provide more insight into the value of separate procedures. By making both 
distinctions, committees may get a clear view on the purpose and the importance 
of separate parts of a protocol. It should however be clear that these are two 
different distinctions. Not all procedures related to the primary research question 
automatically provide direct benefit. Procedures that are performed to monitor 
the safety of the (beneficial) intervention are indeed not performed for data 
collection only. However, in a research setting such monitoring is often performed 
more frequently than strictly required for monitoring the safety of the partici-
pants. Moreover, when not participating in the study, the participants would not 
have needed the monitoring procedures at all.  
Thus, claiming that they offer direct benefit is not the right way to justify their 
risks and burdens. Net benefits of the intervention can compensate for higher 
than minimal risks and burdens of procedures that relate to the intervention, but 
the procedures themselves should not be considered as offering direct benefit. 
RECs should assess the risks and burdens of those procedures critically and 
transparently and should be convinced that these are not higher than what the net 
benefits can justify. In our analysis we found some studies that contained many 
extra research procedures. It would require a lot of expected benefit to outweigh 
that many, sometimes rather burdensome, procedures. As the intervention itself 
already entails certain risks and burdens, it is doubtful whether that intervention 
can offer that much benefit at all. 
It would probably help if researchers were asked to make the proposed distinc-
tions already in their protocols and indicate which procedures offer possible direct 
benefit and which do not, as well as which procedures relate to the primary 
research question and which to the secondary ones. This could result in adjust-
ments to the design in an earlier stage, more precise protocols and hence to 
quicker and easier ethical review.  
Concluding, we argue that both RECs and research professionals should adopt a 
procedure-level focus. Not only does this expectedly lead to better ethical review, 
it may also potentially improve informed consent and research practices. A 
procedure-level approach requires a clear definition of what direct benefit is, like 
the one we suggested. Providing clear formats for dividing between procedures 
with- and without the prospect of direct benefit to researchers and RECs can also 
be helpful for implementing the method in practice.  
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ABSTRACT 
Background and objective: More empirical data on the burden of research proce-
dures for children is needed for RECs to accurately assess paediatric research 
protocols. Our objective was to assess how paediatricians estimate the burden of 
research procedures for children, related to the categories of minimal burden and 
(more than) a minor increase over minimal burden and which factors they think 
may influence the experienced burden.  
Methods: Data were collected using a two-page questionnaire. Respondents 
classified thirteen research procedures into three categories. Second, they ranked 
the procedures and third, they wrote down factors that influence the experienced 
burden. 
Results: The majority categorised buccal swab, echocardiography and spirometry 
as minimal burden. Allergy skin test, hospitalisation and insertion of a venous 
cannula were categorised as a minor increase over minimal burden. More than a 
minor increase over minimal burden was chosen for repeated venipunctures, bone 
marrow aspiration, lumbar puncture and muscle biopsy. There was no majority 
opinion on a single venipuncture, bronchial challenge test and MRI. Buccal swab 
was ranked as least burdensome and bone marrow aspiration as most burden-
some. Age and former experience with hospitals were mentioned as influencing 
factors most. 
Conclusions: There is disagreement on how burdensome certain procedures are 
for children. We hypothesise that this is partly due to differing experiences of the 
same procedure by various children. It implies that categories like minimal burden 
should be used with caution. Empirical data can help RECs, but during trials the 
experiences of all individual children should have the primary focus.  
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INTRODUCTION 
How burdensome research procedures are for children is very relevant in the 
context of paediatric research ethics. Research ethics committees (RECs) are 
responsible for assessing the burden (and the risks) of paediatric research 
protocols.(1) They have to assess whether the burden is minimised, and whether 
the burden is acceptable in relation to the anticipated benefit (if any) for the 
participants. In the absence of direct benefit, paediatric research is usually 
considered justifiable if, among other requirements, the research burden is no 
more than minimal.(2, 3) This demand appears as a common requirement in laws 
and ethical guidelines.(4-6)  
Burden is both a difficult and a diverse concept. It has not yet exactly been fully 
explicated what does, and what does not fall within in the scope of burden. 
Moreover, different ideas exist about how the concept of burden relates to the 
concept of risk. Regarding the scope of burden, it can reasonably be concluded 
that both discomforts (like pain, itchiness, nausea and anxiety) and inconvenienc-
es (like missing a school day and going to the hospital) are types of burden.(7, 8) 
However, not all legal and ethical documents clearly recognise that.  
With regard to the relation to risk, there seem to be two approaches. One ap-
proach regards burden as incorporated in the concept of risk. The rationale is that 
regardless of whether the possible negative outcomes concern harm or discom-
fort, both include a certain probability and are therefore to be considered risks.(9) 
This interpretation appears in the US Code of Federal Regulations as risk of 
discomfort. The definition of minimal risk given in the US Code is: ‘the probability 
and magnitude of harm or discomfort anticipated in the research are not greater 
in and of themselves than those ordinarily encountered in daily life and of routine 
examinations’.(5) This definition was also chosen in the recommendations for 
implementing the European Clinical Trials Directive.(10) A disadvantage of this 
approach is that it makes no reference to inconveniences and it is difficult to see 
what place inconveniences could have, as inconveniences do not necessarily 
include a probability component. Westra and colleagues proposed a new defini-
tion for minimal risk of discomfort that incorporates empirical evidence and 
expert experience, namely that the risk of discomfort is minimal when: ‘empirical 
data, expert opinions and/or the procedural characteristics (e.g. invasiveness; 
disturbance of normal routines) suggest that at most a quarter of the persons 
concerned will experience considerable discomfort’.(9) 
A second approach is to regard burden as a separate concept. Examples of this 
Chapter 7 
 
96 
approach are the new European Clinical Trials Regulation (that will replace the 
Clinical Trials Directive), the European Convention on Human Rights and Biomedi-
cine (Oviedo Convention) and the Declaration of Helsinki.(4, 6, 11) These 
documents separate burden from risk, but are still not very explicit about what 
constitutes a burden. The Additional Protocol to the Oviedo Convention defines 
minimal burden as: ‘it is deemed that it bears a minimal burden if it is to be 
expected that the discomfort will be, at the most, temporary and very slight for 
the person concerned’.(12) During the drafting of the Dutch national law on 
medical research with humans, a definition of minimal burden was provided that 
includes both discomforts and inconveniences, namely that the research is 
‘altogether not disruptive; the disturbance of daily life that research participation 
involves is limited and the burden in the sense of pain may not be more severe 
than for example a blood draw’.(13, 14)  
Regardless of the relation to risk, the fact remains that RECs have to assess 
whether the expected burden of a proposed study is acceptable for the partici-
pants. To do so, placing research procedures in the categories of minimal burden, 
a minor increase over minimal burden and more than a minor increase over 
minimal burden may be helpful but also challenging. Obviously, assessing the 
accumulated burden of the totality of research procedures within a protocol is 
even more complicated. Burden has both an objective and a subjective compo-
nent. The objective component is what is imposed on children, which can be 
described factually; e.g. the child will undergo an allergy skin test that takes 30 
minutes, will probably cause itchiness and possibly some mild pain. The subjective 
component is how the child concerned actually experiences the procedure. The 
same level of pain might not at all bother the first child, but may cause panic in 
the second.(15) While a venipuncture is generally known to cause more distress in 
toddlers than adolescents, there is still a considerable amount of adolescents that 
experience high levels of distress.(16)  
Some data are available on the self-reported levels of pain children perceive while 
undergoing medical procedures, but little research is done on the overall level of 
burden (pain, fear, nausea, etcetera) of medical procedures.(8, 15, 17, 18) Evidence 
on burden related to the categories of minimal burden and so on, is especially 
scarce. To properly estimate the expected burden of a protocol, RECs need more 
empirical data on how burdensome procedures are for children.(19) There are 
tables that categorise medical procedures by degrees of risk (including risk of 
discomfort) for paediatric subjects, but it is unclear what evidence supports these 
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categorisations.(20, 21) 
The objective of our study was to assess how paediatricians estimate the burden 
of research procedures for children, related to categories like minimal burden. The 
procedures that are used in research are also frequently carried out in the setting 
of medical care. Paediatricians often have plenty of experience with these proce-
dures and therefore are a valuable source of information.  
METHODS 
RESPONDENTS 
Respondents were recruited at meetings in paediatrics departments in four Dutch 
hospitals. We recruited respondents at regional training days in academic hospi-
tals for paediatricians from non-academic hospitals (at Leiden University Medical 
Centre and VU University Medical Centre, Amsterdam), at routine meetings at 
paediatrics departments (Leiden University Medical Centre and Juliana Children’s 
Hospital, the Hague) and at a monthly meeting of the paediatric department (Isala 
Hospital, Zwolle). This selection included academic and non-academic hospitals 
from different regions. All attendees of the meetings were asked to fill out the 
questionnaire.  
QUESTIONNAIRE 
The visits to the paediatric departments took place between September and 
December 2015. Our two-page questionnaire included a short introduction about 
the rationale, the purpose of our research project and the definition of minimal 
burden as used in the drafting of the Dutch national law.(14) In question 1 and 2 
the respondents were asked to specify their exact profession and their years of 
experience working in paediatrics.  
In question 3 the respondents were asked to classify 13 procedures (bronchial 
challenge test, a single venipuncture, repeated venipunctures (8x in 6 months), 
spirometry/pulmonary function test, muscle biopsy, insertion of a venous cannula, 
allergy skin test, lumbar puncture, buccal swab, bone marrow aspiration (with 
sedation), 1 hour MRI scan (without sedation), echocardiography and hospitalisa-
tion for two days), into the categories of minimal burden, a minor increase over 
minimal burden and more than a minor increase over minimal burden, or I can’t 
judge about this. In question 4, the respondents were asked to rank the proce-
dures from least burdensome (1) to most burdensome (13). In question 5 we asked 
Chapter 7 
 
98 
which factors, according to them, influence the burden of research procedures for 
children. Finally, in question 6 there was space for any further remarks. The 
selected procedures were chosen because (1) some of the procedures are very 
common in paediatric research and (2) some are procedures with which research 
ethics committees experience difficulty when deciding whether the procedure is 
(more than) minimally burdensome. The Dutch Central Committee on Research in 
Human Subjects provided us with a list of procedures they perceived as compli-
cated. 
ANALYSIS 
We included all questionnaires that were completed by physicians. Medical 
students and specialised nurses were excluded. The classification and ranking of 
the procedures were analysed using descriptive statistics. For the classifications 
the percentages of each category were calculated for the individual procedures. 
For the ranking the median was calculated for each individual procedure. The 
answers to question 5 were collected and the answers that related to the same 
subject were grouped into categories.  
RESULTS 
RESPONDENTS 
A total of 122 respondents returned the questionnaire, of which 86 respondents 
were physicians. The remaining 36 respondents, which were excluded from the 
analysis, were mostly medical students in residency, some specialised nurses and 
a physician assistant. Of the included 86 physicians, 36 were general paediatri-
cians, 27 were subspecialists, 12 were specialist registrars, 4 were senior house 
officers and 7 reported another profession (for example general practitioner). 
Experience in paediatrics varied from 0 to 40 years (see table 1). The subspecial-
isms included neonatology (7), pulmonology (4), endocrinology (3), 
gastroenterology (3), cardiology (2), social paediatrics (2), allergology (1), 
congenital diseases (1), hemato-oncology (1), nephrology (1), neurology (1) and 
rheumatology (1). Those who reported 0 years of experience in paediatrics were 
visiting physicians from other departments, such as neurology. 
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Table 1: Characteristics of respondents 
 
 
 
  
Characteristics of respondents 
Number (%) of physicians 
(N=86) 
Profession     
General Paediatrician 36 (42) 
Subspecialist 27 (31) 
Paediatric resident in training 12 (14) 
Intern 4 (5) 
Other 7 (8) 
Years of experience in paediatrics     
0-2 years 9 (10) 
3-5 years 11 (13) 
6-10 years 11 (13) 
11-20 years 33 (38) 
21-30 years 16 (19) 
31+ years 6 (7) 
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Table 2: Classification of procedures (including I can't judge about this) 
 
Procedure 
N (N=86), 
(%) 
I can't  
judge  
about this 
(%) 
Minimal 
burden  
(%) 
A minor 
increase 
over 
minimal 
burden (%) 
More than a 
minor 
increase 
over 
minimal 
burden 
(%) 
Buccal swab 83 (97) 3 (4) 77 (93) 2 (2) 1 (1) 
Echocardiography 82 (95) 1 (1) 62 (76) 16 (20) 3 (4) 
Spirometry/pulmonary 
function test 
83 (97) 3 (4) 56 (67) 24 (29) 0 (0) 
Single venipuncture 83 (97) 0 (0) 32 (39) 40 (48) 11 (13) 
Allergy skin test 83 (97) 10 (12) 18 (22) 46 (55) 9 (11) 
Hospitalisation  
(2x 1 day) 
81 (94) 2 (2) 15 (19) 46 (57) 18 (22) 
Bronchial challenge test 81 (94) 19 (23) 12 (15) 33 (41) 17 (21) 
MRI scan  
(unsedated, 1 hour) 
83 (97) 1 (1) 9 (11) 36 (43) 37 (45) 
Insertion of a venous  
cannula 
82 (95) 0 (0) 7 (9) 50 (61) 25 (30) 
Bone marrow aspiration 83 (97) 4 (5) 4 (5) 15 (18) 60 (72) 
Repeated venipunctures 
(8x in 6 months) 
82 (95) 0 (0) 2 (2) 26 (32) 54 (66) 
Muscle biopsy 82 (95) 7 (9) 1 (1) 6 (7) 68 (83) 
Lumbar puncture 83 (97) 0 (0) 0 (0) 19 (23) 64 (77) 
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CLASSIFICATION 
Table 2 shows the number and percentage of each category per procedure, 
including I can’t judge about this. In figure 1 this category is left out, as it would 
give a distorted image of the distribution over the three categories. Therefore, 
figure 1 is a graphical representation of only those respondents who gave an 
actual estimation of the burden of the procedure. 
The majority of the respondents categorised buccal swab, echocardiography and 
spirometry as minimal burden (respectively 93%, 76% and 67%). Allergy skin test, 
hospitalisation of two days and insertion of a venous cannula were categorised as 
a minor increase over minimal burden by the majority (55%, 57% and 61%). The 
category more than a minor increase over minimal burden was chosen by a 
majority of the respondents for repeated venipunctures (8x in 6 months), bone 
marrow aspiration, lumbar puncture and muscle biopsy (66%, 72%, 77% and 82%). 
There was no majority opinion for the remaining three procedures. A single 
venipuncture was categorised as minimal burden by 39%, as a minor increase over 
minimal burden by 48% and as more than a minor increase over minimal burden 
by 13%. For a bronchial challenge test the distribution was respectively 15%, 41% 
and 21%. For a 1 hour MRI scan without sedation the distribution was respectively 
11%, 43% and 45%. 
RANKING 
The ranking (question 4) was completed by 61 respondents, though not all of 
them included all procedures in the ranking. For example, respondents who felt 
they could not judge about a certain procedure did not include that procedure in 
their ranking. By calculating the median of the rank allocated per procedure, we 
came to the following ranking from least to most burdensome (the median is 
between brackets). Buccal swab (1), echocardiography (2), spirometry (3), allergy 
skin test (5), a single venipuncture (5), bronchial challenge test (6), hospitalisation 
for two days (7), insertion of a venous cannula (7), 1 hour MRI without sedation 
(8), repeated venipunctures (8x in 6 months) (9), lumbar puncture (11), muscle 
biopsy (12), bone marrow aspiration (sedated) (12). Note that these numbers only 
describe an order and that the steps between the numbers might not be equally 
large (see figure 2). 
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FACTORS THAT INFLUENCE BURDEN  
The answers to question 5 (which factors influence the burden of medical proce-
dures for children) were grouped into 11 categories. We ordered the categories of 
answers from most to least mentioned. Age of the children was mentioned the 
most (57 times). Whether children had previous experience with research, with 
undergoing the procedure or with hospitals in general, was mentioned 40 times. 
Factors related to the parents (attitude, behaviour, stress, fear of the parents) 
were mentioned 39 times and factors related to the child (character, developmen-
tal stage, fear, attitude of the child) 30 times. Both preparing the child and parents 
(including informing and explaining) and guidance and support during and after 
study participation were mentioned 25 times. Characteristics of the procedure 
(e.g. whether it causes pain and whether it is possible to provide relief) were 
mentioned 24 times. 14 answers referred to the length of the procedure, the time 
investment and the point of time. The experience and skilfulness of the person 
who performs the procedure was mentioned 10 times. Lastly, sedation (5 times) 
and distraction (3 times) were mentioned. Eighteen remaining answers could not 
be categorised. Not enough respondents used the space for further remarks to 
yield significant information. 
DISCUSSION 
It is often rather difficult for REC members to classify the burden of a paediatric 
research protocol into the categories of minimal burden, a minor increase over 
minimal burden and more than a minor increase over minimal burden. It could 
help REC members to have access to more empirical data on the burden of 
research procedures for children. To this end we investigated how paediatricians 
estimate the burden of research procedures for children. 
Our results show that there is more agreement among physicians on the burden 
of some procedures than on others. A buccal swab is clearly considered to pose 
only minimal burden by a vast majority of the respondents, whereas a muscle 
biopsy is clearly seen as posing more than a minor increase over minimal burden 
to children. What strikes as remarkable is that for most procedures the answers 
are distributed over all three categories, which shows explicit disagreement 
among doctors.  
Some research ethics documents provide tables that classify procedures in 
categories like minimal risk etcetera, to provide guidance to ethics committees. 
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On some procedures these tables differ from the results of our study. Although 
these tables do not explicitly focus on burden, it can reasonably be assumed that 
burden is incorporated in these tables, as both documents that provide such a 
table, regard burden as risk of discomfort. The table on risk for paediatric research 
subjects of the NHRPAC classifies a single venipuncture as minimal risk, and both 
a lumbar puncture and a bone marrow aspiration (with topical pain relief) as a 
minor increase over minimal risk.(21) All three procedures were classified as more 
burdensome by a majority of the respondents in our study. In the table from the 
ethical considerations accompanying the European Clinical Trials Directive, a 
venipuncture is labelled as minimal risk, a MRI scan and a bone marrow aspiration 
as a minor increase over minimal risk and a biopsy (not specified) as more than a 
minor increase over minimal risk.(20) The respondents of our study classified 
venipunctures and bone marrow aspirations as more burdensome than the table 
does and classified MRI and biopsies (in our study specified as muscle biopsy) the 
same as in the table.  
What could explain the diversity in classifications that we found, as well as the 
differences with the existing tables? It could be the case that physicians have 
actual varying experiences because their patient groups differ, for example with 
regard to age.(16) Moreover, the severity of the disease of the patient groups they 
work with and whether it concerns chronic or acute diseases may also (partly) 
explain the diverse answers. The respondents in our study also indicated that age 
and prior experience with doctors and hospitals are important influencing factors. 
More data on burden related to various age groups and to various patient groups 
would therefore be helpful for reviewing paediatric protocols. In addition to that, 
children differ from each other in many respects. There are fearless children who 
find hospitals and doctors exciting, but there are also children who are scared 
already by the idea of seeing a doctor. The physicians in our study acknowledged 
that individual differences between children are an influencing factor.  
Another possible explanation is that the content of the three classifications is not 
clear enough. Although we have provided a definition of minimal burden along-
side the questionnaire, it is still likely that people interpret it differently. If, for 
instance, two physicians both share the experience that about 50% of all children 
cries when undergoing a venipuncture, the first may classify that as minimal 
burden, whereas the second may regard it as more than that. A more operational 
definition of minimal burden, like the one suggested by Westra et al may help to 
solve the problem of interpretation, although terms like considerable discomfort 
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are still multi-interpretable. However, a certain degree of indistinctness in defini-
tion of minimal burden seems inevitable.  
As the concept of burden itself is already difficult to define, it is even more 
difficult to know what level of burden can be considered minimal. And if there is, 
as our study shows, much disagreement on the level of burden that specific 
procedures pose to children, how can categories like minimal burden be used in a 
meaningful way? Empirical data on the burden of protocols, whether reported by 
children themselves, or derived from the experience of physicians, can at best 
provide an overall idea on how burdensome procedures are for most children. 
However, they cannot take into account those children who diverge from the 
majority. The variation in answers that the physicians in our study gave, as well as 
the varying experiences of children, are reasons to apply categories like minimal 
burden with caution. In ethical review these data should be used as guidance in 
decision-making. Yet RECs and researchers should be aware that even if a study is 
reviewed as posing minimal burden, that does not necessarily mean that this will 
be the case for all children. During the performance of trials, the experiences of all 
individual children should be closely monitored. If a child in a study experiences a 
higher burden than what was deemed acceptable, the researcher should inter-
vene.(22) We recommend paying special attention to those procedures about 
which the physicians in our study disagreed with regard to how burdensome they 
are. 
CONCLUSION 
Our study showed that paediatricians estimate the burden of research procedures 
for children rather differently. Some procedures were clearly classified as posing 
minimal burden (buccal swab, echocardiography, spirometry), or as more than a 
minor increase over minimal burden (lumbar puncture, muscle biopsy, repeated 
venipunctures). For the other procedures, our study shows substantial disagree-
ment on the burden for children. Our results imply that the categories of minimal 
burden and (more than) a minor increase over minimal burden should be used 
with caution.  
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ABSTRACT 
Children participating in clinical research may show signs of discomfort, discon-
tent, dissent and so on, which cannot be solved by comforting the child. When, 
and on what ground, should such signs lead to the decision to withdraw the child 
from the trial? In order to adequately protect children participating in clinical 
research, it is important to know how to determine during the course of a trial 
whether participation is still justified. Yet to date, legislation, ethical guidelines and 
medical ethical literature do not provide sufficient guidance. Therefore, in this 
chapter we aim to provide the required clarity. We identify two types of reasons 
for taking signs of discomfort, discontent, dissent and so on, very seriously: 1) the 
principle of respect for the growing autonomy of the child, in those cases where a 
child expresses a clear, explicit and persistent wish to be withdrawn from the 
study; and 2) the principle of non-maleficence, in those cases where for an 
individual child, the research burden appears to be higher than acceptable. We 
recommend to closely monitor each child during the course of the study, thereby 
being vigilant to whether the child still wants to continue and to whether the 
actual burden the child experiences is still acceptable in relation to the permitted 
levels of burden.  
  
Protecting children during the performance of research 
 
111 
 
INTRODUCTION 
Think of a healthy 11-year-old girl participating in a clinical trial. A research ethics 
committee (REC) approved the trial and a good informed consent procedure 
ensured both the child and the parents were well informed about the research. 
One of the procedures in the study is an MRI scan. When the girl is in the tube, the 
scan scares her more than she expected, she feels uncomfortable and she resents 
the noise. She tells the nurse she wants to get out. She also clearly says that she 
no longer wants to participate in the study.  
Now, imagine a 5-year-old boy participating in another trial. While undergoing 
physical examination he screams and wrestles. Both his mother and a nurse try to 
comfort him, but when the researcher starts to examine him again, the same thing 
happens. He is clearly uncomfortable and not willing to be examined. Obviously, it 
is unclear whether he is protesting against the trial or just had a bad night and 
protests against anything? Moreover, he could have shown rather different signs. 
What if he would literally say: ‘don’t touch me’ or what if he would not scream and 
wrestle, but would silently tremble? 
Why these examples? These are children participating in clinical trials and their 
behaviour raises the question whether their participation is (still) morally accepta-
ble. There is a general consensus that children need and deserve to be protected 
extra carefully when participating in clinical trials. The main reason is that they are 
a vulnerable population, dependent on others and not yet (fully) capable of 
making a rational and voluntary decision to participate. A certain risk of exploita-
tion exists, especially in cases of research without any prospect of direct benefit 
for the participants (also called non-therapeutic or non-beneficial research), as 
there is no benefit to outweigh the research related risk and burden they have to 
undergo. Children in research with the prospect of direct benefit (or therapeutic 
or beneficial research) however also deserve extra protection, as their vulnerabil-
ity and incompetence is the same.(1)  
Several measures have the purpose of guaranteeing this extra protection. First, 
laws and ethical guidelines set stricter requirements for research with children 
than for research with competent adults. These include requirements regarding 
the proxy consent of parents/caregivers and the assent of older children, as well 
as strict upper limits on the acceptable levels of risk and burden in research 
without the prospect of direct benefit. Second, RECs review whether research 
protocols comply with these requirements. Third, during the informed consent 
process, researchers, parents/caregivers and (if possible) the individual child 
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concerned carefully estimate whether participation is acceptable for that child.(2) 
Children must be informed about the study and involved in the decision making 
process in a way that suits their level of understanding.  
Protection should continue after inclusion, but the rules and safeguards that need 
to be in place during the course of the study are not yet clear enough. Most 
research ethics guidelines and regulations do mention the need for the monitoring 
of risks and some also mention possible consequences this may have for trial 
participation, but the requirements remain vague and are not related to the 
acceptable levels of risk and burden.(3, 4) In addition, they all state that adults are 
free to withdraw their consent for whatever reasons, during the entire course of 
the trial. However, despite the fact that laws and guidelines require respect for 
dissent, they fail to clearly define what dissent is, what expressions count as 
dissent and how they should be acted upon. Children usually do not provide any 
formal consent, so there is no consent to withdraw. Once included, they can only 
be formally withdrawn from the study when the researcher and/or the parents 
think that is necessary. The researcher and parents may base their decisions on 
the behaviour of the child. Yet, how exactly should they do this? How should it be 
guaranteed that children are withdrawn from a study when their behaviour 
suggests that participation may no longer be justified?  
In this chapter we will formulate recommendations on how to react to signs of 
discomfort, discontent, dissent and so on that cannot be solved by comforting the 
child. The central question is when, and on what ground, such signs should lead to 
withdrawing a child from a study. We present our normative analysis and also 
discuss how this problem is currently dealt with in legislation and ethical guide-
lines. We argue that there are two types of reasons related to signs of discomfort, 
discontent and dissent for deciding that a child should be withdrawn from 
research, related to two basic ethical principles. In cases where a child shows 
actual dissent, the need to withdraw follows from the principle of respect for the 
developing autonomy of the child, as failing to act upon the child’s wish would 
violate this principle. In cases where a child is unduly burdened by the study, the 
need to withdraw follows from the principle of non-maleficence because the 
higher burden may affect the child to an unacceptable extent. The two principles 
also play an important part in other protective measures, such as legislation, 
ethical review and informed consent (see figure 1). Our recommendations are 
directed towards law- and policymakers, as well as to research professionals 
directly. 
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Monitoring and 
evaluation during the 
course of the trial
Individual children
Recruitment and
Informed consent
Individual children
Ethical review
All eligible participants 
of a proposed protocol
Legislation and
Ethical guidelines
All potential pediatric 
research participants
Non-maleficenceRespect for growing autonomy
Requirements:
- minimisation of risk and
 burden
- risk and burden no more 
than minimal, or 
proportional
 in relation to expected
benefit for the participant
Review by REC of:
- minimisation of risk and 
burden
- acceptability of risk and 
burden in relation to 
expected benefit (if any) 
Responsibility of parents and 
research professional:
- to consider the acceptability 
of the risks and burdens of 
the study for the individual 
child concerned
Responsibility of research 
professional:
- to actively evaluate
participation with the child 
and parents
- to respect the wish of the 
child in case he / she wants 
to stop
Responsibility of research 
professional:
- to monitor the risks and 
experienced burden
- to evaluate the observed / 
reported burden in relation 
to the acceptable level of 
burden (either minimal or 
proportional)
Requirements:
- voluntary participation 
(proxy consent, assent, 
respect for dissent) 
- age-appropriate information
Review by REC of: 
- participant information
- informed consent procedure
Responsibility of research 
professional:
- to provide age-appropriate 
information 
- to guarantee a good quality 
informed consent procedure
- to seek assent and respect 
dissent
Figure 1:  Operationalisation of the principles of respect for growing autonomy and non-
maleficence (on top) within the various protective measures (on the left) con-
cerning paediatric research. The texts in the boxes present the content of the 
principles in each form of protection. 
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RESPECT FOR THE GROWING AUTONOMY OF THE CHILD 
The first type of reasons for having to withdraw a child from a trial relates to the 
principle of respect for the growing autonomy of the child. As children grow they 
gradually become autonomous persons and become increasingly capable of 
expressing their wishes. Having their wishes respected helps children develop 
their autonomy further. Most research ethics guidelines recognise this developing 
autonomy by demanding that all children are involved in the informed consent 
procedure in a way that fits their developmental stage and level of understanding. 
Those children who are capable of co-deciding should provide assent. The child’s 
dissent should be respected. The Declaration of Helsinki (article 29) is an example 
of the use of this terminology.(3) Instead of using the term ‘dissent’, some docu-
ments speak of ‘objection’ or ‘deliberate objection’.(5, 6)  
Aside from dissenting during the informed consent procedure prior to inclusion, 
children can express a wish to stop during the study. The first example in the 
introduction illustrates that. The 11-year old girl is not yet considered fully capable 
of providing informed consent, but is capable of expressing an explicit wish to 
stop participation. Being 11-years old will qualify her as not fully autonomous, but 
her autonomy may well be established enough to not be ignored. Figure 1 displays 
the existing protective measures related to the principle of respect for growing 
autonomy, and also how protection with respect to this principle can be contin-
ued during the course of a study.  
As the concept of dissent is put forward in almost all documents, it seems that for 
those children who are capable of expressing an explicit wish, the option for them 
to withdraw themselves from a study is safeguarded. However, some unanswered 
questions remain; we name three. First of all, many documents only discuss the 
concepts of assent and dissent in relation to the informed consent process prior 
to inclusion. They do not explicitly state that these concepts may also play a role 
in a later phase, when the study is already being carried out. Some guidelines are 
explicit about this though, and it seems reasonable to assume that the others hold 
the same intention. The European Clinical Trials Directive (CTD), for example, 
states in article 4c: ‘the explicit wish of a minor who is capable of forming an 
opinion and assessing this information to refuse participation or to be withdrawn 
from the clinical trial at any time is considered by the investigator or where 
appropriate the principal investigator’.(4) Moreover, the accompanying ethics 
document on trials in minors emphasises that assent is a continuous process, 
which means that it can be withdrawn at any time during the trial. It also states 
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that the child should not be forced to provide reasons for withdrawal.(7) We 
agree with this view and recommend other regulations and guidelines adopt this 
as well.  
The second question asks at what point children should be considered old enough 
to express meaningful dissent. Unfortunately it is impossible to point at an exact 
age at which children are capable of providing assent. This relates to the fact that 
there is no consensus on the exact aim and content of assent.(9) Furthermore, 
age in years is not the only relevant factor.(8) The age-limits for assent mentioned 
in guidelines and literature vary from 7 till 14 years of age.(9) To set an age limit 
for dissent is even more difficult. While there is a growing body of literature about 
the concept of assent(10-12), the notion of dissent is not thoroughly discussed and 
not (yet) clearly defined. There is some agreement that dissent does not neces-
sarily require the same level of understanding of the study and the same decision-
making capacities as assent does.(13) As a consequence, the term objection has 
even been used for expressions of objection in preverbal children.(6, 14) We 
suggest reserving terms like dissent and objection for those children who can 
express a clear, explicit and persistent wish to stop participating. The age at which 
this is the case may differ between children and even between situations. This 
does however not mean that children who can not express a clear, explicit and 
persistent wish do not deserve any respect for their developing autonomy. It 
means that if a child cannot meaningfully answer the question whether they want 
to stop or not, dissent should not be put forward as the reason to stop. In these 
cases the decision can better be based on the burden the child experiences, which 
will be explained more thoroughly in the next section of this chapter.  
The third question is whether this explicit wish should always and automatically be 
respected. It is remarkable that in the European Clinical Trials Regulation, which 
will replace the Clinical Trials Directive next year, the wording of the aforemen-
tioned article 4c is changed from ‘considered’ to ‘respected’ (article 31.1.c).(15) 
This seems to imply that the child’s wish should be respected without exceptions. 
A similar statement can be found in the Declaration of Helsinki.(3) For research 
without the prospect of direct benefit, we think this is the right approach. Partici-
pation in this kind of research is not a moral duty and refusal to participate or the 
wish to stop participation does not need to be informed and rational, like the 
decision to stop of an adult also does not need to be informed and rational.(16) 
But the situation is somewhat more complex for children in research with the 
prospect of direct benefit. In certain select cases a child is likely to benefit from, or 
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even dependent on a particular treatment that is not available outside the context 
of research. Only in such select cases, where participation is critical to the health 
of the child because there are no valid alternatives, can it be reasonable to 
overrule the wish of the child. So far, only the CIOMS guidelines and the IRB 
guidebook that accompanies the US Code of Federal Regulations point out these 
important nuances.(6, 8)  
NON-MALEFICENCE 
The second type of reasons relates to the principle of non-maleficence. When the 
research related burden for an individual child turns out to be higher than what 
was found acceptable during the ethical review of the study concerned, trial 
participation might become unjustified. A child who cries, screams, wrestles, 
trembles etcetera, might be burdened by research participation to a more than 
acceptable extent. The example of the 5-year old boy illustrates this. His scream-
ing and wrestling could mean that he is scared or stressed by the physical 
examination; especially as comforting him does not help. This boy may experience 
burden that is higher than justified and that probability should be taken seriously.  
Most research ethics guidelines and regulations do not explicitly touch upon this 
issue. Some address the younger age groups by suggesting that their concepts of 
‘dissent’ or ‘objection’ can be used for all ages, but as we argued before, non-
explicit signs of discomfort should not qualify as meaningful dissent. For example, 
the code of conduct accompanying the Dutch law on research with human 
subjects explicitly includes infants and toddlers (see box 1). Other documents 
argue for the need to monitor the levels of distress, discomfort and so on that 
children may experience during research. The CTD for example states in article 4g 
that ‘both the risk threshold and the degree of distress have to be specially 
defined and constantly monitored’.(4) This requirement is valuable because it is 
generally recognised that the way children experience procedures can vary a lot 
between children and even for the same child between situations.(17) That means 
that there is always a fair chance that a child experiences a higher level of distress 
than expected. However, how such monitoring should take place and what the 
consequences should be is not specified. 
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Box 1: Dutch code of conduct relating to objection by minors participating  
in medical research 
The Dutch national law on medical research with human subjects requires that 
children who object against trial participation are being withdrawn: ‘If a subject 
involved in trials (…) should object to the treatment administered or behavioural 
strategy imposed, the person in question will be excluded from participation’ (Art 
4.2).(18) In order to explicate how the concept of ‘objection’ should be used, a 
code of conduct was written in 2001. The code acknowledges that every child 
behaves differently and that identifying cases of actual objection is especially 
difficult with neonates. However, the code states that ‘as a general rule it is 
reasonable to suggest that a child may be thought to object if its behaviour 
clearly differs in nature or degree from that normally displayed by the child when 
confronted with situations not encountered in everyday life’.(14) This means that 
if a child reacts differently or more severely to a research procedure than he or 
she would normally do to an unusual situation, the child should be withdrawn 
from the trial. 
The Dutch approach reveals the weaknesses of applying concepts such as 
dissent or objection to younger children. It is very difficult to translate the signals 
of a child unable to clearly express itself, into a term like dissent or objection. The 
problem seems to be that such terms suggest that a child knowingly and actively 
states that he or she wants to stop participating. But this is not the case for 
young children who can express discomfort or distress but cannot express an 
explicit wish to be withdrawn. Therefore, using terms like dissent and objection 
does not help to interpret signs of distress in a meaningful way. The primary 
question should be: what level of distress is unacceptable? 
 
We suggest relating the observed signs to the level of burden that was found 
acceptable for that study. Again, strict limits are set for the risks and burdens 
children may be exposed to during research. In research without the prospect of 
direct benefit these are no more than ‘minimal’ (or a ‘minor increase over mini-
mal’), and in research with the prospect of direct benefit they must be 
proportional to the expected benefit.(3, 5, 19) During the ethical review phase, 
RECs ensure that research protocols comply with these requirements for all 
eligible children.(2) Then, during the informed consent process, all persons 
concerned estimate whether participation is acceptable for the individual child 
concerned.(1) In the present analysis we suggest to also systematically check 
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during the trial whether the actual burden indeed can be regarded as minimal or 
as proportional for each participating child. The permitted levels of burden apply 
to all children and all children should be monitored, not only those who are too 
young to express dissent. The core question is: is the actual experienced burden 
indeed minimal (in research without the prospect of direct benefit), or propor-
tional (in research with the prospect of direct benefit)? Figure 1 shows the existing 
protective measures related to the principle of non-maleficence, and how the 
principle should be operationalised during the course of the study. Thus our 
recommendations are well connected to the protective measures that are already 
in place. 
Obviously, in practice it is not easy to judge whether the observed burden can be 
considered minimal or proportional. Recognising and interpreting signs of discom-
fort and relating them to the acceptable levels of burden are difficult tasks. 
Parents should play an important role in recognising and interpreting signs of 
discomfort. However the task of relating them to what is acceptable and permit-
ted is more difficult, as the permitted levels of burden are usually not well enough 
defined. Lists exist in which research procedures are grouped into categories like 
‘minimal’ and ‘a minor increase over minimal’, but those lists do not do justice to 
the subjective or personal component of burden; defined by the experience of the 
person concerned. Putting research procedures in categories like ‘minimal bur-
den’, ‘a minor increase over minimal burden’ etcetera can provide direction for 
RECs, but should not be regarded as rigorous standards, as the actual experience 
of an individual child can be different. When a child shows signs of fear, distress, 
discomfort, panic and so on, the research team should be aware of the level of 
burden that was thought to be acceptable in the present setting. The team will 
then have to judge whether the observed level of discomfort can be considered to 
be within these limits. It would certainly help to develop a more operational 
definition of ‘minimal burden’.  
When an observed expression of burden is judged as being too high, lowering the 
burden for that child should be the first step, for example by comforting the child, 
by pain reducing interventions, by watching videos or listening to music, and so 
on.(20) However, if such interventions appear to have no, or insufficient effect, the 
child should be withdrawn from (that part of) the trial.  
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DISCUSSION 
To date there is no sufficient guidance on how to deal with cases where the 
behaviour of a child raises doubts whether the child should be kept in a trial or 
should be withdrawn. We have identified two types of reasons for taking such 
behavioural signs very seriously: 1) respect for the growing autonomy of the child, 
in those cases where the child expresses a clear, explicit and persistent wish to be 
withdrawn from the study; and 2) the principle of non-maleficence, in those cases 
where the research burden for a specific child appears to exceed the level that 
was found acceptable during the ethical review process (for all eligible children) 
and was agreed to during the informed consent process (for the individual child). 
We recommend systematic monitoring of each child throughout the course of the 
study. We recommend such monitoring during the performance of research 
procedures both when the procedure can, and cannot directly benefit the partici-
pant. When a child shows signs of discomfort or distress it may be important to 
know whether there is any prospect of direct benefit. In cases of direct benefit the 
burden must be proportional to the expected benefit, and if no direct benefit can 
be expected, the burden must be no more than minimal. 
The withdrawal of a child from a trial should remain an exception and should 
always be a last resort. The informed consent process should be carried out in 
such a way that in principle all children for whom participation is expected to be 
too burdensome, are excluded from participation. Minimising the burden before 
and during the trial is important, because it is not only an ethical requirement, but 
also the best way to prevent the need for withdrawal. Besides choosing the least 
burdensome procedures, this also includes providing a child friendly setting, good 
preparation, distraction and experienced research professionals. When despite 
such measures the actual burden for a particular child appears to be higher than 
acceptable, one should attempt to modify procedures in such a way that the child 
can stay in the trial. Unnecessarily withdrawing a child from a trial would mean 
that the former efforts of the child (including the exposure to risks and burden) 
were for nothing. In some cases it may also be possible to withdraw a child only 
from a certain part of the study, which is preferable over withdrawal from the 
entire study.  
Exceptions ask for an individual and tailored approach. Children can experience 
and express their discomfort in rather different ways. Moreover, not all children 
feel equally confident in expressing their dissent. Research professionals should 
be sensitive to these differences. We are aware that the approach we present may 
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not provide a clear way forward in all possible situations. For example, what to do 
in situations in which the research burden seems unacceptably high for a certain 
child, but the child does not wish to stop? It is not possible to fully answer this 
question, because, as we just mentioned, a personal approach is needed. Howev-
er, the first step is trying to lower the burden. Moreover, it is important to learn 
more about the child’s motivation to continue. Vigilance to therapeutic miscon-
ceptions is essential here. If the child persists to continue because of an expected 
therapeutic benefit, where in fact there is no chance of a therapeutic benefit, it is 
important to uncover this wrong belief and to be sure that the child understands 
the purpose of the study.  
CONCLUSION 
In this chapter we addressed the importance of clarity and guidance on how to 
decide whether trial participation is still justified for a certain child. The failure to 
recognise and respect a child’s dissent may harm the child as his developing 
autonomy is disrespected. Moreover, without clarity on this matter children may 
be kept in a trial for too long and may be harmed by the burden they experience, 
which means the child’s well-being is insufficiently protected. Research ethics 
guidelines should be clear about the meaning of the used concepts. We recom-
mend that terms like dissent and (deliberate) objection be reserved for those 
children who are capable of expressing a clear, explicit and persistent preference 
to stop participation. We also recommend that guidelines explicitly link the 
required monitoring of burden to the permitted levels of burden for the various 
kinds of research. We realise that our approach asks for some extra regulatory 
measures and a certain effort from research professionals, but we believe that 
when aiming to properly protect children in paediatric research against undue 
harm, these efforts are worthwhile. 
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The ethical governance of clinical research with children is an ever-changing field. 
During the development of treatments for childhood diseases new challenges 
continually arise to which scholars, as well as law- and policymakers, have to 
react. The emergence of new technologies, new types of research, medical 
development, and new empirical data feed the ethical debate. The balance 
between the need for more paediatric research to facilitate medical-scientific 
innovation, and the need to protect children against possible harm associated 
with research participation, is dynamic.(1-5) Moreover, paediatric research prac-
tice shows that there are still certain ethical challenges in this field that deserve 
attention.(6) In this thesis we have identified some of those challenges, analysed 
them, suggested possible solutions and provided practical recommendations. 
Our research project began with three main topics, each with their own research 
questions. These topics concerned the procedure-level approach to ethical review 
(chapter 6), the burden of research procedures for children (chapter 7), and the 
protection of children during the performance of paediatric research (chapter 8). 
The research questions on these three main topics will be answered in the next 
section. Along the way, other questions came up. The interesting case of a 
multinational trial on Duchenne Muscular Dystrophy (chapter 3) revealed that the 
ethical issues sketched in chapter 2 are still timely and relevant and that views on 
these matters can differ profoundly. In chapter 4 we have compared children with 
another group of vulnerable research subjects, namely dementia patients, to see 
which morally relevant characteristics these two groups share and how that is 
represented in legal and ethical guidelines. In chapter 5 we discuss the new 
European Clinical Trials Regulation, which was drafted and approved during the 
course of our research project. As the final version of the Regulation had us 
concerned about the quality of the risk-benefit assessment and the quality of 
research ethics committees (REC), we took the opportunity to write a critical 
analysis on the new Regulation. Apart from the results of our three main subpro-
jects, the totality of our work lead me to evaluate the regulatory changes made in 
the last five years, and to sketch my view on the opportunities for future progress. 
I will discuss these two topics after an overview of our main conclusions.  
MAIN CONCLUSIONS AND ANSWERS TO RESEARCH QUESTIONS 
SUBPROJECT 1: A PROCEDURE-LEVEL APPROACH TO ETHICAL REVIEW 
The primary aim of this subproject was to investigate the practical need and 
feasibility of a procedure-level approach to ethical review. To this end, we asked 
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the following research questions: - To what extent are there elements without direct benefit 
in paediatric studies with direct benefit and vice versa? - What are the practical drawbacks for using a procedure-
level approach to ethical review? 
Our study showed that a majority of paediatric intervention studies consist of a 
combination of both procedures with- and procedures without the prospect of 
direct benefit (68%). Of the protocols labelled without the prospect of direct 
benefit, 42% included an intervention that could possibly offer direct benefit. Vice 
versa, of the protocols labelled with the prospect of direct benefit, 94% also 
included one or more procedures without the prospect of direct benefit. Practical 
drawbacks that were mentioned during group discussions with REC-members 
concerned the extra time and special expertise that using this method would 
expectedly cost. Also the need for a clear format was put forward. 
The percentages that we found need to be put in perspective. First, the protocols 
we analysed came from the archives of the Central Committee on Research 
Involving Human Subjects (CCMO) that supervises local committees and is 
responsible for the policy on ethical review, and from three local research ethics 
committees. In the Netherlands, the distinction between paediatric intervention 
studies with- and without direct benefit (the terminology used in practice in the 
Netherlands is ‘therapeutic’ and ‘non-therapeutic’) has organisational implications. 
The CCMO is the only Dutch research ethics committee qualified to review 
paediatric intervention studies without direct benefit. All other accredited re-
search ethics committees are only qualified to review paediatric intervention 
studies with direct benefit.(7) The classification on protocol-level is based on this 
policy. That classification could partly explain the relatively high number of 
protocols without the prospect of direct benefit that nevertheless included an 
intervention that could possibly offer direct benefit. It could be the case that when 
RECs are in doubt about the direct benefit in a protocol, they send it to the CCMO 
to be on the safe side, thereby classifying it as ‘without direct benefit’. This could 
possibly explain the relatively high number of protocols that have a beneficial 
element in them. Still, this does not affect our general conclusion that a substantial 
majority of the paediatric intervention studies that we analysed, consisted of both 
procedures with- and without the prospect of direct benefit. 
The high percentage (94%) of protocols with direct benefit that include at least 
one procedure without direct benefit is in itself not surprising. Administering an 
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investigational drug without properly testing the (side) effects would be bad 
science; therefore additional procedures to test the (side) effects are almost 
inevitable. Only in rare cases it is possible to test for effect without any extra 
blood draws or other procedures. The fact that procedures without direct benefit 
are included is not worrisome in itself. However it is worrisome that some studies 
include a very large amount of extra research procedures without the prospect of 
direct benefit, the so-called package deals.(8) Package deals are studies with an 
intervention that can possibly provide direct benefit, but that also contain a lot of 
extra research procedures that are done for data collection only. In some cases 
additional research questions are added to the protocol and extra measurements 
are done to answer these additional questions.  
A procedure-level approach can help assess such package deals more precisely. 
The model we proposed in chapter 6 focuses on the distinction between proce-
dures with- and procedures without the prospect of direct benefit.(9) However, a 
primary focus on procedures also provides the opportunity to ask other questions 
about each separate procedure, such as the purpose, the value and the relation to 
the various research questions within the protocol. For that reason our proposed 
model seems to be more versatile than other models that have been suggested, 
such as “component analysis” and the “net-risk test”.(10, 11) Also it takes into 
account Wendler’s concern about component analysis, namely that it is prone to 
accepting therapeutic but insignificant interventions. We have also proposed a 
more thorough definition of an intervention or procedure with direct benefit 
alongside our model. Our proposed definition is: an intervention or other proce-
dure that forms a valid therapeutic, diagnostic or preventive option for the 
participants in the study at stake. By ‘a valid option’ we mean that it can expect-
edly compete with other available (therapeutic/diagnostic/preventive) options for 
the patient concerned, so that the patients will not receive inferior care. It also 
acknowledges that procedures can be distinguished based on whether they 
provide direct benefit or not, and we are convinced that this is a relevant distinc-
tion to make. The net-risk test was criticised by Weijer and Miller for unfoundedly 
regarding the therapeutic/non-therapeutic distinction as arbitrary.(12) By propos-
ing our procedure-level approach we aim at a clean approach with a clear 
definition and enough space for dealing with complexities.  
Several REC members whom we spoke to during our study mentioned that some 
procedures may not cause any therapeutic effect, but neither are they done solely 
for data collection purposes. For example, when administering an investigational 
General discussion 
 
127 
 
drug, the safety of the drug has to be monitored throughout the course of the 
study in order to protect the participants from undue harm. Given the fact that 
the participants receive the investigational drug, safety monitoring is by all means 
necessary. Indeed such procedures are not done solely for research purposes, but 
also for safety purposes within the setting of clinical research. However, that does 
not mean that these safety-monitoring procedures provide potential direct 
benefit, as some of the REC members claimed. They do provide protection, but 
only given the administration of the investigational drug. The monitoring proce-
dure in itself does not provide any direct benefit. How, then, should these 
procedures be framed? We propose the following: safety-monitoring procedures 
should not be regarded as offering the prospect of direct benefit, but are con-
nected to the study intervention that does offer the prospect of direct benefit as 
they provide protection within the context of receiving the study intervention. 
Safety-monitoring procedures with higher than minimal risks and/or burdens, can 
be acceptable if the study intervention has net-benefits. For example because it is 
a promising intervention that is expectedly much better than existing alternatives, 
or because it is a new drug for a disease for which no treatment yet exists. These 
net-benefits can compensate for the higher risks or burdens of the safety-
monitoring procedures. 
When approaching such complex protocols on the procedure-level, several 
questions need to be asked: 
1. What is the purpose/are the purposes of each individual procedure 
(providing potential direct benefit, safety monitoring, data collection etc.)? 
2. Which procedures relate to the primary and which to the secondary re-
search questions? 
3. What are the risks/burdens and the benefits (if any) of each procedure? 
4. How do the risks and burdens of each procedure relate to the anticipated 
benefit (i.e. are they minimal or proportional, and are they minimised)? 
5. How do the anticipated risks/burdens and benefits of the intervention re-
late to other available therapeutic/diagnostic/preventive options for the 
participants? 
The approach that we propose is a flexible one. It does justice to the large diversi-
ty and complexity of research protocols. Assessing risks, burdens and benefits 
first on the procedure-level, rather than on the protocol-level, is the most promis-
ing way forward when aiming for fair, precise, clear and transparent ethical 
review. 
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SUBPROJECT 2: DOCTORS VIEWS ON RESEARCH BURDEN FOR CHILDREN 
This subproject aimed to generate more empirical data on research burden for 
children. Such data are helpful for RECs when reviewing paediatric research 
protocols. Until now, not a lot is known on how burdensome certain research 
procedures are for children, especially not in relation to the categories often used 
by RECs; minimal burden, a minor increase over minimal burden and more than a 
minor increase over minimal burden.(13, 14)  
The following research question was asked: - What is the burden of several research procedures for 
children, according to paediatricians? 
To answer this question we asked paediatricians to classify thirteen research 
procedures into the categories of minimal burden, a minor increase over minimal 
burden and more than a minor increase over minimal burden. The following 
research procedures were included; bronchial challenge test, a single venipunc-
ture, repeated venipunctures (8x in 6 months), spirometry/pulmonary function 
test, muscle biopsy, insertion of a venous cannula, allergy skin test, lumbar 
puncture, buccal swab, bone marrow aspiration (sedated), 1 hour MRI scan 
unsedated, echocardiography and hospitalisation for two days. 
Our questionnaire study showed that on some procedures there was more 
consensus than on others. For example a buccal swab was seen as minimally 
burdensome by a very large majority of the respondents, and also an echocardi-
ography was classified thus by most respondents. A large majority classified a 
muscle biopsy and a lumbar puncture as more than a minor increase over minimal 
burden. However, on most procedures there was either only a small majority for 
one of the classifications, or no majority at all.  
The spread in classifications may either have to do with actual differing experi-
ences of the respondents, or with the content of the three classifications not being 
clear enough. With regard to the first issue; physicians might have differing 
experiences due to working with different age- and/or patient groups. To under-
stand those differences it would help if more was known about how factors like 
age, the nature of the disease and prior experience with hospitals, influence 
children’s experience of burden.(15, 16) Knowledge on burden experienced by 
various age- and patient groups is helpful for RECs while assessing the risks and 
burdens compared to the benefits of paediatric studies. With regard to the 
second issue; the content of the classifications, it could be the case that even with 
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similar experiences, physicians would categorise a procedure differently because 
the definitions of the categories are fuzzy. A clear and more operational definition 
of minimal burden may be helpful. Westra and colleagues have proposed such a 
definition, namely that the burden, or risk of discomfort, is minimal when: ‘empiri-
cal data, expert opinions and/or the procedural characteristics (e.g. invasiveness; 
disturbance of normal routines) suggest that at most a quarter of the persons 
concerned will experience considerable discomfort’.(17) 
SUBPROJECT 3: DISCOMFORT AND DISSENT 
The starting point of this subproject was the evaluation of the Dutch Code of 
conduct related to expressions of objection by minors participating in medical 
research.(18) We collaborated with the core working group ‘Guideline criteria for 
research with children’, installed by the Paediatric Association of The Netherlands. 
While evaluating the Code, we found that the issue is broader than objection 
alone and that on an international scale guidance on this issue is inconsistent and 
incomplete. We therefore aimed to analyse the issue thoroughly and to provide 
the required clarity. To that end we set out to answer the following research 
question: - When, and on what ground should signs of discontent 
and dissent lead to withdrawing a child from a trial? 
A proper ethical review process together with a proper informed consent process 
provides a solid basis for including a child in a paediatric research study. Still, for a 
certain child participation can be harder or more burdensome than expected. The 
child may show signs of discomfort, discontent and dissent in a multitude of ways. 
Our analysis showed that there are two types of reasons to take such signs very 
seriously. These two types of reasons are related to two central ethical principles, 
namely: (1) respect for the growing autonomy of the child, in those cases where a 
child expresses a clear, explicit and persistent wish to be withdrawn from the 
study; and (2) non-maleficence, in those cases where the research burden for a 
specific child appears to exceed the level what was found acceptable during the 
ethical review process (for all eligible children) and was agreed to during the 
informed consent process (for the individual child). 
We have recommended that during the course of a study all individual children 
should be monitored systematically. This monitoring should focus on the following 
two questions: (1) does the child still want to continue its participation?, and (2) is 
the level of burden that the child experiences still acceptable in relation to the 
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permitted level of burden for the study concerned? It is advisable to relate the last 
question to whether or not the research can provide direct benefit. Also in this 
case the focus should preferably be on the procedure-level.  
We also provided practical recommendation to the working group ‘Guideline 
criteria for research with children, for revising the current code of conduct. These 
recommendations are discussed more extensively later on in this chapter. 
MISSED OPPORTUNITIES IN RECENT REGULATORY CHANGES 
In the past years several laws and ethical guidelines concerning the regulation of 
biomedical research with humans have been revised or replaced, which brought 
changes in the governance of medical research with children. The European 
Clinical Trials Regulation (CTR), which regulates drug trials, repeals the European 
Clinical Trials Directive (CTD).(19, 20) With that replacement both the content and 
the legislative force were changed. The CTR will apply directly to all EU member 
states without the intervention of national laws, thereby having direct legislative 
force. In this section I will reflect on the recent regulatory changes and point out 
some opportunities that in my view were missed. 
A RELATIVE STANDARD FOR RISK AND BURDEN 
One of the changes with regard to the inclusion of children in drug trials con-
cerned the acceptability of risk and burden. The CTD did not explicitly distinguish 
between research with- and without the prospect of direct benefit and as such it 
did not set any upper limit regarding the risk and burden in research without 
direct benefit. It only required (in article 4) that the research had ‘some direct 
benefit for the group of patients’ and that the risks and burdens were minimised in 
relation to the disease and developmental stage.(20) The CTD was the only 
document not to set any upper limit for risk and burden in paediatric research 
without direct benefit. The new CTR does set an upper limit, namely; minimal risk 
and minimal burden related to the standard treatment of the patient.(19) Whether 
this new standard is an absolute or a relative one depends on its interpreta-
tion.(21) However, the most obvious interpretation would be that it represents a 
relative standard, meaning that a higher level of risk and burden is allowed in 
research without direct benefit with patients who face higher risks and burdens in 
the context of their treatment, than for similar research with patients undergoing 
less severe treatments.  
It is remarkable that a relative standard was adopted in the Clinical Trials Regula-
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tion. There has been extensive debate in the United States about whether the 
definition of minimal risk used in the Federal Regulations (the probability and 
magnitude of harm or discomfort anticipated in the research are not greater than 
those ordinarily encountered in daily life or during routine physical or psychologi-
cal examinations or tests) should be regarded as an absolute or a relative one.(17, 
22-26) Obviously, the routine examinations and tests some patients undergo 
involve far more risk than the ones other patients, or even healthy children, usually 
undergo. In the context of that debate many scholars have convincingly argued 
that a relative standard is unjust, as it would mean that healthy children would 
receive a higher level of protection than patients.(27) By consequence, patients 
receiving the most severe treatments would receive the lowest protection (in 
terms of the acceptability of risk) in the context of research without direct benefit. 
Those in favour of a relative standard argue that this is justified because children 
who undergo risky and burdensome medical procedures in the context of stand-
ard care are more used to them and as such it would be less of a problem for 
them to also undergo them in the context of research.(28) This argument is 
problematic in two respects. First, while it might be correct that children can get 
used to certain procedures in terms of burden (or risk of discomfort), one cannot 
get used to the risks (of harm). Second, while some children do get used to 
certain procedures in terms of burden and by consequence experience less 
discomfort when undergoing them again, others have bad experiences with the 
same procedures and experience more discomfort the next time around.(27) Thus, 
children in the latter category would receive inferior protection with a relative 
minimal risk standard, as those children will likely experience more discomfort 
than what can reasonably be considered minimal. A counterargument would be to 
trust that these children and their parents, after being informed about the pur-
pose, the design and the risks of a trial, would not consent to those trials, as they 
know it contains a procedure that the child is uncomfortable with. That argument 
is somewhat naïve, as therapeutic misunderstandings and sloppy informed 
consent practices have long been and still are prevalent.(29-31) Until those 
problems are solved, accepting more than minimal risk and burden for research 
without direct benefit should only be done with the greatest caution.  
Adopting a relative standard for all paediatric drug research in the Clinical Trials 
Regulation does not demonstrate such caution. Apparently, the American debate 
on the minimal risk standard was not taken into account while drafting the CTR, 
which is a missed opportunity. It would have been better to clearly formulate an 
absolute standard of minimal risk and burden for research without direct benefit, 
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and to allow exceptions for extraordinary valuable research, while clearly stating 
in which situations, under which conditions and by which regulatory bodies such 
exceptions can justifiably be made.  
PROCEDURE-LEVEL APPROACH 
Alongside the drafting of the European Clinical Trials Regulation, the CIOMS 
guidelines (2015) and the Declaration of Helsinki (2013) were revised as well.(32, 
33) The revised CIOMS guidelines have been drafted in 2015 and were approved 
by the General Assembly in 2016. The CIOMS guidelines are the only ethical 
guidelines in which a procedure-level approach to the risk-benefit assessment was 
explicitly adopted. Due to the lack of agreement among ethicists about which 
procedure-level approach is preferable (component analysis or the net-risk test), a 
more general approach was chosen in the revised guidelines.(10, 11) In paragraph 
4 it is stated that ‘it is essential not to directly judge the risks and potential 
benefits of studies as a whole in order to avoid missing potential concerns about 
individual interventions. Rather, the risks and potential benefits of each individual 
research intervention or procedure in the study must first be evaluated. Then, in a 
second step, the aggregate risks and potential benefits of the entire study must 
be assessed and must be considered appropriate’.(33) This requirement grasps 
the mere basics of a procedure-level approach, but still emphasises why it is 
important to assess all procedures separately first.  
Unlike the CIOMS guidelines, the Declaration of Helsinki and European Clinical 
Trials Regulation did not choose to adopt a procedure-level approach in their 
latest revision or drafting. This is unfortunate, as both are highly influential 
documents that could have taken the opportunity to incorporate recent develop-
ments in research ethics, thereby potentially contributing to improvement of 
ethical review practices. 
WAYS FORWARD  
The protection of children as subjects in biomedical research has been greatly 
improved ever since the drafting of the Nuremberg Code in which basic principles 
like voluntariness, the avoidance of unnecessary harm and the proportionality of 
risks were first declared in an internationally adopted document in the context of 
research with humans.(34) Since then, many other ethical guidelines and legal 
documents have started to govern medical research with human subjects on the 
national and international level, with the aim to foster ethical research conduct 
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and to properly protect research participants.(19, 20, 22, 35-39) Over time these 
documents got more specific. They started to focus on specific groups of subjects 
and have zoomed in on specific ethical challenges in research, such as the use of 
placebo and research in developing countries.(38, 40)  
As I mentioned in the general introduction of this thesis, ethics stories rarely come 
with actual endings. Ethics is a philosophical discipline that aims to answer the 
question ‘what should I do?’.(41) Medical ethics strives to know what is the right 
thing to do within the context of medical care, and in this case specifically, in the 
context of paediatric research. The context continually changes, develops and 
innovates and with that, new ethical challenges arise. Currently existing measures 
of protection leave space for strengthening and improvement and could be better 
directed to actual questions from this evolving context. With this thesis I aim to 
contribute to the strengthening of the existing protective measures. In this section 
I will propose several ways forward concerning this space for improvement, that 
follow from the results of my research project. 
THE VALUE OF A PROCEDURE-LEVEL FOCUS BEYOND ETHICAL REVIEW 
As was described in chapter 6, a procedure-level approach to the assessment of 
risks and benefits has the potential to seriously improve the ethical review of 
paediatric research protocols. I also shortly mentioned that such a procedure-level 
approach may benefit other steps in the research process as well. Ideally, all 
professionals involved in paediatric research are aware of the distinction between 
procedures with- and procedures without direct benefit and of the accompanying 
requirements concerning risk and burden.  
The first step in which a procedure-level approach can be valuable is the design of 
research projects. A primary focus on procedures stimulates critical thinking 
about the intention and the value (for science only or also for treatment/diagnos-
tics/prevention) of each separate research procedure. While designing a research 
project it seems helpful to ask the following questions about every single proce-
dure; (1) what is the aim/are the aims of the procedure? (2) can the procedure 
provide therapeutic/diagnostic/preventive benefit to the participants themselves? 
and (3) what are the risks and the burdens of the procedure and are they mini-
mised? Obviously, researchers know that paediatric research is subject to certain 
rules concerning the acceptability of risk and burden. However, they are not 
always exactly aware of the ethical considerations underlying these rules. This 
offers space for improvement and the opportunity to improve ethical research 
practices. It is not unlikely that more knowledge of the ethical principles on which 
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legal rules are founded, helps researchers to construe research designs that are 
better balanced in terms of risks, burdens and benefits, especially when combined 
with a procedure-level focus.  
Second, a procedure-level approach will likely improve ethical review of protocols, 
as was described extensively in chapter 6. Summarising, a procedure-level 
approach has substantial advantages compared to the conventional approach 
that approaches protocols as a whole. In addition to a more precise and transpar-
ent risk-benefit assessment, it could account for an earlier identification of other 
ethical concerns, such as procedures that are unlikely to yield important data or 
procedures that can be replaced by a less risky or burdensome one. 
Third, the process of informed consent may benefit from the awareness that a 
research protocol can consist of a combination of procedures that are done in 
order to collect data, and of procedures that can (also) benefit the participants 
themselves. Clearly, a valid informed consent requires a proper understanding of 
the research risks and burdens. In order to decide whether they accept the risks 
and burdens of a study, children and parents should know which risks and bur-
dens relate to a beneficial procedure and which risks and burdens relate solely to 
the purpose of research. Proper, clear and honest information is more likely to 
lead to a durable decision.  
Lastly, for the monitoring of risk and burden during the course of the trial, a 
procedure-level focus is important as well. The level of burden that a study is 
expected to impose on children, does not always align with the actual experi-
enced burden of a specific child. This can lead to situations that raise doubt about 
whether it is still justified to keep a child in a trial.(42) A proposal for guidance on 
how to react to such situations was provided in chapter 8. While monitoring the 
actual burden a child experiences, a procedure-level focus can be helpful as it 
makes clear which level of burden is acceptable for the procedure concerned. 
Procedures that cannot offer any direct benefit for the participants should impose 
no more than minimal burden (as was argued in chapter 6). Otherwise, the burden 
of procedures that can offer direct benefit should be proportional in relation to 
the expected benefit. A clear and well thought out decision therefore relies on a 
clear view on the purpose and value of each procedure.  
It could be helpful for both researchers and research ethics committees to use a 
clear format for the identification and assessment of separate procedures.  
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ALLOWING EXCEPTIONALLY VALUABLE, BUT HIGHER RISK RESEARCH 
In the general introduction of this thesis I have described the long process of 
changing the Dutch national law on research involving human subjects, with 
regard to paediatric research. It had started with discontent among paediatricians 
about the restrictiveness of the law. They felt that the law did not provide enough 
possibility for doing paediatric research without direct benefit and that the  
Netherlands lagged behind other countries in terms of medical-scientific innova-
tion.(43, 44) Around the same time the CCMO expressed the wish to be able to 
approve valuable studies that until that time laid beyond the scope of what the 
law permitted.(45) The Committee Doek then concluded that the ‘negligible risk 
and minimal burden’ requirement should be removed from the law altogether.(46) 
Yet, the advice of the Committee Doek was not adopted in the draft of the revised 
law. Instead, the American standard of ‘a minor increase over minimal risk (and 
burden)’ was chosen in the new proposal.(47, 48) However meanwhile the 
European Clinical Trials Regulation was drafted and approved, so the final version 
of the revised Dutch law was adjusted to the CTR, as the CTR would have direct 
legislating force. The new minimal risk requirement is therefore that research 
without the prospect of direct benefit may impose only ‘minimal risk and minimal 
burden related to the standard treatment of the patient’.(19) 
As argued before, expanding the leeway for paediatric research without direct 
benefit by replacing the absolute minimal risk standard for a relative one was 
irresponsible, as it gives too much space for research that is riskier than accepta-
ble. The proposal of allowing a ‘a minor increase over minimal risk’ was less 
problematic, but it is doubtful whether it would have even been necessary. 
Regardless of the idea that exists among paediatric researchers that research 
without direct benefit is nearly impossible because of legal limitations, research by 
Westra et al shows otherwise. They studied all decisions by the CCMO about the 
165 proposed paediatric research protocols without direct benefit between the 
years 2000 and 2007. Of these 165 protocols, 111 were observational studies and 
54 were intervention studies. The analysis by Westra et al shows that the CCMO 
rejected only three protocols for the single reason that the risks or burdens 
exceeded the minimal level. Eight other protocols for which the minimal risk and 
burden requirement was a reason for rejection, also failed to meet other ethical 
requirements, like group relatedness. In 26 other cases protocols ultimately got 
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approved after modification related to the requirement of minimal risk and 
burden.(49)1 It could be the case that researchers do not propose protocols they 
judge to be out of bounds, to research ethics committees, thereby leading to a 
‘proposal bias’. Unfortunately no data are available on how many protocols are 
not proposed to research ethics committees, or even not designed at all because 
of the expectancy that they will be rejected.(46) Still, the question remains 
whether changing the minimal risk and burden requirement is the best solution. 
The analysis by Westra et al showed that many protocols without direct benefit 
did get approval, either immediately or after modification.(49) Apparently, the 
CCMO is willing to work with researchers in order to adjust the proposed proto-
cols towards an acceptable level of risk and burden. Maybe researchers are 
insufficiently aware of the possibilities of doing paediatric research without direct 
benefit, despite the legal restrictions. If this were the case, the solution would be 
to educate researchers on this matter, rather than to change the law. 
Sometimes a higher-risk protocol without direct benefit is so promising and 
valuable, that the higher risks are justified for that specific case and it is important 
that there is a way to approve such protocols. The same study by Westra et al 
shows examples of valuable studies that should have been rejected when strictly 
following the legal framework. Still, because of their importance the CCMO 
approved them by stretching the notion of direct benefit.(49) Such regulatory 
detours are not a desirable and durable solution. But expanding the minimal risk 
standard itself gives space to all protocols without direct benefit to incorporate 
higher risks, not only the really promising ones. A much more elegant and far less 
cumbersome solution than changing the concerning law article, would be to grant 
the CCMO the discretion to make exceptions to the minimal risk and burden 
requirement in cases of exceptionally promising and valuable research, under the 
condition that the committee seeks expert advice and transparently reports how 
it came to the decision to deviate from the minimal risk requirement. Obviously, 
this is not possible as long as the European Clinical Trials Regulation requires 
otherwise.  
  
                                                  
 
1 The CCMO uses its own interpretation of the national law for distinguishing  
between research with-, and research without direct benefit. It may be the case 
that following that interpretation, relatively many protocols are labelled as without 
direct benefit. 
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THE QUALITY OF RESEARCH ETHICS COMMITTEES 
It has always been important to guarantee the quality of RECs. Yet, with the high 
number of RECs in some EU countries, it has been questionable whether all these 
committees have adequate (paediatric) expertise and experience. It seems that in 
several EU countries the number of RECs has somewhat decreased in past years, 
for example in the Netherlands and the United Kingdom.(50, 51) That could be a 
positive development, as individual committees will probably gain more reviewing 
experience with paediatric protocols.  
The approval of the new Clinical Trials Regulation brought changes in the govern-
ance of paediatric drug research. All EU member states will be bound to the 
requirement of minimal risk and burden in relation to the standard treatment of 
the patient for paediatric drug research without direct benefit. For some EU 
member states that is a stricter requirement than before (e.g. Belgium), while for 
others it is a wider requirement (e.g. the Netherlands, that had a stricter version of 
the requirement before but chose to adjust the national law in accordance with 
the CTR). Whether stricter or wider than before, for all EU countries counts that 
quite a complex risk-benefit assessment needs to be carried out for paediatric 
drug research without direct benefit. This requires that committees that review 
such research have excellent paediatric expertise and sufficient experience.  
On top of that, with the new CTR coming into force, more authority is granted to 
the so-called ‘reporting member state’ in multinational trials. The reporting 
member state, proposed by the sponsor, makes the final decision about the risk-
benefit assessment. While the other participating member states are to be 
consulted about the risk-benefit assessment, this needs to be done in a rather 
limited time frame. Their main task is to assess local aspects such as the informed 
consent material, the qualifications of the investigators and the trial site.(19, 52) 
With these large responsibilities, the quality of the assessment should be guaran-
teed, but unfortunately it is not. The Clinical Trials Regulation includes no 
measures that can guarantee the quality of RECs. This was discussed in chapter 5.  
An example of efforts to guarantee adequate experience and expertise is found in 
the Netherlands. The REC of the UMC Utrecht in the Netherlands has a dedicated 
and specialised chamber that reviews research with children.(53) Moreover, as 
mentioned before, the central committee (CCMO) is the only REC that is qualified 
to review paediatric intervention studies without direct benefit.(7) Lastly, the 
revised national law requires that at least one paediatrician should be part of 
every REC that reviews paediatric protocols.(54) 
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GUIDANCE FOR PROPER PROTECTION DURING THE PERFORMANCE OF 
RESEARCH 
The ethics of including children in clinical research remains a topic of great 
interest and this is not surprising. It is easy to relate to the harm potentially 
inflicted by both the lack of proper treatments for childhood diseases, as well as 
by the risks of testing new interventions on children. This is the basic dilemma 
underlying all challenges in paediatric research ethics.(1) Some topics within this 
domain have been researched and discussed extensively, especially the legal 
requirements, the ethical review process and the informed consent process. 
Examples are the debates about the minimal risk standard and about the value of 
assent. Still, surprisingly little was written on how to properly protect children 
when they are already participating in the trial.(55, 56) Besides that, the relevant 
laws and ethical guidelines provide rather sparse and inconsistent guidance on 
how to guarantee the protection of children during trial participation. Although 
voluntariness has been a central value ever since the emergence of research 
ethics, during the performance of research studies it is safeguarded in a rather 
minimalist way. Looking at laws and ethical guidelines, it seems that requiring 
respect for dissent or objection of a child, is regarded as good enough protection. 
Yet, the exact content of concepts like ‘dissent’ and ‘objection’ remain quite 
vague, as do the consequences that should follow on dissent or objection. Such 
vagueness hardly contributes to proper protection.  
Meanwhile, many research professionals are interested in protecting children 
during a trial. From a workshop we organised for research nurses and from 
discussions after presentations we gave, it became apparent that in practice it is 
very difficult to decide when to withdraw a child from a study. Many of the 
research nurses we spoke to, could name one or more examples of children 
having such a hard time undergoing research procedures that it raised doubt 
about whether the research should continue with that child.  
In chapter 8 we proposed a more thorough view on how the protection of 
children during the performance of studies should be safeguarded. In that chapter 
we showed that respect for dissent should not be confused with protection 
against undue burden. Both the voluntariness of, and the degree of burden for 
each individual child should be closely monitored throughout the entire course of  
paediatric studies.  
As a part of our study we evaluated the Dutch ‘Code of conduct relating to 
expressions of objection by minors participating in medical research’ and pro-
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posed a revised version of the code.(18) Our recommendations for a revised code 
were, apart from the evaluation of the initial code, based on our conceptual 
analysis, our analysis of the most influential legal and ethical guidelines (chapter 
8) and on feedback from research nurses during a focus group and a workshop. 
The revised code, which we co-wrote, is currently in the process of approval. We 
recommended that the following elements be included in the revised code: - Instead of asking the question whether the child shows signs of objection, 
ask the question whether the child should be withdrawn from the study. - When deciding about whether a child should be withdrawn from a study, 
distinguish between decisions based on high levels of experienced burden, 
and decisions based on the explicit wish of the child. - Both the experienced burden and the voluntariness of the child should be 
closely monitored throughout the entire course of a study. - While monitoring the degree of burden a child experiences, the purpose of 
the research procedure at stake should be kept in mind. The burden of 
procedures that can offer direct benefit for the child should be proportion-
al in relation to the anticipated benefit. Procedures that do not offer any 
direct benefit, i.e. are done for research purposes only, should pose no 
more than minimal burden. Research professionals need to be vigilant that 
the experienced burden of each individual child does not exceed these 
permitted levels of burden. For example, research ethics committees usual-
ly assume that a single blood draw poses no more than minimal burden. 
Still, a child can be overly scared of a single blood draw and start to panic. 
In that specific case the burden is likely to exceed the minimal level, and 
that should be taken seriously. Also, research professionals should be sen-
sitive to the various ways children show their discomfort. While the one 
child panics, the other child may feel less confident in expressing discom-
fort and remains relatively silent. However difficult it is to monitor such 
vague signs of discomfort, it is worthwhile to do it as well as possible.  - The research protocol should provide information on how the monitoring 
of burden is to be done. Standardisation of monitoring is not necessary. - When monitoring reveals that the burden is too high for a certain child, the 
research team, together with the parents, should attempt to lower the bur-
den. Comforting the child, distraction by music or a video, waiting for a 
little while and so on are examples of possible ways to lower the burden.  
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- The parents should be involved in the interpretation of the behaviour of the 
child. - The burden of research procedures should always be minimised. Apart 
from choosing the least burdensome procedure, this also involves a child-
friendly setting, experienced research professionals and proper information 
and preparation for the child concerned.  - When a child expresses an explicit wish to stop participating, this wish 
should be respected. - At various points in time during the course of a study, a research profes-
sional should evaluate the research participation with the child and the 
parents. The research professional can remind the child and the parents 
that participation is voluntary and that the decision to stop can be made at 
any time.  
SUGGESTIONS FOR FURTHER RESEARCH 
We have argued why a procedure-level approach to ethical review is a promising 
way forward towards a more clear and precise risk-benefit assessment. We have 
proposed a clear and useful definition of direct benefit as well as a model of the 
various steps of the procedure-level approach. Research into the implementation 
of this method would be advisable and would ideally start with a pilot project, 
which is carefully evaluated afterwards to detect bottlenecks and opportunities 
for improvement. Attention should be given to the development of a format in 
which procedures with- and without direct benefit can be distinguished, as well as 
procedures related to the primary and the secondary research questions. 
We have conducted an exploratory study on research burden for children as 
estimated by paediatricians. Simultaneously, a study on the self-reported burden 
of children was carried out.(15) An interesting follow up would be to compare the 
experiences or estimations by the various parties involved in the same trial. 
Ideally, the reviewing REC, the research professionals performing the study, the 
children undergoing the study and their parents are asked about the burden of 
the research. This way the viewpoints of the different parties can be meaningfully 
compared. 
The revised code of conduct on objection, which we co-wrote, should be evaluat-
ed after several years of use. A code of conduct is only useful when it is readable 
and understandable; both content-wise and language-wise. Evaluation should 
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focus on this. It should be researched how the key concepts in the code are 
understood and how they are brought to practice. It would be interesting to see 
what monitoring strategies are used and how they could be improved. The 
improvement and/or development of monitoring strategies could also be an 
interesting and important research subject itself. 
CONCLUDING REMARKS 
Lewis Carroll taught us how to tell a story, but he taught us another lesson too. 
The right road to take depends a great deal on where we want to go.(57) Where I 
want to go in this case is a paediatric research context in which children are 
approached respectfully with regard to all their relevant characteristics. Children 
are vulnerable and they cannot (fully) consent to research participation. All 
protective measures for children as research participants evolve around this 
notion. But children are not only vulnerable and unable to consent.(2) They are 
persons, with experiences, with ideas and with opinions. Growth and development 
are essential and inherent characteristics of childhood. As such, children should be 
regarded partners in the research project, rather than subjects alone. Yes, children 
deserve the best protection, and that should include protection of their develop-
mental growth and their emerging autonomy. That means that besides 
recognising what they cannot yet do, we also need to see and recognise what 
children can do. Whenever possible, we should strengthen the position of children 
by involving them in issues that concern them, encourage them to voice their 
wishes, questions and concerns and create an environment in which they can feel 
confident to do so.  
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ENGLISH SUMMARY 
In chapter 1, the general introduction, I sketch the central dilemma around which 
all questions in paediatric research ethics evolve. Either we accept that children 
who are ill cannot be properly treated or receive treatments that are not well 
researched, or we have to include children - who are vulnerable and unable to 
consent - in clinical research, which can possibly harm them. Children deserve to 
be protected against such harm, but they also deserve timely access to medical 
treatments. The large number of off-label and unlicensed prescriptions in  
paediatrics illustrates the need for more clinical research with children. The main 
challenge then is to find the most responsible way to regulate and perform 
research with children. While in general this is a much-discussed topic, there are 
specific questions that still need reflection and research.  
Chapter 2 sketches the central ethical issues of clinical research with children. I 
give an overview of the regulatory landscape within the European Union. I 
specifically address two major ethical concerns; namely the acceptability of 
research risks and the informed consent process. The biggest challenges ahead 
are the implementation of legal requirements and the fostering of ethical research 
conduct in practice. By means of a short appendix I describe the repealing of the 
European Clinical Trials Directive by the European Clinical Trials Regulation, which 
was approved after the publication of our paper. 
Then, after overviewing the regulatory framework and central ethical concerns, 
the thesis moves to an example from paediatric research practice in chapter 3. 
This chapter describes the case of a multinational paediatric research protocol on 
Duchenne muscular dystrophy that was approved in Belgium and Sweden but not 
in the Netherlands. All three countries are member states of the European Union 
and as such are subjected to the Clinical Trials Directive. The Directive aimed to 
harmonise the ethical review of multinational trials, but nevertheless ethical review 
outcomes differ. We took the case of this protocol to start a discussion on the 
acceptability of risk and burden. After illustrating the case, we asked the various 
parties involved in the case to reflect on whether and why the risks and burdens 
of this protocol were acceptable. Afterwards, two independent commentators 
reflected on the same question. Although the question we asked largely remained 
undiscussed, the discussion revealed some other questions that still need to be 
researched.  
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Chapter 4 focuses on the morally relevant characteristics of children as research 
subjects. Children are compared with another vulnerable group of subjects; 
namely dementia patients. These two groups of research subjects have certain 
characteristics in common and differ in others. The relevant characteristics of 
these two groups are not always well reflected in the regulatory framework. This 
chapter provides an overview of the relevant criteria and requirements in interna-
tional legislation and ethical guidelines and identifies inconsistencies with respect 
to the two groups.  
As mentioned before, during the course of our research project the new European 
Clinical Trials Regulation was drafted and approved. Chapter 5 presents a critical 
analysis of the new regulation. The new regulation will replace the Clinical Trials 
Directive, which did not reach its goals of simplifying and harmonising the process 
of scientific and ethical review. However, the new Regulation also fails to guaran-
tee the quality of the review process. Two main concerns described in this chapter 
are the quality of the risk-benefit assessment and the quality of ethics commit-
tees. 
Chapter 6 presents the results of the first main subproject. This chapter discusses 
the need for a procedure-level approach to the risk-benefit assessment of paedi-
atric research protocols. This means that research protocols are not primarily 
approached as with- or without the prospect of direct benefit as whole, but 
instead the first focus is on the separate procedures within the protocol. The 
theoretical advantages of a procedure-level approach, like a more fair and precise 
risk-benefit assessment, have been made clear already, but little empirical re-
search has been done on the practical aspects. We showed that a majority of the 
research protocols consist of both procedures with- and without a prospect of 
direct benefit for the participants and that a rigid distinction on protocol-level is 
not tenable. Moreover, we discuss some related questions as well as practical 
concerns. 
The second main subproject is presented in chapter 7. It describes paediatricians’ 
views on research burden for children. Research with children is strictly regulated, 
and the permitted levels of burden for the participants are limited. For example, 
research that offers no possible direct benefit for the participants is usually 
considered acceptable when it, among other requirements, entails no more than 
(a minor increase over) minimal burden. The concept of burden therefore plays an 
important role in paediatric research ethics. This chapter presents the results of a 
questionnaire study among 86 physicians. The physicians were asked to put 
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thirteen common research procedures into the categories of ‘minimal burden’, ‘a 
minor increase over minimal burden’ and ‘more than a minor increase over 
minimal burden’. Although some procedures are clearly put in the category of 
‘minimal burden’ by a large majority of the respondents, and other procedures on 
the other end of the spectrum, there is disagreement among physicians about 
most of the procedures. This raises ethical questions. For example; given such 
disagreement, how can the concept of minimal burden be used in a meaningful 
way? 
Chapter 8 presents the results of the third main subproject. It focuses on the 
protection of children after their inclusion in clinical research. However profound 
and precise the efforts of research ethics committees and research professionals 
are during the ethical review and the informed consent phase, they are no guaran-
tees that participation is not harder than expected for a specific child. Adequately 
protecting children during the course of a study also means ‘to react properly to 
signs of discomfort and dissent’. It needs to be clear in what kind of situations 
participation is still justified, and in what kind of situations it is not. In this chapter 
we show that guidance on this matter is scarce and inconsistent. We propose a 
more thorough approach as well as practical recommendations on how to safe-
guard the protection of children, also during this phase of the study. We argue 
that during research participation each child should be constantly monitored. 
Monitoring should focus on whether research participation of the child is still 
voluntary, and on whether the actual experienced research burden is not higher 
than acceptable. 
Ultimately, practical proposals are needed for the improvement of ethical research 
conduct. In chapter 9, the general discussion, I present the main conclusions of 
our research project, but I also identify missed opportunities concerning the 
recent regulatory changes. Lastly, I present my ideas on the possible ways 
forward for the future of paediatric research ethics. 
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NEDERLANDSE SAMENVATTING 
In hoofdstuk 1, de algemene inleiding, schets ik het centrale dilemma van de ethiek 
van medisch-wetenschappelijk onderzoek met kinderen. Ofwel we accepteren dat 
zieke kinderen niet goed behandeld kunnen worden of behandelingen krijgen die 
niet goed zijn onderzocht. Ofwel we moeten kinderen – die kwetsbaar zijn en niet 
zelfstandig kunnen beslissen - includeren in medisch-wetenschappelijk onderzoek 
dat risico’s en belasting met zich mee brengt. Kinderen verdienen bescherming 
tegen zulke risico’s en belasting, maar ze verdienen ook tijdige toegang tot 
medische behandelingen. Het grote percentage off-label gebruik van geneesmid-
delen in de kindergeneeskunde illustreert de noodzaak om meer onderzoek te 
doen bij kinderen. De voornaamste uitdaging is om onderzoek met kinderen op de 
meest verantwoordelijke manier te reguleren en uit te voeren. Hoewel dit in het 
algemeen een veel bediscussieerd onderwerp is, zijn er specifieke vragen die 
onderzoek en reflectie verdienen. 
Hoofdstuk 2 schetst de centrale ethische kwesties met betrekking tot medisch-
wetenschappelijk onderzoek met kinderen. Ik beschrijf in dit hoofdstuk de wet- en 
regelgeving binnen de Europese Unie. In dit hoofdstuk noem ik twee belangrijke 
ethische kwesties; namelijk de aanvaardbaarheid van onderzoekrisico’s en het 
informed consent proces. De grootste uitdagingen voor de toekomst zijn de 
implementatie van wettelijke vereisten in de praktijk en het bevorderen van 
ethisch onderzoeksgedrag in de praktijk. In een kort nawoord beschrijf ik dat de 
Europese Richtlijn Geneesmiddelen Onderzoek is vervangen door de Europese 
Verordening Geneesmiddelen Onderzoek, welke door het Europees Parlement 
werd aangenomen na de publicatie van ons paper. 
Na het overzicht van het wettelijke kader en de centrale ethische kwesties, 
vervolgt mijn proefschrift in hoofdstuk 3 met een voorbeeld uit de praktijk van 
onderzoek met kinderen. Dit hoofdstuk beschrijft een multinationale studie naar 
Duchenne spierdystrofie. Deze studie werd goedgekeurd in België en Zweden, 
maar niet in Nederland. Deze landen zijn alle drie lid van de Europese Unie en 
vielen daarmee destijds binnen het bereik van de Europese Richtlijn Geneesmid-
delen Onderzoek. Deze Richtlijn had als doel de ethische toetsing van 
multinationaal onderzoek binnen de EU te harmoniseren, maar toch verschilde het 
besluit tussen deze landen. We hebben deze casus gebruikt om een discussie te 
beginnen over de aanvaardbaarheid van risico’s en belasting. Na het beschrijven 
van de casus hebben we verschillende betrokkenen gevraagd om te reflecteren 
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op de vraag waarom de risico’s en belasting van deze studie wel of niet aan-
vaardbaar waren. Daarna hebben we twee onafhankelijke commentatoren 
gevraagd om op dezelfde vraag te reflecteren. Hoewel onze vraag voor een groot 
deel onbeantwoord bleef, heeft de discussie wel een aantal andere vragen 
blootgelegd die verder onderzocht moeten worden. 
Hoofdstuk 4 richt zich op de moreel relevante eigenschappen van kinderen als 
proefpersonen in onderzoek. Kinderen worden vergeleken met een andere groep 
van kwetsbare proefpersonen; namelijk mensen met dementie. Deze twee groe-
pen van proefpersonen delen bepaalde eigenschappen maar verschillen in andere 
eigenschappen. De relevante eigenschappen van deze twee groepen zijn niet 
altijd terug te vinden in het wettelijke kader. Dit hoofdstuk geeft een overzicht van 
de relevante criteria en vereisten in internationale wetten en ethische richtlijnen en 
identificeert inconsistenties met betrekking tot de twee groepen. 
Zoals eerder genoemd is tijdens de uitvoering van ons onderzoek de nieuwe 
Europese Verordening Geneesmiddelen Onderzoek opgesteld en aangenomen 
door het Europees Parlement. Hoofdstuk 5 geeft een kritische reflectie op de 
nieuwe Verordening weer. De nieuwe Verordening neemt de plaats in van de 
Europese Richtlijn Geneesmiddelen Onderzoek, die het beoogde doel om het 
proces van wetenschappelijke en ethische toetsing te simplificeren en te harmoni-
seren, niet heeft waargemaakt. Toch lukt het ook de Verordening niet om de 
kwaliteit van het toetsingsproces te waarborgen. De twee voornaamste bezwaren 
zijn het niet waarborgen van de kwaliteit van de afweging van risico’s en voorde-
len en van de kwaliteit van toetsingscommissies. 
Hoofdstuk 6 geeft de resultaten weer van het eerste subproject. Dit hoofdstuk 
bespreekt de noodzaak van toetsing van onderzoek met kinderen op procedure-
niveau. Dat wil zeggen dat onderzoeksprotocollen niet primair benaderd worden 
als studie die in hun geheel wel of geen direct medisch voordeel voor de proef-
persoon bieden. In plaats daarvan ligt de primaire focus bij de afzonderlijke 
procedures binnen het protocol. De theoretische voordelen van een benadering 
op procedureniveau zijn duidelijk; onder andere een eerlijkere en preciezere 
afweging van de risico’s en de voordelen. Maar er is nog nauwelijks empirisch 
onderzoek gedaan naar de praktische aspecten. Onze resultaten laten zien dat de 
meerderheid van onderzoeksprotocollen bestaan uit een combinatie van procedu-
res met- en procedures zonder direct medisch voordeel en dat daarom een rigide 
onderscheid op protocolniveau niet houdbaar is. Ook bespreken we in dit hoofd-
stuk een aantal gerelateerde vragen en praktische aspecten. 
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Het tweede subproject wordt beschreven in hoofdstuk 7. Hierin wordt besproken 
hoe kinderartsen de belasting van meedoen aan onderzoek voor kinderen inschat-
ten. Onderzoek met kinderen wordt strikt gereguleerd en de toegestane mate van 
belasting voor de proefpersonen is beperkt. Bijvoorbeeld, onderzoek dat geen 
potentieel voordeel voor de proefpersonen biedt wordt over het algemeen 
acceptabel bevonden wanneer, naast andere vereisten, de belasting niet meer is 
dan minimaal. Het concept minimale belasting speelt daarom een belangrijke rol in 
de ethiek van onderzoek met kinderen. In dit hoofdstuk staan de resultaten van 
een vragenlijststudie onder 86 artsen. De artsen (overwegend kinderartsen) 
werden gevraagd om dertien onderzoeksprocedures te classificeren in de catego-
rieën ‘minimale belasting’, ‘in gerichte mate meer dan minimale belasting’ en ‘meer 
dan in geringe mate meer dan minimale belasting’. Een aantal procedures werden 
duidelijk geclassificeerd in de eerste of de laatste categorie door een meerderheid 
van de respondenten. Echter, voor veel procedures geldt dat de respondenten het 
niet eens waren over hoe belastend deze zijn voor kinderen. Dit roept ethische 
vragen op. Bijvoorbeeld, als men het niet eens is over de belasting van onder-
zoeksprocedures, hoe kan het concept minimale belasting dan op een zinvolle 
manier worden toegepast? 
In hoofdstuk 8 staat het derde subproject beschreven. Het hoofdstuk richt zich op 
de bescherming van kinderen na de inclusie in medisch-wetenschappelijk onder-
zoek. Hoe grondig en zorgvuldig de ethische toetsing en het informed consent 
proces ook worden uitgevoerd, het geeft geen garanties dat deelname aan 
onderzoek voor een specifiek kind niet zwaarder is dan verwacht. De adequate 
bescherming van kinderen tijdens de uitvoering van een onderzoek betekent ook 
dat er goed moet word gereageerd op signalen van ongemak en verzet. Het moet 
duidelijk zijn in welke situaties deelname van een kind nog verantwoord is, en in 
welke situaties niet. In dit hoofdstuk laten we zien dat het wettelijke en ethische 
kader erg weinig houvast geeft met betrekking tot dit onderwerp. Wij stellen een 
meer grondige en volledige benadering voor met daarbij praktische aanbevelin-
gen over hoe ook tijdens de uitvoeringsfase van onderzoek de bescherming van 
deelnemende kinderen kan worden bewaakt. Wij beargumenteren dat ieder kind 
tijdens een onderzoek continu zou moeten worden gemonitord. Monitoring zou 
zich moeten richten op twee vragen; (1) is deelname van het kind nog steeds 
vrijwillig, en (2) is de werkelijk ervaren belasting voor een kind niet hoger dan 
acceptabel? 
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Uiteindelijk zijn er praktische voorstellen nodig om de bescherming van kinderen 
die meedoen aan onderzoek te waarborgen en te verbeteren. In hoofdstuk 9, de 
algemene discussie, presenteer ik de belangrijkste conclusies van mijn onderzoek. 
Daarnaast identificeer ik gemiste kansen bij recente wijzigingen van wetten en 
ethische richtlijnen. Tot slot presenteer ik mijn ideeën over mogelijke vooruitgang 
van de ethiek van medisch-wetenschappelijk onderzoek met kinderen. 
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SAMENVATTING VOOR KINDEREN 
Dit boek gaat over kinderen die meedoen aan medisch-wetenschappelijk onder-
zoek. Zulk onderzoek is nodig om goed te begrijpen hoe een kinderlichaam werkt. 
Het is ook nodig omdat we willen weten hoe we zieke kinderen beter kunnen 
maken. Daarom worden er soms nieuwe medicijnen getest. In hoofdstuk 1 staat 
wat er allemaal komt kijken bij dat soort onderzoek. Je mag kinderen niet zomaar 
gebruiken als ‘proefkonijnen’. Een nieuw medicijn kan kinderen beter maken, maar 
ook zieker maken. Dat weten we niet van tevoren omdat het nog niet eerder is 
onderzocht. Er zijn daarom regels wanneer onderzoek doen bij kinderen wel en 
niet mag. Dit boek gaat over hoe die regels eruit moeten zien en hoe ze uitge-
voerd moeten worden.  
HOOFDSTUK 2: WETTEN EN REGELS 
Wat we wilden weten: Wanneer mag een kind volgens de wet meedoen aan een 
medisch-wetenschappelijk onderzoek met kinderen? Kunnen deze regels beter? 
Hoe we daar achter zijn gekomen: We lazen de wetten die er zijn in Europa goed. 
We hebben ook gelezen wat andere wetenschappers van de wetten vonden. 
Welk antwoord we hebben gevonden: De belangrijkste regels zijn:  
1. onderzoek mag alleen bij kinderen worden gedaan als het echt niet bij 
volwassenen kan  
2. kinderen moeten informatie krijgen over het onderzoek op hun eigen 
niveau (want ze moeten het kunnen begrijpen)  
3. de ouders moeten toestemming geven en als het kan, het kind zelf ook  
4. onderzoek mag niet te gevaarlijk of te vervelend zijn voor kinderen die 
eraan meedoen.  
Wat beter kan is ervoor te zorgen dat het niet blijft bij regels. Onderzoekers 
moeten zo goed mogelijk omgaan met kinderen die meedoen aan onderzoek. 
HOOFDSTUK 3: EEN VOORBEELD 
Wat we wilden weten: In 2008 hebben wetenschappers een onderzoek bedacht. 
Aan het onderzoek deden kinderen mee met een zeldzame spierziekte. Dit 
onderzoek mocht wel in België en Zweden worden gedaan, maar niet in Neder-
land. Was dit onderzoek nu wel of niet te gevaarlijk en vervelend voor kinderen? 
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Hoe we daarachter zijn gekomen: We vroegen aan de mensen die met het 
onderzoek te maken hadden waarom ze het onderzoek wel of niet te gevaarlijk en 
vervelend vonden. Ook vroegen we hetzelfde aan twee deskundigen die niets met 
het onderzoek te maken hadden. 
Welk antwoord we hebben gevonden: we kregen helaas geen duidelijk antwoord 
op onze vraag. Dus eigenlijk weten we het nog steeds niet. We zijn wel iets anders 
te weten gekomen. Er zijn vragen waar mensen het niet over eens zijn en deze 
vragen moeten onderzocht worden. Bijvoorbeeld: mag je soms een uitzondering 
maken op de regels? Bijvoorbeeld als de ziekte heel erg is en een nieuw medicijn 
later misschien kan helpen?  
HOOFDSTUK 4: KINDEREN ALS KWETSBARE PROEFPERSONEN 
Wat we wilden weten: Kinderen kunnen nog niet goed zelf beslissen of ze mee 
willen doen aan een onderzoek. Mensen met dementie kunnen dat ook niet goed. 
Wat zijn de verschillen én de overeenkomsten tussen kinderen en mensen met 
dementie? Staan die verschillen en overeenkomsten ook in de wet? 
Hoe we daarachter zijn gekomen: We lazen de Nederlandse, Europese en wereld-
wijde wetten over onderzoek doen met mensen. We onderzochten of de regels 
die daarin staan hetzelfde of verschillend zijn voor kinderen en voor mensen met 
dementie.  
Welk antwoord we hebben gevonden: Sommige wetten hebben dezelfde regels 
voor alle proefpersonen die niet zelf kunnen beslissen. Andere wetten hebben 
verschillende regels voor kinderen en voor volwassenen die niet zelf kunnen 
beslissen. Die verschillen hebben bijvoorbeeld te maken met dat mensen met 
dementie vroeger wel nog konden beslissen over onderzoek. Ze konden dus 
‘vooruit’ beslissen. Bij kinderen moet je juist rekening houden met wat zij er later 
van zullen vinden, als ze volwassen zijn. 
HOOFDSTUK 5: DE NIEUWE EUROPESE WET 
Wat we wilden weten: Is de nieuwe Europese wet beter voor kinderen die mee-
doen aan onderzoek? 
Hoe we daarachter zijn gekomen: We lazen de nieuwe wet goed. We vergeleken 
de wet met wat wetenschappers zeggen over hoe je kinderen het best kunt 
beschermen. 
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Welk antwoord we hebben gevonden: De nieuwe wet is voor een deel beter 
geworden. Maar we maken ons ook zorgen. In de wet staat namelijk dat het 
beoordelen van de gevaren en de voordelen voor de kinderen die meedoen, niet 
hoeft te worden gedaan door een ethiekcommissie die hier veel verstand van 
heeft. Wij maken ons daar zorgen over omdat deze beoordeling heel belangrijk is, 
maar ook heel moeilijk. Alleen mensen die daar veel verstand van hebben, kunnen 
dat goed genoeg doen. 
HOOFDSTUK 6: KIJKEN NAAR ‘STUKJES’ VAN HET ONDERZOEK 
Wat we wilden weten: Soms kan een kind door mee te doen aan onderzoek beter 
worden. Er is ook onderzoek waar kinderen niet beter van kunnen worden. 
Bijvoorbeeld omdat alleen wordt onderzocht hoe snel het lichaam een medicijn 
opneemt. De regels zijn strenger voor onderzoek waar kinderen zelf niet beter van 
kunnen worden. Soms is niet helemaal duidelijk of kinderen wel of niet beter 
kunnen worden van een onderzoek. Wij hebben een idee om dat op te lossen. 
Vaak bestaat een onderzoek namelijk uit stukjes waar kinderen wel beter van 
kunnen worden en stukjes waar kinderen niet beter van kunnen worden. Wij 
wilden weten hoe vaak dit voorkomt.  
Hoe we daarachter zijn gekomen: We zochten in ongeveer 75 onderzoeken naar 
stukjes onderzoek waar kinderen wel beter van kunnen worden, en stukjes waar 
kinderen niet beter van kunnen worden. 
Welk antwoord we hebben gevonden: De meeste onderzoeken met kinderen 
bestaan uit beide soorten stukjes. Een speciale commissie moet altijd beoordelen 
of een onderzoek gedaan mag worden. Wij vinden dat zulke commissies beter 
eerst naar deze aparte stukjes kunnen kijken. De commissie kan dan beter bepalen 
of een onderzoek niet te gevaarlijk en te vervelend is voor kinderen. 
HOOFDSTUK 7: BELASTING VAN ONDERZOEKSPROCEDURES 
VOOR KINDEREN 
Wat we wilden weten: Hoe vervelend zijn onderzoeksprocedures (bijvoorbeeld 
een MRI scan of een allergietest) voor kinderen? 
Hoe we daarachter zijn gekomen: We lieten een vragenlijst invullen door ongeveer 
85 kinderartsen. De artsen moesten bij dertien procedures aankruisen hoe verve-
lend deze zijn voor kinderen. 
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Welk antwoord we hebben gevonden: Over sommige procedures waren de 
kinderartsen het helemaal eens. Bijvoorbeeld: met een borsteltje een beetje 
wangslijmvlies afnemen is bijna niet vervelend voor kinderen. Maar met een dikke 
naald een stukje spier wegnemen is wel heel erg vervelend voor kinderen. Ook 
waren er veel procedures waarover kinderartsen verschillend dachten. Bijvoor-
beeld: hoe vervelend het is om een MRI scan te laten maken. Of hoe vervelend het 
is om een paar keer op een dag bloed te laten prikken. Daarover waren de 
kinderartsen het niet met elkaar eens. 
HOOFDSTUK 8: ALS MEEDOEN AAN ONDERZOEK TEGENVALT 
Wat we wilden weten: Wanneer moet een kind uit een onderzoek gehaald wor-
den? 
Hoe we daarachter zijn gekomen: We lazen de Nederlandse, Europese en wereld-
wijde wetten goed. Ook lazen we de ‘Code Verzet’. Daarin staan regels waar 
onderzoekers zich aan moeten houden als een kind zich verzet tegen het onder-
zoek. We keken wat er goed en wat er niet goed aan is.  
Welk antwoord we hebben gevonden: Ieder kind dat meedoet aan onderzoek 
moet goed in de gaten worden gehouden. Van tevoren bepaalt een commissie 
hoe vervelend een onderzoek mag zijn voor kinderen. Als een kind het veel 
vervelender vindt dan verwacht dan moet dat kind uit het onderzoek worden 
gehaald. Sommige kinderen zijn al oud genoeg zijn om duidelijk te zeggen dat ze 
niet meer mee willen doen. Als dat zo is moeten ze ook uit het onderzoek worden 
gehaald. De meeste wetten noemen wel één van deze twee dingen, maar niet 
allebei. Sommige wetten zijn niet duidelijk. In de wetten staat bijvoorbeeld niet 
wat er precies moet gebeuren als een kind zegt dat hij of zij niet meer mee wil 
doen.  
De conclusie van het hele boek staat in hoofdstuk 9. Er staat ook in welke dingen 
in de toekomst beter kunnen. Bijvoorbeeld: de manier waarop de speciale com-
missies kijken of een onderzoek niet te gevaarlijk of te vervelend is. Volgens ons is 
er een manier om dat preciezer en eerlijker te doen. Namelijk door eerst te kijken 
naar de losse stukjes van het onderzoek. Ook moeten we meer te weten komen 
over hoe vervelend onderzoek eigenlijk is voor kinderen. Ons onderzoek heeft 
daar een begin voor gemaakt. Een andere onderzoeker heeft deze vraag aan 
kinderen zelf gesteld. Maar we weten het nog niet goed genoeg. Onderzoekers 
moeten ook goed weten hoe ze moeten omgaan met kinderen die meedoen aan 
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onderzoek. Het is belangrijk dat onderzoekers goed kunnen inschatten wanneer 
het beter is om een kind uit een onderzoek te halen. Wij hebben een voorstel 
gedaan over hoe onderzoekers dat moeten doen. Namelijk door alle kinderen die 
meedoen altijd goed in te gaten te houden. Ze moeten steeds controleren of 
kinderen wel door willen gaan en of kinderen het niet te zwaar vinden worden. 
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APPENDICES 
Appendix 1: Case record form (chapter 6) 
 
Case Record Form – Componentanalyse 
Deel 1 – Algemene informatie 
 
1. Onderzoeksnummer (uitsluitend voor eigen gebruik) ………………………. 
 
2. Type interventie-onderzoek: 
o 0: Geneesmiddel onderzoek 
o 1: Vaccinatie onderzoek 
o 2: Voedingsmiddel onderzoek 
o 3: Stamcel onderzoek 
o 4 Onderzoek naar nieuwe vormen van diagnostiek 
 
3. Initiatie: 
o 0: Investigator-initiated 
o 1: Door farmaceutische industrie 
 
4. Doelstelling inclusief, indien van toepassing, naam geneesmiddel/vaccin/voedingsmiddel: 
………………………………………….……………………………………………………………………………
………………………….…………………………………………………………………………………………… 
 
5. Bestaande kennis over het middel (uit adult studies/off-label gebruik), voor zover te vinden in het 
onderzoeksprotocol: 
o 0: Geregistreerd voor deze groep (leeftijd en indicatie) 
o 1: Geregistreerd, maar niet voor deze groep  
o 1a: In de praktijk wel standaard behandeling voor deze groep (off label) 
o 1b: In de praktijk wel af en toe gegeven aan deze groep, en/of wel geregistreerd voor  
vergelijkbare groep, en/of veel off label ervaring met middel bij vergelijkbare groep 
o 1c: Helemaal nog geen ervaring nog met dit middel bij deze of vergelijkbare groep 
o 2: Ook voor volwassenen nog niet geregistreerd 
o 2a: Ook bij kinderen al een aantal studies gedaan 
o 2b: Adult studies afgerond maar nog nooit aan kinderen gegeven. 
o 2c: Adult studies lopen nog 
o 3: Iets anders, namelijk: ………….................................................. 
 
Extra informatie:  
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………… 
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6. Fase (volgens protocol/onderzoekers): 
o 0: I 
o 1: II 
o 2: III 
o 3: IV 
o 4: nvt 
 
7. Algemene beschrijving van het study design: 
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………… 
 
8. Proefpersonen: 
o Aantal: ………………………………………………………………………………… 
o Leeftijdsrange: ….……………………………………………………………………. 
o Wel/niet (at risk voor) de ziekte waar het om gaat: …………………………….... 
o Overige relevante informatie: ………………………………………………………. 
 
9. Wat is de ‘standard of care’ voor deze ziekte (voor zover duidelijk wordt uit het protocol)?  
- Therapie: …………………………………………………………………………………………………………. 
………………………….……………………………………………………………………………………………. 
- Controles: ……………………………………………………………………………………………………….... 
………………………….……………………………………………………………………………………………. 
 
10. Toedienen geneesmiddel/vaccin/voedingsmiddel/stamcellen/diagnostiek: 
o Controlegroep: ……………………………………………………………………..... 
o Toedieningswijze: ….………………………………………………………………... 
o Duur: ………………………………………………………………………………….. 
o Dosering ……………………………………………………………………………… 
 
11. Indien er therapie bestaat: wordt kinderen die behandeling in het onderzoek onthouden? 
o 0: Ja, op de volgende wijze: ………………………………………………………..  
o 1: Nee 
 
12. Overige procedures (naast de te toetsen interventie): 
…………………………………………………………………………………………………………………….…
………………………………………………………………………………………………………………………. 
………………………………………………………………………………………………………………………. 
 
13. Belang/nut van de studie (volgens onderzoekers): 
……………………………………………………………………………………………………………………….
………………………….…………………………………………………………………………………………… 
………………………………………………………………………………………………………………………. 
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14. Onderzoek door onderzoekers gezien als: 
o 0: Therapeutisch 
o 1: Niet-therapeutisch 
 
Deel 2 – Beoordeling van de METC/CCMO 
 
15. Onderzoek door METC/CCMO beoordeeld als: 
o 0: Therapeutisch 
o 1: Niet-therapeutisch 
o  
16. Beoordeling: 
o 0: Positief 
o 1: Negatief, redenen: 
………………………….…………………………………………………………………………………
…………………………………….……………………………………………………………………… 
o  
17. Opmerkingen over (niet-) therapeutische aard van de studie en/of over risico en belasting: 
……………………………………………………………………………………....………………………………
…………………………………………………………………..……………......................................................
.................................................................................................................................................................. 
 
Deel 3 - Beoordeling Componenten 
 
18. Vormt de interventie in het kader van dit onderzoek, voor deze groep proefpersonen, tevens (een 
deel van) de therapie of diagnostiek voor hun ziekte, of preventie van een ziekte die zij kunnen krijgen?  
o Ja  
o Nee  
o Bij een deel van de groep wel, bij een ander deel niet 
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Appendix 2: Questionnaire (chapter 7) 
 
 
 
 
 
Hoe belastend is het ondergaan van  
medische procedures voor kinderen? 
 
Medisch wetenschappelijk onderzoek dat niet direct aan de deelnemende kinderen zelf ten goede kan 
komen (zogenoemd niet-therapeutisch onderzoek) mag alleen plaatsvinden als de risico's 
verwaarloosbaar zijn en de belasting minimaal. De achtergrond hiervan is dat kinderen niet in staat 
worden geacht om weloverwogen en vrijwillig te kiezen voor deelname aan dergelijk onderzoek. De 
toepassing van de begrippen “verwaarloosbaar risico” en “minimale belasting” blijkt in de praktijk 
echter erg lastig; toetsingscommissies worstelen er mee. 
  
Daarom vragen we u om uw input. In het kader van het onderzoeksproject “Geneesmiddelen 
onderzoek bij kinderen: ethische kwesties in de praktijk” van de afdeling Medische Ethiek van het 
Erasmus MC, leggen wij u graag onderstaande vragenlijst voor over het begrip “minimale belasting”. 
Want de procedures waar de toetsingscommissies mee worstelen, worden ook buiten de setting van 
wetenschappelijk onderzoek vaak verricht. Waarschijnlijk heeft u als kinderarts (in opleiding) met de 
meeste wel te maken gehad in uw klinische werk. Onze vraag is dus: hoe schat u naar aanleiding van 
deze ervaringen, de belasting van onderstaande procedures in? 
 
Ter ondersteuning: over het begrip minimale belasting staat in de toelichting op de Nederlandse wet 
(WMO) dat hetgeen de proefpersoon moet ondergaan: “alles bij elkaar opgeteld niet ingrijpend is; de 
verstoring van het dagelijks leven die deelname met zich meebrengt, moet beperkt zijn en de belasting 
in de zin van pijn mag die van bijvoorbeeld een bloedprik niet overschrijden.”  
 
Bij voorbaat hartelijk dank voor uw deelname. 
 
1. Wat is uw functie? 
  algemeen kinderarts 
  subspecialist (namelijk: __________________________________________) 
  AIOS kindergeneeskunde 
  ANIOS kindergeneeskunde 
  co-assistent 
  anders (namelijk: _______________________________________________) 
 
2. Hoeveel jaren ervaring heeft u in de kindergeneeskunde?  
______ jaren 
3. Kruis in tabel 1 (z.o.z.) per procedure aan, hoe belastend deze in uw ogen is voor kinderen. 
4. Zet in de meest linker kolom van tabel 1 de procedures op volgorde van minst belastend (1) 
tot meest belastend (13). 
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5. Welke factoren zijn, volgens u, van invloed op de belasting van deze medische procedures 
voor kinderen (bijv. leeftijd, geslacht, ervaring met de procedure etc.)? 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
6. Ruimte voor verdere opmerkingen / toelichting: 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
Tabel 1                                 Vraag 3 
 
 
 
Vraag 4 
Geen goed 
beeld van /  
niet te  
beoordelen 
Minimale  
belasting 
In geringe 
mate meer  
dan minimale 
belasting  
Meer dan in 
geringe mate 
meer dan  
minimale  
belasting  
 Histamine/metacholine provocatietest     
 Venapunctie     
 Herhaalde venapuncties (8x in 6 maanden)     
 Spirometrie / flow- volume meting     
 Spierbiopt      
 Infuusnaald inbrengen     
 Allergie huidtest op arm     
 Liquorpunctie      
 Wangslijmvliesafname (met borsteltje, 15 sec)     
 Beenmergpunctie  (onder narcose)     
 MRI scan (zonder  narcose, 1 uur lang)     
 Echo cor     
 2x dagopname     
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DANKWOORD 
Tijdens mijn sollicitatiegesprek voor de promotieplaats waarvan dit proefschrift 
het resultaat is, vroeg Inez de Beaufort mij of ik het wel zag zitten, zo’n solopro-
ject. Het is toch een eenzaam proces, dat promoveren. Later in het gesprek vroeg 
ze me of ik wel een beetje sociaal was. Omdat het een afdeling is waar iedereen 
voor elkaar klaar staat als het moeilijk is of tegenzit. “Dus toch niet zo eenzaam?” 
vroeg ik. “Nee, in dat opzicht niet” antwoordde Inez. Ik heb in de jaren daarna 
mogen ondervinden dat het allebei waar was. Een soloproject, een klein beetje 
eenzaam, maar met veel hulp en ondersteuning waar dat nodig was. 
Drie bijzondere en zeer verschillende personen waren in dit proces mijn begelei-
ders en (co-)promotoren; Inez de Beaufort, Suzanne van de Vathorst en Anna 
Westra. Met ieder hun eigen stijl hebben zij mij begeleid, ondersteund en mij 
vooral heel veel geleerd. Inez de Beaufort, hoofd van de afdeling Medische Ethiek, 
dank ik voor haar bijzondere persoonlijkheid, haar kennis en haar gave om te 
spelen met vorm en stijl, zonder af te doen aan de inhoud. Suzanne van de 
Vathorst dank ik voor haar zorgzaamheid en daadkracht, en voor hoe zij altijd de 
juiste bemoedigende woorden vindt. Van haar heb ik geleerd doelgericht te werk 
te gaan, hoofdzaken van bijzaken te onderscheiden en teksten te ontdoen van wat 
onnodig is. Met Anna Westra heb ik verreweg het meest intensief samengewerkt 
bij dit project en zelden heb ik zo goed met iemand kunnen samenwerken. Zowel 
qua werkwijze als op persoonlijk vlak klikten wij goed en dat heeft het proces 
soepel en aangenaam gemaakt. Ik ben haar zeer veel dank verschuldigd voor haar 
inzet voor dit onderzoek, haar betrokkenheid en haar uiterst zorgvuldige manier 
van werken. Van haar heb ik geleerd mijn eigen werk steeds te herzien en verder 
te structureren en verfijnen.  
Graag dank ik professor van Dijk, professor Tiddens en professor Hennekam voor 
het lezen en beoordelen van mijn proefschrift en voor hun bereidheid zitting te 
nemen in de promotiecommissie. 
De Onderzoeksschool Ethiek, later de Onderzoeksschool Wijsbegeerte, dank ik 
voor de vele cursussen, congressen, symposia en werkgroepen. Het was fijn een 
netwerk van medepromovendi en onderzoekers te hebben om ideeën uit te 
wisselen en ervaringen te delen. Te weten dat we met zo velen aan onze eigen 
soloprojecten werkten. 
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Tijdens mijn onderzoek heb ik veel hulp en input gekregen van verschillende 
Medisch-Ethische Toetsingscommissies. Graag bedank ik daarvoor de CCMO (in 
het bijzonder Monique Al), de NV-METC en de (secretariaten van) de METCs van 
het Erasmus MC, het LUMC, de MEC-U, het AMC en het UMC Utrecht. 
Waardevol waren ook de gesprekken die ik voerde met, en de input die ik kreeg 
van de kinderartsen op de afdelingen kindergeneeskunde van het LUMC, het 
VUmc, de Isala Klinieken en het Juliana Kinderziekenhuis. 
Enorm veel dank ben ik verschuldigd aan de vele researchverpleegkundigen die ik 
heb mogen ontmoeten gedurende mijn onderzoek. Met enkele van hen mocht ik 
een dagje meelopen in het Sophia Kinderziekenhuis, anderen sprak ik tijdens 
focusgroepen en workshops. Deze groep van zeer toegewijde (overwegend) 
dames staat midden in de praktijk, dichtbij de kinderen waar dit boek over gaat. 
Hun verhalen, ervaringen en inzichten zijn van grote waarde geweest voor dit 
proefschrift. 
Liztophe Verhoeven wil ik graag bedanken voor het lezen en verbeteren van de 
inleiding en de samenvatting voor kinderen. Ik vind het heel leuk dat je dat wilde 
doen! 
In 2012, less than a year after I started my PhD project, our department hosted the 
11th World Congress of Bioethics in Rotterdam. On the first morning Inez intro-
duced me to Hans-Jörg Ehni from Tübingen University, letting him assure her “to 
take good care of me as I was very young”. In the following days Hans-Jörg 
guided me through the wondrous world of bioethics and its people, all gathered 
then and there in Rotterdam. We kept in touch afterwards and I thank him for the 
many pleasant conversations, his useful feedback and reassuring words. I really 
hope we will manage to keep meeting from time to time. 
Alle lieve en leuke collega’s van de afdeling Medische Ethiek ben ik dankbaar voor 
de fijne werkplek. Annemieke van Tintelen dank ik voor haar behulpzaamheid en 
voor het zorgen dat dingen altijd goedkomen. Hannie Aartsen dank ik voor haar 
tomeloze energie en passie voor het onderwijs. Karin Jongsma en Krista Tromp 
ben ik dankbaar voor, tsja, waarvoor niet eigenlijk. We zijn min of meer tegelijk 
begonnen aan dit avontuur dat promoveren heet. We hebben veel samen gewerkt 
en leuke dingen beleefd (de roadtrip naar Straatsburg bijvoorbeeld, en de high-
tea met onze moeders). Ik dank Frans Meulenberg voor zijn betrokkenheid en 
voor wat hij kan met taal. Vele keren maakte hij mijn teksten beter, scherper, 
correcter en mooier. Ooit begonnen wij samen verhalen te schrijven. Nu mijn 
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proefschrift af is, moest dat maar eens snel een vervolg krijgen. Tineke Terpstra 
ben ik buitengewoon dankbaar voor haar wijsheid en haar bereidheid die met mij 
te delen. Wij hebben een aantal bijzondere gesprekken gevoerd waar zowel mijn 
proefschrift als ikzelf beter van zijn geworden.  
Eline Bunnik en Hafez Ismaili M’Hamdi, ik vind het zo leuk dat jullie mijn paranim-
fen willen zijn. Ik ben blij dat ik jullie heb leren kennen, en dat wij elkaar nog steeds 
af en toe zien en spreken, ook al zijn we feitelijk geen collega’s meer. Eline, dank 
voor jouw oprechte interesse, jouw bijzondere stijl die zachtheid en directheid zo 
mooi combineert en voor alle keren dat we samen naar het theater gingen (en dan 
vooral die keer dat ik met zwangere buik in jouw bakfiets mocht zitten en jij ons 
dwars door Amsterdam naar Frascati fietste). Hafez, dank voor jouw humor en 
jouw vele talenten, voor dat je zo’n gezellige kamergenoot was en zo’n goede 
gesprekspartner bent.  
Ook in mijn persoonlijke leven zijn er mensen die me hebben geholpen dit proef-
schrift te schrijven, direct of indirect. Lieve vrienden, ver en dichtbij, dank voor alle 
momenten van plezier en ontspanning, van praten over andere dingen dan werk. 
Lieve schoonfamilie, dank dat jullie er altijd voor ons zijn. Rietje en Frans, bij jullie 
in Nuenen is het per definitie gezellig. Iedereen is altijd welkom en er is nooit 
teveel bezoek. Toon en Thera, wij komen zo graag bij jullie in Maastricht. En al 
komt het er te weinig van, het is altijd fijn als we weer een lange avond hebben 
kunnen bijpraten. Dank voor jullie interesse in mijn werk, voor het doorvragen en 
het luisteren. Lieve schoon(stief)zussen en broers, Christianne, Fieke, Rogier, Hugo 
en Marnix, dank dat ik erbij mag horen, al tien jaar, en voor de leuke tantes en 
ooms die jullie voor Pelle zijn. 
I owe many thanks to Lisa Madlberger (and Jeroen Smith too), whose home I 
regularly got to use as my office and whose company and lunches made thesis 
writing a much more productive and much more enjoyable enterprise. 
Michiel Wijtenburg en Sander Vlek, door toeval leerden we elkaar kennen en wat 
een geluk was dat. Behalve de liefste vrienden zijn jullie ook een inspiratie, 
toonbeelden van wilskracht die ik vaak in gedachte heb als het leven uitdagingen 
brengt. Ik weet zeker dat dat niet alleen voor mij geldt. En Michiel, heel veel dank 
voor het prachtige ontwerp van de omslag van mijn proefschrift.  
Mijn zus Diane, haar vriend Sven en hun lieve zoontje Pepijn. Jullie huis voelt als 
een tweede thuis. Onze jongetjes spelen er samen, er is koffie, een grasveldje  
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en Sven steekt de BBQ aan (ongeacht het seizoen). Meer hebben we niet nodig. 
Wat fijn dat ik jullie heb, dank voor alles! 
Mijn ouders, de twee mensen waarvan ik altijd zeker weet dat ze er zijn, dag en 
nacht. Jullie zorgzaamheid kent geen grenzen, jullie behulpzaamheid ook niet. Mijn 
moeder, Oma Elly, bedankt voor het vele oppassen op Pelle. Jullie hebben zo’n 
goede band. “Hoe jonger je bent, hoe makkelijker je leert.” Met een vader die veel 
met hersenwetenschappers werkt, kreeg ik dit als kind vaak te horen. De bood-
schap was dat het niet echt uitmaakt wat het precies is dat je leert. Maar als je 
toch iets wil leren, doe het dan zo vroeg mogelijk. Met deze gedachte hebben 
jullie mij gestimuleerd om te leren, en mij tegelijkertijd vrij gelaten. Een bijzondere 
combinatie. Ik ben jullie er nog altijd dankbaar voor, het heeft me op mooie 
plekken gebracht. 
Mijn lieve Pelle. Wat ben ik gelukkig en trots om jouw mama te zijn. Je bent zo lief, 
zo open en sociaal. Jouw vrolijkheid en energie maken overal een feestje van. 
Zoals jij luistert, observeert en associeert, schuilt er al een kleine onderzoeker in 
jou. Ik wens dat jij jouw eigen koers vindt in het leven, welke dat ook zal zijn. Voor 
mij is er geen groter plezier dan de wereld te ontdekken door jouw ogen, jouw 
kleine handje in mijn hand. Je andere hand in die van je papa. 
En mijn lieve Pim. Wat ik aan jou niet allemaal te danken heb. Feitelijk heb je de 
volledige technische productie van mijn promotietraject gedaan. En als dat nu 
alles was. Ik dank jou voor jouw liefde, jouw vertrouwen, jouw hulp en support, 
voor hoe je voor ons gezin zorgt. Ik ben niet de eerste die dit tegen je zegt, en ik 
weet dat deze woorden gestolen zijn, maar het is nu eenmaal de best mogelijke 
samenvatting; jij maakt dingen beter.  
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